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Figure 2.1. Inactivation of MAPK and NF-κB signaling pathways by bacterial 
protein effectors: YopJ, AvrA and VopA. Effectors acetylate the 
serine and/or threonine residues of the kinase loops of MAPK 
signaling molecules preventing their phosphorylation. The specific 
mechanism of action of these effectors on the NF-κB pathway 
remains to be elucidated. 16 
Figure 3.1. Purity of Ni-NTA purified recombinant fusion proteins. (A) 
Representative SDS-PAGE gel for YopJ-GST and mYopJ-GST. Lane 
1 is protein standard, lane 2 YopJ-GST and lane 3 mYopJ-GST. (B) 
Representative western blot showing anti-5xHis antibody recognition 
of the bands observed in the gel, indicating they are (m)YopJ-GST. 
Two bands are observed, one at the expected molecular weight (60 
KDa) and the second one at lower molecular weight. The second band 
is the result of protein degradation from the GST terminus, leaving a 
protein containing the entire (m)YopJ sequence and part of the GST 
sequence. 33 
Figure 3.2. Western Blot of a native protein electrophoresis gel. YopJ and mYopJ 
are observed in the upper section in which smears of these proteins 
are visible. Smears indicate the presence of proteins of different sizes 
or aggregates of proteins. We used as controls mCherry and eGFP 
which are proteins with high solubilities, these can be observed in the 
lower section in which spots of protein are visible. 35 
Figure 3.3.  Results of digest reaction for YopJ and mYopJ with thrombin. 
Western Blot image of purified and cleaved YopJ using penta-HIS 
antibody. Notice in the western blot image that most of the protein has 
been cleaved but small amounts remain as full length fusion protein. 
Native (nat) and denaturing (denat) elutions were performed. 37 
Figure 4.1. Effect of desolvation agent on the size of protein nanoparticles made 
with eGFP and BSA, at 1:4 protein solution to desolvation agent ratio 
and cross-linked with DTSSP for 2 h. There is no significant 
difference in measured particle diameters. 48 
Figure 4.2. Effect of NaCl concentration on the diameter of protein nanoparticles: 
(a) size distribution curves for representative samples of BSA 
nanoparticles, (b) average diameter of BSA nanoparticles, (c) size 
distribution curves for representative samples of eGFP nanoparticles, 
and (d) average diameter of eGFP nanoparticles. 49 
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Figure 4.3. Effect of imidazole concentration on particle size: (A) size 
distribution curves for eGFP nanoparticles, (B) average diameter of 
eGFP nanoparticles, (C) size distribution for BSA nanoparticles, and 
(D) average BSA particle diameter. 51 
Figure 4.4. Variation in particle size distribution across three different particle 
productions made from the same batch of eGFP and same fabrication 
conditions (125mM imidazole buffer and DTSSP). No significant 
variation in particle size and size distribution is observed within the 
same batch of protein. 53 
Figure 4.5. Effect of cross-linkers on particle size: (a) size distribution curves for 
eGFP nanoparticles, (b) average hydrodynamic diameter of eGFP 
nanoparticles, (c) size distribution curves for BSA nanoparticles (note 
GTA cross-linking time was 20 min) and (d) average hydrodynamic 
diameter of BSA nanoparticles. 55 
Figure 4.6. Effect of cross-linker on eGFP fluorescence. Relative fluorescence of 
nanoparticles suspended in PBS, after protein desolvation and cross-
linking with BS3, DTSSP and GTA for 2 h. Data are the measured 
fluorescence of eGFP nanoparticles relative to soluble eGFP (* 
p<0.05). 56 
Figure 4.7. eGFP particle break-up in HeLa cell lysates. (a) Western blot showing 
break-up of particles cross-linked with BS3 (Bt) or DTSSP (Dt) over 
time in minutes (indicated by subscript). (b) Western blot for eGFP 
particles cross-linked with GTA at 0 and 30 minutes. All particles 
were produced with ethanol and cross-linked for 2 h. 57 
Figure 4.8. Effect of enzyme on particle size: (a) size distribution curves of eGFP 
nanoparticles, eGFP+βgal and eGFP+AvrA nanoparticles produced 
with 250 mM imidazole buffer and (b) average particle diameter of 
eGFP+βgal nanoparticles with varying imidazole concentrations. 58 
Figure 4.9. (A) Relative β-gal activity retention for different particle 
formulations. Particles were produced from pure β-gal (β-gal NP) or a 
mixture of eGFP and β-gal (eGFP+β-gal) and cross-linked for 2 h 
with DTSSP. Data are the measured β-gal activity in the nanoparticles 
relative to soluble β-gal. (B) Effect of cross-linker on β-gal activity              
(* p<0.05, ** p<0.01). 60 
Figure 4.10. Size distribution curves of particles used for cell experiments. eGFP 
or eGFP+β-gal particles were produced with ethanol and cross-linked 
with DTSSP and BS3 for 2 h, or with GTA for 20 min to obtain 
similar nanoparticle average sizes and size distributions. 63 
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Figure 4.11. Uptake of protein nanoparticles compared to soluble protein: (a) 
Relative fluorescence of different cell lines after 6 hours of incubation 
with eGFP nanoparticles and (b) SK-BR-3 cell uptake of eGFP 
nanoparticles over time. Data reported here shows the measured 
fluorescence of cells treated with soluble or nanoparticle protein 
relative to the fluorescence of cells treated with PBS. Error bars 
represent standard deviation, N=3 (* indicates p<0.05) 65 
Figure 4.12. Energy dependent particle uptake. SK-BR-3 cells were incubated 
with eGFP nanoparticles for 6 h at 4°C and 37°C. Particles used for 
this experiment were produced with ethanol, 250 mM imidazole 
buffer and cross-linked with DTSSP for 2 h. Average particle 
diameter was 117 nm and zeta potential was –11.5 mV in PBS. Data 
are the measured fluorescence of cells incubated with soluble or 
nanoparticle eGFP relative to the fluorescence of cells incubated with 
PBS. Error bars represent standard deviation, N=3  (* p<0.05). 66 
Figure 4.13. β-gal activity levels in HeLa cells after 6h of incubation. Cells were 
incubated with PBS, soluble of eGFP and β-gal, or eGFP+β-gal 
nanoparticles. The latter two samples contain the same amount of 
total protein and a 1:24 molar ratio of β-gal to eGFP.  Error bars 
represent standard deviation, N=3 (* indicates p<0.05) 67 
Figure 4.14. Effect of cross-linkers on: (a) eGFP+β-gal particle uptake in 3T3 
cells, and (b) β-gal activity levels in 3T3 cells incubated with 
eGFP+β-gal nanoparticles relative to cells incubated without particles. 
Error bars represent standard deviation, N=3. 68 
Figure 4.15. eGFP+β-gal particle break-up in cells. Western blot showing break-
up of particles cross-linked with GTA (G), DTSSP (D) or BS3 (B). 
Confluent monolayers of HeLa cells were incubated with particles for 
6h. eGFP+β-gal (1:5 enzyme:eGFP) particles were produced with 
ethanol and cross-linked with DTSSP and BS3 for 2 h, or with GTA 
for 20 min. Particles sizes were 263, 241 and 233 nm, respectively. 69 
Figure 4.16. Effect of storage at 4°C on eGFP+β-gal (representative) particle size 
distribution. GTA cross-linked nanoparticles and DTSSP cross-linked 
particles are shown immediately after fabrication and after 6 months 
of storage and sonication. 70 
Figure 4.17. Effect of lyophilization on eGFP+β-gal (representative) particle size. 
GTA cross-linked nanoparticles and DTSSP cross-linked particles are 




Figure 5.1. Schematic representation of the effect of particle size and surface 
properties on effective AvrA delivery to cells. Large particles (>500 
nm) are unable to penetrate the mucus layer and thus, are unable to 
deliver the effector to the cells. Medium sized particles (200-500 nm) 
are able to penetrate the mucus layer but are not readily internalized 
by cells. Small particles that adhere to mucin are able to penetrate the 
mucosa but do not effectively reach the cells. Small particles 
(<200nm) traverse the mucosal layer and are readily internalized by 
cells. Adhesive nanoparticles (hydrophobic and/or cationic) bind to 
mucin fibers and are unable to deliver the effector to the cells. 
Schematic representation not drawn to scale. 81 
Figure 5.2. eGFP+AvrA nanoparticle design. Small particles (50-200nm) made 
of DTSSP cross-linked AvrA and eGFP are expected to penetrate the 
mucus barrier, enter target cells and break-up in reducing conditions 
observed inside cells to release AvrA. 83 
Figure 5.3. Effect of imidazole on eGFP+AvrA particle size and distribution. 
Different concentrations of imidazole were used in the initial protein 
solution to control particle size. 85 
Figure 5.4.  Effect of imidazole on eGFP+AvrA particle size polydispersity. (A) 
comparison of size distribution peak width for particles fabricated in 0 
mM and 250 mM   (B) average full-width at maximum height 
(FWMH) for particles fabricated in different imidazole 
concentrations. Error bars represent standard deviation, N=3. 86 
Figure 5.5. SEM image of eGFP+AvrA nanoparticles. Particles were further 
cross-linked with GTA after fabrication, frozen in liquid nitrogen and 
then lyophilized. 88 
Figure 5.6. AFM image of eGFP+AvrA nanoparticles. 3D simulation of surface 
topography, note the existence of the small particles and large 
aggregates. Particles were prepared by further cross-linking with 
GTA, frozen in liquid nitrogen and lyophilized. 89 
Figure 5.7. eGFP+AvrA particle degradation in 5mM GSH. Western blot probed 
with anti penta-His antibody showing release of soluble protein 
separated using a native protein electrophoresis gel. GTA cross-linked 
particles and soluble eGFP were used as controls 91 
Figure 5.8. Time analysis of AvrA-eGFP nanoparticle break-up in 10mM GSH 
solution. (left) SDS-PAGE gel stained with coomasie blue (right) 
western blot probed with anti penta-His antibodies. 92 
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Figure 5.9. Effect of reducing conditions on size distribution of AvrA-eGFP 
nanoparticles. Particles were incubated with 5 mM GSH for 10-30 
minutes. Size distribution of particles before incubation is shown for 
comparison (0 mM). 93 
Figure 5.10. DLS measurements of eGFP+AvrA nanoparticles in 5 mM GSH 
(left) comparison of size distribution before and after centrifugation, 
and (right) size distribution detail of centrifuged eGFP+AvrA 
nanoparticles in 5mM GSH. 94 
Figure 5.11. Particle internalization of J774.A1 cells. Representative 
flowcytometry fluorescence intensity histogram for cells incubated for 
6 hours with PBS, soluble AvrA with eGFP and eGFP+AvrA 
nanoparticles. 95 
Figure 5.12. Particle internalization of SK-CO15 cells. Representative 
flowcytometry fluorescence intensity histogram for cells incubated for 
6 hours with PBS, soluble AvrA with eGFP and eGFP+AvrA 
nanoparticles. 96 
Figure 5.13. AvrA internalization studies on SK-CO15 cells. Topographical map 
shows distribution of cell populations for cell incubated for 6 hours 
with cell media, eGFP+AvrA nanoparticles or eGFP nanoparticles 
(from left to right). Cells were studied for anti-AvrA antibody 
fluorescence (y-axis) and eGFP fluorescence (x-axis). 96 
Figure 5.14. AvrA internalization studies on J774 cells. Heat map shows 
distribution of cell populations for cell incubated for 6 hours with cell 
media, eGFP+AvrA nanoparticles or eGFP nanoparticles (from left to 
right). Cells were studied for anti-AvrA antibody fluorescence (y-
axis) and eGFP fluorescence (x-axis). 97 
Figure 5.15. Summary of flow cytometry internalization data measuring AvrA in 
SK-CO15 and J774.A1 cells incubated with protein for 6 hours. 
Positive events were established by counting the population of cells 
that showed a simultaneous increase in eGFP and anti-AvrA. 98 
Figure 5.16. LDH cytotoxicity assay for J774.A1 cells incubated with soluble and 
nanoparticle formulations of eGFP+AvrA/mAvrA for 6 or 24 hours. 
Control cells were incubated with media and PBS, whereas positive 
cells were incubated with a cell lysis agent. 99 
Figure 6.1. EPR effect in tumor vasculature. Passive targeting of nanoparticles 
between 50-550 nm to tumors occurs through the increased 
permeability of the tumor vasculature (schematic not drawn to scale). 114 
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Figure 6.2. Schematic representation of bacterial T3SS effector delivery and 
proposed protein nanoparticle delivery. Bacterial pathogens inject 
effector proteins directly into the cytoplasm of host cells through 
needle-like structures (left). In the cytoplasm effectors bind their co-
activator or chaperone that refolds them and potentiates their action 
[31]. Effectors are capable of subverting multiple intracellular 
pathways to control multiple cellular functions. The proposed strategy 
is to deliver the YopJ in self-assembled effector nanoparticles (right) 
to cancer cells to induce cell death and decrease activity in metastasis-
associated pathways. 116 
Figure 6.3. Characterization of self-assembled YopJ-GST nanoparticle size. (A) 
Representative DLS nanoparticle size distribution in 2X PBS + 5% 
dextrose. (B) Representative DLS nanoparticle size distribution in 8M 
urea, shows particle swelling in denaturing conditions. 118 
Figure 6.4. Analysis of SDS-PAGE gel shows YopJ-GST nanoparticle 
disassembly in the presence of denaturing agents (detergent: SDS and 
heat: 100°C), reducing agent (β-mercaptoethanol) or under native 
conditions. Band intensity is correlated to amount of protein released. 119 
Figure 6.5. Interaction of YopJ-GST nanoparticles with SKBR-3 cells. (A) Flow 
cytometry analysis of untreated cells (black) compared to cells treated 
with 0.4 µM mYopJ-GST nanoparticles for 24 or 72 hours (green, 
red), labeled with anti-GST Dylight 488. (B-E) Confocal 
immunofluorescence analysis of (B, C) untreated cells or (D, E) cells 
treated with 2x dose (0.8 µM) of mYopJ-GST nanoparticles for 72 
hours, using anti-GST Dylight 488 (green). Actin filaments are 
labeled with rhodamine phalloidin (red) and DNA (nucleus) with TO-
PRO-3 (blue). Scale bar is 20 µm. 121 
Figure 6.6. Viability of SKBR-3 cells treated with YopJ-GST nanoparticles. Cell 
metabolic activity, measured by flowcytometry, after 72 hours of 
treatment with 0.4 µM YopJ-GST or mYopJ-GST nanoparticles or 2 
µM dox, compared to control cells incubated with 2X PBS + 5% 
dextrose. Error bars represent standard deviation, N=3 (**p<0.01). 122 
Figure 6.7. Fluorescence microscopy images of cells incubated with YopJ-GST 
nanoparticles and controls for 72 hours. Cell nuclei were stained with 
Hoechst and cells were imaged with 10X objective. 123 
Figure 6.8. Cytoxicity of YopJ-GST nanoparticles on SKBR-3 cells. Cell 
metabolic activity, measured by MTT assay, after 72 hours of 
treatment with 0.4 µM YopJ-GST or mYopJ-GST nanoparticles or 2 
µM dox, compared to control cells incubated with 2X PBS + 5% 
dextrose. Error bars represent standard deviation, N=3 (*p<0.01). 124 
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Figure 6.9. In vitro assessment of apoptosis in SKBR- 3 breast cancer cells 
treated with YopJ-GST. (A) Flow cytometry analysis using annexin 
V-Alexa 488 and PI was used to observe the induction of apoptosis or 
necrosis. Doxorubicin was used as a positive control for annexin-V 
and PI staining. (B) Flow cytometry analysis using annexin V-Alexa 
488 and Sytox green. An increase in population fluorescence intensity 
indicates the presence of apoptotic or necrotic cells. 125 
Figure 6.10. Phosphorylation of ERK 1/2 pathway measured as relative 
fluorescence intensity of cells treated with sub-lethal doses (0.16 µM) 
of nanoparticles in serum-free media and stimulated with 20 ng/ml 
EGF for 15 min, compared to stimulated control. Error bars represent 
standard deviation, N=3 (*p<0.05). 127 
Figure 6.11. Effect of YopJ-GST nanoparticles on IκBα degradation. Western 
blot on cell lysates probed with anti-IκBα antibody. NFκB pathway 
was stimulated with 20 ng/ml TNFα in Hank’s buffer and basal 
pathway levels were accomplished by incubating the cells in Hank’s 
buffer for 24h. 128 
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Results shown here represent measured phospho-IκBα normalized 
with GADPH. Cells were serum starved and incubated with YopJ or 
mYopJ for 24 hours, then stimulated with 20 ng/ml of TNFα for 15 
minutes. 129 
Figure 6.13. Cell migration of treated SKBR-3 cells. Migration of cells treated 
for 24 hours with sub-lethal doses of nanoparticles in Boyden 
chambers, stimulated with 10% FBS as a chemoattractant. Migration 
of samples is normalized to migration of stimulated control. Error 
bars represent standard deviation for N=3 (*p<0.05). 130 
Figure 6.14. Relative cell invasion of SKBR-3 cells treated with YopJ-GST and 
dox. Invasion was measured in a wound healing assay. Wounds were 
created at t=0 and cells were treated with 0.4 µM nanoparticles or 0.4 
µM dox for 24 hours. Error bars represent standard deviation, N=3 
(*p<0.05). 131 
Figure 6.15. Cytotoxic effect of YopJ-GST nanoparticles on SKBR-3 
doxorubicin resistant cells. Relative cell viability after 72 hours of 
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live cells in sample relative to control. Error bars represent standard 
deviation for N=3 (* p<0.05, ** p<0.01). 132 
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Figure 6.17. Effect of YopJ-GST nanoparticles on a breast cancer cell line panel. 
(A, C, E) Relative cell viability after 72 hours of treatment with 0.4 
µM nanoparticle or dox, unless otherwise indicated, for (A) MCF-7 
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Proteins and enzymes are dynamic and versatile macromolecules that have the 
capacity to perform a complex set of functions while being highly specific. This grants 
them an advantage over small molecules and has led to a dramatic increase in their use 
for therapeutic purposes over the past couple of decades. Intracellular delivery of 
therapeutic proteins or enzymes has the potential to restore normal cellular function by 
substitution of deficient proteins or regulation of intracellular signaling pathways.  
Bacterial pathogens have evolved mechanisms by which they can control the fate 
of host cells during infection. Some Gram-negative bacteria inject effector proteins 
directly into the cytoplasm of eukaryotic host cells. These effector proteins have high 
potential as therapeutic agents because they are capable of efficiently subverting a variety 
of eukaryotic signaling pathways by regulating protein factors involved in signal 
transduction. However, bacterial delivery of effector proteins for therapeutic purposes is 
not a viable option. 
Effectors and other therapeutic proteins and enzymes require modification, 
encapsulation or immobilization to improve their stability and limited distribution. 
Hence, there is a critical need to develop delivery systems that will improve accessibility 
of enzymatic drugs to intracellular compartments. The production of protein-enzyme 
nanoparticles was investigated in this thesis with the goal of developing a protein carrier 
for active enzyme delivery. 
In Chapter 4 of this thesis, β-galactosidase –a model enzyme– is incorporated into 
enhanced green fluorescent protein (eGFP) nanoparticles prepared via desolvation. 
Particle size is shown to be sensitive to type of cross-linker, cross-linking time, and the 
presence of imidazole. Enzymatic activity is shown to be highly retained after particle 
fabrication and high protein encapsulation yields are demonstrated. Protein-enzyme 
 xix 
 
nanoparticles are shown to effectively deliver the enzyme to multiple cell lines in vitro. 
More importantly, delivered enzymes are shown to retain their biological activity. This 
data demonstrates that protein nanoparticles are a biocompatible, high efficiency 
alternative for intracellular delivery of active enzyme therapeutics. Thus, the potential of 
protein nanoparticles for therapeutic protein and enzyme delivery is studied in two 
diseases models: inflammatory bowel disease (IBD) and breast cancer. 
AvrA an acetyltransferase effector from Salmonella, suppresses acute 
inflammatory responses such as those observed in inflammatory bowel disease. Bacterial 
delivery of this effector is substituted in Chapter 5 with protein nanoparticles made 
directly from AvrA and a carrier protein, eGFP. eGFP+AvrA nanoparticle size is shown to 
be controlled by imidazole concentration during particle fabrication. These nanoparticles 
are shown to effectively deliver AvrA to model intestinal epithelial and immune cells. 
Furthermore, in vivo studies performed by an Emory collaborator reveal that eGFP+AvrA 
nanoparticles inhibit inflammatory signaling and confer cytoprotection in vitro, and in 
murine colitis models decrease clinical and histological indices of inflammation. 
In Chapter 6, the use of YopJ –an effector from Yersinia pestis– is evaluated for 
the treatment of breast cancer. YopJ is known to down-regulate the MAPK and NF-κB 
pathways to induce apoptosis in specific cell types. In this chapter YopJ is produced in E. 
coli as a fusion protein with glutathione S-transferase (GST), forming self-assembled 
protein nanoparticles. YopJ-GST nanoparticles are shown to efficiently deliver proteins 
to breast cancer cells. These nanoparticles are also shown to induce dose and time-
dependent death in SKBR-3 breast cancer cells, more effective than the same molar dose 
of doxorubicin. More importantly, the results of treatment with sub-lethal doses of 
nanoparticles exhibit decreased cell migration in vitro and down-regulated the MAPK 
ERK 1/2 pathway, which has been correlated to metastasis. Moreover, YopJ-GST 
nanoparticles are shown to induce cell death in a panel of breast cancer cell lines, but are 
not cytotoxic to healthy fibroblasts or cervical cancer cells. Consequently, YopJ-GST 
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nanoparticles demonstrate the potential of effector proteins as breast cancer therapeutics 
with selective cytotoxicity and the capacity to decrease metastatic predictive-behaviors. 
Finally, in Chapter 7, conclusions are reported and protein particles are discussed 
as an interesting and potentially useful strategy for delivery of protein and enzyme 
therapeutics. Bacterial effector proteins are presented as novel therapeutic agents and 




1CHAPTER 1: INTRODUCTION 
 
 
In the past decades, the mechanisms and causes of many diseases have been 
elucidated. This knowledge made the design and discovery of new therapies possible. For 
years the pharmaceutical industry focused its efforts in the development of small 
molecule drugs that would target cell receptors, enzymes and proteins. With the 
development of protein chemistry and recombinant techniques the identification, 
isolation, purification and engineering of large proteins as drugs became possible. 
Protein-based drugs now represent an increasing share of the pharmaceutical sector and 
have become highly successful in the clinic, enjoying unprecedented recognition of their 
potential [1]. Currently, there are more than 130 biological drugs in the market, which 
include monoclonal antibodies, peptides, proteins and enzymes.  
Enzyme therapeutics offer multiple advantages over small molecule drugs. 
Enzymes, like many other proteins, can bind to their targets with high affinity and act 
with high specificity [2]. Most importantly, an enzyme’s catalytic activity allows it to 
rapidly convert multiple target molecules into products, which significantly amplifies its 
effect compared to small molecules and binding proteins [3, 4]. These unique properties 
make enzymes promising therapeutic agents, and an important and growing segment of 
pharmaceuticals. 
Although most targets of FDA approved enzymatic drugs are extracellular, there 
are many diseases for which treatment requires intracellular delivery [5]. Intracellular 
enzyme therapy has the potential to restore normal cellular function by substitution of 
defective or deficient enzymes, regulation of intracellular signaling pathways and/or 
proteolysis. Effective enzyme replacement for treatment of genetic diseases such as 
Pompe and Krappe, two types of lysosomal storage diseases, requires intracellular 




enzymes are expected to emerge, including inhibition or reversal of ubiquitination for 
cancer [7], phosphorylation of Tau protein for Alzheimer’s disease [8] and regulation of 
specific intracellular pathways that contribute to disease pathogenesis. For example, in 
chronic inflammatory diseases, such as rheumatoid arthritis and systemic lupus 
erymathosus, alterations in the Ras family of small GTPases contribute to the observed 
dysfunctions [9]. Similarly, in multiple autoimmune diseases, reactivation of the Notch-
signaling pathway is at the center of abnormal behavior [10]. In many types of cancer the 
Ras family of oncogenes, Notch, TGF-β, WNT, MAPK and NF-κB are common aberrant 
pathways [11-13]. Enzymes can effectively inhibit or modify many of these pathways 
[14-17] and thus, could be used as a new generation of intracellular therapeutics.  
Bacterial pathogen evolution has produced a broad spectrum of enzymes that 
subvert and control normal cellular functions during infection [18]. These enzymes, 
known as effectors, actively regulate host cell cycle, inflammation, immune signaling, 
apoptosis, and the actin cytoskeleton by manipulating intracellular signaling pathways 
[19-22]. Some effectors interfere with phosphorylation cascades or ubiquitinylation 
processes [23], while others mimic the functions of protein kinases and phosphatases. 
These hijacking mechanisms have been proven to be highly efficient [20] and therefore, 
bacterial effectors have high potential as therapeutic enzymes.  
The YopJ family of effectors is an example of enzymes of bacterial origin with 
therapeutic potential. These are homologue acetyltransferases capable of simultaneously 
down-regulating nuclear factor κB (NF-κB) and mitogen activated protein kinase 
(MAPK) pathways by preventing phosphorylation of key kinases. These pathways are 
critical for the development of diseases such as inflammatory bowel disease (IBD) and 
breast cancer. YopJ, from Yersinia, simultaneously blocks several MAPK cascades and 
NFκB signaling to induce apoptosis. Whereas AvrA, from Salmonella, modifies and 




inflammation, without inducing cell death [24]. These functions make YopJ and AvrA 
ideal therapeutic agents for breast cancer and IBD, respectively. 
However, effectors and other potential therapeutic enzymes require modification, 
encapsulation or immobilization on biocompatible matrices to improve their stability and 
limited distribution [2, 3, 25]. Thus, there is a critical need to develop delivery systems 
that will improve accessibility of enzymatic drugs to intracellular compartments. There 
are many challenges associated with the delivery and retention of activity, given the large 
size of enzymes and their complex tertiary or quaternary structure that can be highly 
sensitive to the environment [3]. Delivery vehicle fabrication conditions must be gentle 
enough for activity retention and be small enough to penetrate tissues and be internalized 
by cells [26, 27]. In general, enzymes packaged in a delivery vehicle possess several 
advantages over soluble formulations, such as higher stability, lower immune response 
and targeting capabilities [25, 26, 28-32]. Most current delivery systems immobilize 
enzymes on the surface of another material or encapsulate them in polymeric, lipid or 
mesoporous materials [3, 5, 33-38]. Other methods involve fusion of an enzyme to other 
proteins or peptides [39]. However, some challenges remain, such as low encapsulation 
efficiencies, reduction in activity from fabrication conditions, or undesirable degradation 
products [40]. 
It is possible to address these delivery challenges and engineer a completely 
biodegradable enzyme delivery method by using protein particles. Protein particles offer 
multiple advantages over their polymeric, inorganic and liposomal counterparts. Some of 
the most striking advantages are their high loading capacity, ease of production, 
surrounding protein environment, and amino acid degradation products [41, 42]. 
Currently, most protein particles are studied for intracellular delivery of small molecule 





The present work shows a comprehensive picture of the use of bacterial effector 
proteins as therapeutic agents. It first focuses on recombinant production and 
solubilization of bacterial effectors that have potential as therapeutic agents for breast 
cancer and inflammatory bowel disease (Chapter 3). This is followed by production and 
detailed optimization of enzyme carrier particles and investigation of intracellular active 
enzyme delivery (Chapter 4). Finally, two candidate bacterial effectors, YopJ and AvrA 
are evaluated in breast cancer and inflammatory bowel disease models (Chapter 5-6). 
This thesis presents an innovative approach for the development of novel potent 
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CHAPTER 2: BACKGROUND 
 
 Many diseases are triggered and sustained by molecular alterations within 
the cell. Enzymes have the potential to restore normal cellular function by reversing 
molecular changes through activation or deregulation of intracellular pathways. As 
described in the previous chapter, bacterial pathogens produce a variety of enzymes that 
target multiple eukaryotic signaling pathways and could potentially be used for 
therapeutic purposes. In the following sections the molecular treatment of breast cancer 
and IBD, a discussion on bacterial effector proteins and intracellular enzyme delivery are 
presented. Eventhough these two diseases and the therapeutic goals associated to each of 
them are significantly different, dysregulated signaling pathways are common between 
them.  
2-1 Molecular treatment of cancer 
Cancer has been described as a disease in which alterations in the genetic material 
deregulate the circuits that govern normal cell proliferation and homeostasis, leading to 
uncontrolled proliferation, abnormal functions and alterations in cell morphology [1-3]. 
An accumulation of defects in DNA leads to transformation of the cell and cellular 
functions. In general, there are two main types of genes involved in this transformation: 
oncogenes and onco-suppressors. Oncogenes have been described as overexpressed or 
mutated genes that promote abnormal cell behavior. While onco-suppressor genes are a 
diverse set of genes whose normal function is to suppress oncogenic phenotype and 
whose inactivity is necessary for cancer development [4].  
Together these damaged genes constitute the molecular basis for the exaggerated 
behaviors and pathway alterations observed in cancer. Some oncogenes or damaged 
onco-suppressor genes are translated into proteins that participate in key signaling 




activation, up-regulation or deregulation of entire signaling pathways [2]. These 
alterations in signaling allow cancer cells to acquire distinctive and complementary traits 
that enable tumor growth, metastatic propagation and drug resistance. These traits, now 
known as the hallmarks of cancer, include: sustaining proliferative signaling, evading 
growth suppressors, enabling replicative immortality, activating invasion and metastasis, 
resisting cell death, inducing angiogenesis, avoiding immune destruction, tumor 
promoting inflammation, genome instability and mutation, and deregulating cellular 
energetics[3].  
The past three decades of research have yielded a better understanding of each of 
these traits and the mechanisms through which the malignant behavior is supported. In 
consequence, molecularly targeted therapies have emerged. These therapies were 
designed to interfere with a specific molecular target (typically a protein) associated with 
tumor growth and progression [5]. Various targeted therapies have been approved by the 
Food and Drug Administration (FDA) to treat specific types of cancer and many others 
are currently being studied. These therapies target growth factor receptors, signaling 
molecules, cell-cycle proteins, modulators of apoptosis and molecules involved in 
invasion and angiogenesis. To date, the more than 20 FDA-approved targeted therapies, 
which include monoclonal antibodies, fusion proteins and small molecules, have had 
substantial success in the market and their projected sales grow everyday [6].   
The small molecule kinase inhibitor imatinib mesylate (Gleevec) is an example of 
this success. Imatinib established a paradigm for treatment of tumors whose growth is 
dependent on specific kinase targets. It has shown remarkable clinical success for the 
treatment of myeloid leukemia and gastrointestinal stromal tumors [7]. Similarly, 
monoclonal antibody drugs like trastuzumab (Herceptin) have been shown in the clinic to 
effectively block the ability of HER-2 positive breast cancer cells to grow [8].  
In general, the main advantage of these molecular-targeted drugs lies in their 
highly specific action that, in principle, leads to relatively fewer off-target effects. 
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Currently, reported side effects of targeted therapeutics tend to be less severe than those 
of traditional chemotherapeutics [5]. Unfortunately, clinical responses to these drugs have 
been observed to be transitory and relapses are common. Experimental data suggests that 
this occurs because these drugs have been developed to target only one specific molecule, 
despite the fact that multiple signaling pathways control each hallmark capability. 
Therefore, the parallel nature of the signaling cascades allows cancer cells to recover and 
reestablish the hallmark trait through a pathway different than the one targeted by the 
drug [3]. Such considerations suggest that more effective therapeutics would require 
selective and simultaneous targeting of multiple pathways to prevent adaptive resistance. 
 
2-1-1 Molecular targets for breast cancer therapy 
Genetic alterations can affect one or multiple signaling pathways in tumor cells, 
but the precise identity of the pathways, level and type of alteration varies among cancer 
types. Several oncogenes, proteins and signaling pathways have been implicated in the 
development and progression of breast cancer. For example, the cell cycle progression 
regulator protein, Cyclin D1, and its binding partners have been found to affect cell 
migration, stem-like cell activity and breast cancer cell growth [9]. Half of triple-negative 
and inflammatory breast cancer cases overexpress EGFR [10] and 30% of all breast 
cancers cases overexpress HER-2 [8]. Vascular endothelial growth factor (VEGF) has 
been observed to be uniquely influenced by female sex steroid hormones to induce 
protumorigenic behavior [11]. Overexpression of cyclooxygenases (COX), c-Jun, c-Myc 
and matrix metalloproteinases was found to contribute to breast cancer development, cell 
proliferation and regulation of cell migration [12-15]. The nuclear factor–kappa B (NF-
κB) and mitogen activated protein kinase (MAPK) transduction pathways are at the 
center of multiple cellular processes and are related to several of these proteins and 
oncogenes known to promote and sustain breast cancer [16, 17]. 
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The NF-κB pathway controls expression of hundreds of human genes involved in 
key cellular processes such as innate immunity, inflammation, angiogenesis, proliferation 
and cell survival [18-20]. Mis-regulation of this signaling cascade, either by mutation or 
epigenetic mechanisms, has been observed in diseases associated with inflammation, 
immunodeficiency or cancer. NF-κB has been directly linked to cell cycle progression 
through cyclin D1, correlated to induction of growth promoter genes (such as c-Myc and 
c-Myb) and is considered a major apoptotic regulator [18, 19]. Aberrant sustained 
activation of NF-κB has been reported in multiple types of mammary tumors [19, 21] and 
has been considered a main target for breast cancer molecular therapy [22].  
NF-κB is an attractive molecular target for multiple reasons. Its anti-apoptotic 
properties abrogate the effectiveness of many chemotherapeutic agents, which have been 
shown to activate the pathway [19]. Furthermore, it has been established that cancer cells 
up-regulate or constitutively activate NF-κB as a protective mechanism. This abnormal 
activation, commonly found in breast cancer, leads to extensive angiogenesis, metastasis 
and can even confer resistance to cancer therapies [20, 23, 24]. For these reasons, NF-κB 
plays a main role in cancer cell survival. 
Although NF-κB is an attractive molecular target for treatment of breast cancer, 
inhibition of NF-κB alone can only induce limited cell death [17]. Therefore, it has been 
deemed necessary to inhibit additional pathways in order induce apoptosis, stop 
proliferation and block growth signaling [18, 23]. As previously mentioned, the MAPK 
signaling network has also been shown to be up-regulated in breast cancer cells and 
multiple oncogenes are known to be related to it [1, 25]. The MAPK signaling cascade is 
known to play a central role in cell growth, cycle, differentiation and proliferation; it also 
interferes in cell survival/death signaling and cross talks with NF-κB [26].  
The mammalian MAPK pathway consists of extracellular signal regulated kinases 
(ERK), p38 and stress-activated protein kinases (SAPK or JNK). Each of these kinases 
exists in several isoforms, and controls multiple cell processes. The activated ERK 
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pathway up-regulates MMP expression and prevents cancer cells from anoikis, another 
form of programmed cell death, providing cell protection and invasion capabilities [26]. 
The phosphorylated JNK pathway has been implicated in promoting cellular 
transformation through the oncogenes c-fos, c-Jun, Ras, Met and BCR-Abl [27]. High 
levels of JNK and c-Jun have been documented in breast cancer tumor cells [28]. There is 
little understanding on the role of p38 in tumorigenesis, but evidence suggests p38 might 
be a tumor suppressor [11].  
In summary, an effective molecularly targeted therapy for breast cancer requires 
inhibition of the NF-κB pathway to sensitize cells to apoptosis, but additional pathways 
must be targeted. The MAPK pathway is an ideal co-target and simultaneous inhibition of 
it could lead to induction of apoptosis, as well as prevention of metastasis and resistance.  
 
2-2 Molecular therapy of IBD 
Inflammatory bowel disease (IBD), which encompasses ulcerative colitis and 
Crohn’s disease, represents a lifelong chronic and debilitating inflammatory disorder of 
the intestinal tract. Though the precise pathogenesis of IBD remains to be elucidated, the 
prevailing theory supports an abnormal immune response to the complex commensal 
flora in the gut [29]. However, environmental factors, altered commensal intestinal 
bacteria and genetic susceptibility combined with disease-precipitating events have not 
been completely excluded [30].  
Evidence suggests that dysregulated immune responses strongly contribute to the 
progression of the disease. Activation of innate cells in the intestinal mucosa leads to 
overproduction of chemokines and proinflammatory cytokines that in turn activate further 
immune response [31]. This results in uncontrolled inflammation and intestinal tissue 
damage [32]. Downregulation of immune response and hence, decrease in production of 
proinflammatory cytokines has been shown to ameliorate IBD [33, 34]. Current 
nonsurgical IBD treatments involve immune or inflammatory suppression with local 5-
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aminosalicylate preparations, systemic corticosteroids or cytotoxic immunosuppressants, 
like azathioprine. However, only 50 % of patients achieve sustained remission [31], and 
these approaches are fraught with the complications of systemic immunosuppression and 
other toxicities[35, 36].  
Recently, therapies that target immune and inflammatory pathways have emerged 
as new treatments for IBD. These include vaccines, monoclonal antibodies (mAbs) and 
nanobodies against cytokines and cell trafficking, as well as small molecule agents that 
inhibit signaling pathways related to cytokine production and activity [37]. To date, 
several molecules have been studied and evaluated as molecular targets for IBD 
treatment.  
Since IBD is characterized by an imbalance in pro-inflammatory and inhibitory 
cytokines, with pro-inflammatory cytokines dominating, these have become the main 
target for therapy. Tumor necrosis factor α (TNF-α) is an important proinflammatory 
cytokine that has been correlated to the development of IBD. This cytokine is known to 
modulate immune cell proliferation, regulation of adhesion molecules and induction of 
apoptosis [31]. In addition, high levels of TNF-α have been found in intestinal tissue 
during active IBD and thus, it has become a prevalent target for IBD therapeutics. For 
over a decade, anti-TNF-α mAbs have been shown to be effective in counteracting cell 
mediated inflammatory damage [38]. Given their success, MAPK p38 and transcription 
blocking agents are also being studied for inhibition of TNF-α production. Interleukin-10 
(IL-10) and IL-11 are inhibitory cytokines whose deficiency is correlated to IBD. 
Delivery of these cytokines through different methods has been evaluated and shown to 
be beneficial for IBD patients [31].  
Other molecular targets are IL-17, interferon gamma (IFN-γ), IL-6 and IL-
12/23p40, which are inflammatory products of activated T cells and can direct 
development of inflammatory T cells that participate in the development and progression 
of IBD [39]. Furthermore, intercellular adhesion molecule-1 (ICAM-1), chemokine 
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receptor 9, α4β1 and α4β7 integrins have been studied and evaluated as targets for 
inhibition of lymphocyte trafficking. Unfortunately, while these strategies are based on 
biologic observations, in clinical applications patients are genetically diverse which leads 
to varied results.  
Despite these significant advances in therapeutic strategies, the need for effective 
therapeutics remains unmet. Since many of the receptors, chemokines and cytokines 
correlated to IBD are connected to the NF-κB and MAPK pathways, these have become 
interesting and more generalized targets for new molecular therapeutics. These two 
pathways are central to recruitment of immune cells in IBD and contribute to the 
pathology of the disease [40]. For this reason, simultaneous down-regulation of these 
pathways could lead to reduction of inflammation and immune response during IBD. 
 
2-3  Bacterial Effector Proteins 
Bacterial pathogens have evolved mechanisms to subvert and control normal 
cellular functions during infection. These pathogens produce a broad spectrum of proteins 
and enzymes capable of interfering with key signaling pathways, inhibiting protein 
synthesis, forming pores on cell membranes or activating the death machinery of host 
cells [41]. A single bacterial protein can attack multiple signaling pathways at several 
points, ensuring an override in important cellular functions [42]. These proteins, known 
as bacterial effectors, are secreted through diverse systems that have been classified in six 
distinct categories (types I-VI) [43].  
Many pathogenic bacteria have acquired sophisticated strategies to breach the cell 
membrane and deliver these effectors. Some Gram-negative bacterial pathogens such 
Escherichia coli, Salmonella, Yersinia, Vibrio and Shigella, use the type III secretion 
system (T3SS) to inject multiple effector proteins directly into the cytoplasm of host cells 
[44]. The T3SS is a needle-like organelle that spans both bacterial membranes and creates 
a pore in the membrane of host cells, through which semi-unfolded bacterial protein 
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effectors are translocated [45, 46]. In the bacteria, effector proteins are often silenced by 
keeping the protein in an unfolded state that is accomplished by association with a 
chaperone or lack of an activator substrate [47, 48]. In general, effectors remain in a 
quiescent state until they are translocated to the cytoplasm of the host [49].  
Once in the cytoplasm of the host cell, effectors bind to their activator substrate or 
separate from the chaperone that accompanied them, becoming active and able to alter 
the signaling circuitry [50]. Many protein effectors manipulate host cell processes by 
attenuating signaling mediated by post-translational modification of proteins [48]. Some 
effectors have been observed to interfere with phosphorylation cascades by mimicking 
the function of kinases and phosphatases [51]. Other effectors are known to interfere by 
ribosylating target molecules, preventing transfer of ubiquitin, or degrading signaling 
molecules [45, 48]. In order to accomplish complete subversion of host cells, bacterial 
pathogens inject an array of effectors that exert different actions. Together these effectors 
contribute to efficient immune system evasion and proliferation of the bacteria [45].  
Several bacterial protein effectors are known to specifically target the NF-κB and 
MAPK pathways that are central to the development and progression of breast cancer and 
IBD. One such effector is the acetyltransferase Yersinia outer protein J (YopJ), one of the 
six virulence factors used by Yersinia pestis the causal agent of plague. Two other 
Yersinia species, Yersinia pseudotuberculosis and Yersinia enterocolitica that are known 
to cause gastrointestinal disorders, produce a homologue effector protein called YopP 
[47, 52-54]. YopJ and YopP have been shown to inhibit innate immune response and 
selectively induce apoptosis by disrupting activation of ERK, JNK and p38 MAPK 
cascades, while simultaneously blocking the NF-κB pathway (Figure 2.1) [42, 45, 47, 53, 
55, 56].  
Studies on the mechanism of action used by YopJ have revealed that the protein 
downregulates MAPK signaling by acetylating serine and threonine residues of all MAP 
kinase kinases (MKKs) and thus, prevents phosphorylation required for activation of 
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these pathways [45, 50, 53]. Similarly, YopJ has been shown to inhibit the NF-κB 
pathway by acetylation of the serine and threonine residues on the activation loop of 
IKKβ, which prevents activation of the IKK complex and phosphorylation of IκB [52]. In 
addition, recent evidence suggests that YopJ may also have de-ubiquitinating activity, 
acting on TRAF6, TRAF2 and IκBα; and the capacity to hydrolyze the SUMO1 
ubiquitin-like protein [41, 43]. Furthermore, YopJ is likely capable of directly activating 
some, not yet identified, caspases to induce host cell death [41].  
 
Figure 2.1. Inactivation of MAPK and NF-κB signaling pathways by bacterial protein 
effectors: YopJ, AvrA and VopA. Effectors acetylate the serine and/or threonine residues 
of the kinase loops of MAPK signaling molecules preventing their phosphorylation. The 





It is predicted that YopJ uses a two-substrate, ping-pong mechanism to acetylate 
serine, lysine or threonine residues [47]. In this mechanism YopJ transfers the acetyl 
group from acetyl-CoA to the residue, forming an intermediate from which water is then 
removed to render the final product [48]. Further studies performed on YopJ/P structure 
and mechanism of action have identified the catalytic triad responsible for MAPK and 
NF-κB inhibition to be the histidine, cysteine and glutamate or aspartate residues located 
at positions 109, 172 and 128, respectively [54]. Mutations of the histidine or cysteine 
residues have been found to yield a version of YopJ (mYopJ) incapable of inhibiting 
MAPK and NF-κB activation [47, 54, 56]. Similarly, the acetyltransferase activity of 
YopJ depends on the availability of inositol hexakisphosphatase (IP6), which acts as an 
allosteric activator of enzymatic activity [50].  
Interestingly, YopJ has been found to induce death in some types of cells and not 
in others. For instance, neutrophils and endothelial cells have been found to be resistant 
to YopJ mediated apoptosis, whereas macrophages and dendritic cells are not [41, 57, 
58]. This indicates that the outcome of intervention with this effector is cell type 
dependent. It is plausible that pathogen-mediated delay or decreased apoptosis in certain 
cell types is the result of a relative required resolution of infection to facilitate Yersinia 
pathogenesis [58].  
Orthologs of YopJ are found in other enteric pathogens such as Vibrio 
parahemaly (VopA) [59] and Aeromonas salmonicida (AopP) [60]. Another member of 
this family is avirulence factor A (AvrA), an effector from Salmonella typhimurium [45]. 
AvrA has been shown to have potent and diverse effects on a wide variety of eukaryotic 
growth, survival and immune pathways [61]. Evidence has demonstrated that AvrA, 
when overexpressed in transfected cells[62] or in a Drosophila transgenic model[63], 
blocks activation of NF- κB, MAPK JNK, and transcriptional activation of a range of 
inflammatory effector genes. AvrA has been shown to acetylate MAPKK MKK4/7, 
accounting for the blockade of JNK activation [64]. This effector has also been shown to 
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inhibit NF- κB nuclear translocation, but the exact mechanisms remains to be elucidated 
[65]. Remarkably, AvrA-mediated signaling disruption in MAPK and NF-κB occurs without 
induction of the apoptotic cell death [66].  
Other examples of effectors that target the MAPK and NF-κB pathways are OspF 
and OspG (Figure 2.1). OspF is a Shigella effector protein that actively suppresses 
activation of MAPK, and indirectly blocks NF-κB activity. This effector directly 
dephosphorylates MKKs at the threonine residue and simultaneously removes a water 
molecule, leading to a modified threonine residue that cannot be re-phosphorylated [45, 
48]. OspG, also a Shigella effector, shares sequence similarity to mammalian 
serine/threonine protein kinases. This atypical kinase binds to ubiquitin, which activates 
its kinase activity and leads to attenuation of host innate NF-κB signaling [67]. 
In summary, bacterial effector proteins can hijack intracellular signaling of 
eukaryotic cells. The activity of these effectors is under tight regulation and has been 
proven to manipulate host processes efficiently and effectively. Thus, effector proteins 
are potent enzymes that could be used to induce cell death in breast cancer cell and 
reduce inflammatory signals in IBD.  
 
2-4 Delivery of Therapeutic Proteins 
In the past few decades, the potential of protein-based therapeutics has been 
recognized. Many protein drugs have been approved and successfully used in the clinic, 
and significantly more are under investigation. Their research, production and market 
have grown significantly in the past years and are expected to continue growing [68].  
The shift towards biological drugs is the result of their specific recognition of 
targets and better mimicking of the complex cellular processes and functions [68, 69]. 
However, protein drugs pose multiple challenges due to their complexity and fragility, in 
terms of production, storage and administration. Therapeutic proteins are required to have 
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high chemical and conformational purity, good stability and a shelf-life of 18-24 months 
for economic viability [69].  
The main challenges involved in the successful application of proteins as 
therapeutic agents are related to their administration, due to relatively low stability and 
short in vivo half-life. Multiple studies have been conducted on improving protein half-
life and preventing early denaturation. Protein engineering has produced multiple options 
to increase stability. Some examples are chemical changes such as PEGylation or 
glycosylation, genetic engineering-rational design in which some residues are changed to 
increase activity or stability, and the creation of fusion proteins to improve the properties 
of the protein [68, 70, 71].  
However, these strategies are not enough for effective intracellular-targeted 
protein drug delivery. At a cellular level, the delivery of macromolecules in vivo is 
hindered by their three-dimensional structure, size and hydrophobicity, as well as 
degradation due to the presence of enzymes and proteases [72, 73]. These factors cause 
proteins to be fragile and highly vulnerable and hence, their delivery in a carrier is an 
ideal option. Drug delivery vehicles not only offer protection for the protein but also 
show several other advantages, such as controlled release, improved biodistribution and 
targeting capabilities. The current methods and developments for peptide and protein 
delivery include the use of liposomes, polymer particles and protein capsules [72-76].  
Although there are multiple protein drug formulations on the market for cancer 
and IBD therapy, there are no examples of therapeutic protein delivery in nanoparticles. 
Nonetheless, there are multiple examples of small molecule drug delivery in nanoparticle 
formulations. Common chemotherapeutic agents such as doxorubicin and daunorubicin 
have been encapsulated in liposomal vehicles, which are now commercially available 
under the names of Caelyx®/Doxil® and DaunoXome®. However, few formulations of 
protein drugs in liposomal carriers have been proposed and analyzed for cancer and IBD 
therapy. One attempt to use liposomes to deliver pro-apoptotic membrane proteins to 
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human colorectal carcinoma cells was successfully carried out in vitro [77]. Other 
examples of therapeutic protein delivery have recently become available. For instance, 
perfluorocarbon nanoparticles have been studied for the delivery of the Nemo binding 
domain peptide for controlling NF-κB signaling in cancer and inflammation [75]. 
Hydrophobically modified glycol chitosan has been used to deliver RGD peptides with 
anti-angiogenic properties to solid tumor models [72]. Schluep et al. conjugated a thyol 
derivate of tubulysin, a powerful antiproliferative and apoptosis inducer peptide, to a β-
cyclodextrin based polymer and produced nanoparticles [78]. These drug carriers were 
effective in transporting their cargo inside target cells and showed equal or greater 
efficacy to that of conventional small drugs, but with reduced off-target toxicity.  
Despite the success demonstrated by some of the developed protein and peptide 
carriers, significant limitations remain [72]. Future protein and peptide delivery vehicles 
should have: (1) safety and biocompatibility of the carrier, (2) high encapsulation 
efficiency, (3) high retention of protein bioactivity, (4) simple and reproducible 
production, (5) easy administration options, (6) economic feasibility, (7) controlled 
release profiles, (8) long circulation times and (9) biodegradability. Protein nanoparticles 
are a feasible alternative that can offer many of these requirements. Particles derived 
from proteins are biodegradable, metabolizable, and due to the primary structure of these 
macromolecules, offer multiple possibilities for the conjugation of drugs, imaging agents 
or peptides [79, 80]. To date, two main groups of protein nanoparticles are being studied 
and developed, self-assembled structures and desolvated particles. Self-assembled 
structures, are naturally occurring, functional macromolecular assemblies that can be 
manipulated for biomedical applications [81]. An example is the dodecahedral protein 
cage formed by the dihydrolipolyl acyltransferase (E2) subunit from pyruvate 
dehydrogenase which has been engineered to  encapsulate doxorubicin [81]. Other 
examples of self-assembled delivery vehicles are elastin polypeptide (ELP) particles that 
have been developed to encapsulate small molecules, peptides, cytokines and proteins for 
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extracellular delivery. In vivo delivery of keratinocyte growth factor was accomplished 
by fusing the growth factor to ELPs and inducing thermoresponsive self-assembly into 
~240 nm particles[82]. Other thermoresponsive ELP particles have been used to 
physically encapsulate and deliver bioactive bone morphogenetic proteins [83] The main 
advantage of this type of protein nanoparticles is simplicity of production and 
reproducibility of their properties.  
Desolvated protein particles are produced by adding a desolvent to a protein 
solution while stirring. This method produces wider particle size distributions than self-
assembly but offers the possibility of tuning particle size and properties [84]. In addition, 
particles produced by this method require stabilization through covalent cross-linking of 
the proteins [79]. Multiple studies have been conducted on the production and 
optimization of protein nanoparticles made of human serum albumin (HSA), bovine 
serum albumin (BSA) and gelatin [79, 84-86]. Particle size has been found to depend on 
the amount of desolvation agent used, initial protein solution concentration, pH and 
temperature [87].  
Most protein particles are studied for intracellular delivery of small molecule 
drugs [81, 85, 86, 88-91] though a few protein drugs have been investigated [92, 93]. An 
example of a commercially available product based on protein particles for small 
molecule drug delivery is the 130 nm albumin bound-paclitaxel (Abraxane®), approved 
by the FDA in January 2005 for the treatment of metastatic breast cancer. Some proteins 
and enzymes have also been encapsulated in albumin microspheres [94, 95] or 
crystallized and cross-linked aggregates [96, 97] but the large size of these particles 
hinders efficient delivery and intracellular uptake. BSA particles have also been used to 
encapsulate and deliver BMP-2, but particles were stabilized with a polymeric coating 
and did not require cellular internalization [81, 98]. Recently, particles made directly with 
glucose oxidase have been shown to be more efficient as biosensors than immobilized 
enzyme on the surface of gold nanoparticles [99]. This suggests that proteins in protein 
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particles can retain activity, but more studies on the production of protein particles for 
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3CHAPTER 3: PRODUCTION OF PROTEIN EFFECTORS 
 
 
During the course of their interaction with host cells, bacterial pathogens inject a 
wide variety of bacterial protein effectors that modulate eukaryotic signaling cascades 
[1]. These effectors regulate or mimic host proteins involved in signaling transduction 
[2]. Some effectors, like YopJ and AvrA, attenuate signaling mediated by post-translation 
modifications. YopJ and AvrA, are known to acetylate the serine/threonine residues that 
need to be phosphorylated for the MAPK and NF-κB pathways to be activated [3]. 
Interestingly, while inside the pathogen these effectors remain quiescent due to a lack of 
substrate or coactivator, or through binding to a bacterial chaperone [1]. YopJ and AvrA 
have been found to bind to IP6 a cofactor present in eukaryotic cells that is necessary for 
full acetyltransferase activity [4].  
Though the effect, secretion and mechanism of action of these effectors in the 
native pathogen and eukaryotic cells have been extensively studied, bacterial delivery of 
effectors for therapeutic purposes is not an option. In this Chapter recombinant 
techniques are used to produce the candidate effectors and create protein nanoparticles 
for their delivery. Recombinant production of YopJ and AvrA is not trivial and requires 
fusion to GST. Protein expression and purification are optimized and finally, recombinant 
effector proteins are characterized.  
  
3-1 Experimental Methods 
3-1-1 Cloning 
YopJ, mYopJ, AvrA and mAvrA genes were a kind gift of Dr. Andrew Neish. 






YopJ and mYopJ: 
  5’-TCATGAATTCCCATGATCGGACCAATATCACAAATAA 
ATATCTCCG-3’ and 5’-GCTGAATATAAAACACTTCTCAAAGTACATCACCATC 
ACCATCACTAAGGGTCGACTCAGGA-3’  
 
AvrA and mAvrA: 





Amplified genes were inserted into the bacterial expression plasmid pGEX-4T-2 
(GE Lifesciences) between HindIII and SacI sites for YopJ and between SalI and EcoRI 
sites for AvrA. Since pGEX-4T-2 does not encode a 6xHis tag, the reverse primer was 
designed to introduce it. All constructs were confirmed by DNA sequencing and final 
sequences are presented below. eGFP and mRFP genes did not require cloning, as they 
were already in a bacterial expression plasmid. Both genes were in a pPROTet plasmid 
(Clontech Labs) and were a kind gift of Dr. Andreas Bommarius. 
 
3-1-2 Protein expression and purification 
Expression of YopJ-GST, mYopJ-GST, AvrA-GST, mAvrA-GST and eGFP was 
performed in BL21 Escherichia Coli. Bacterial cultures were grown to O.D. 0.7 at 37°C 
and GST fusions were induced with 0.4 mM isopropyl β-D-thiogalactoside (IPTG) at 
25°C for 4 hours, while eGFP was not induced and grown at 37°C. AvrA-GST, mAvrA-
GST and eGFP proteins were purified on Ni-NTA agarose (Qiagen) following 
manufacturer’s native purification protocols in imidazole-containing buffers. YopJ-GST 
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and mYopJ-GST protein were also purified on Ni-NTA agarose following the 
manufacturer’s denaturing purification protocol. Purified proteins were buffer exchanged 
using 10K MWCO centrifugal ultrafiltration devices (Millipore) into PBS buffer (10 mM 
NaH2PO4, 137 mM NaCl, 2.7 mM KCl, 2 mM KH2PO4; pH 7.4) or 2X PBS + 5% 




3-2 Recombinant production on YopJ and AvrA 
Recombinant production of YopJ and AvrA in E. coli required fusion to GST. 
The AvrA and YopJ genes were initially cloned into pET101/D-TOPO® and pQE80 
plasmids, but recombination occurred and the effectors were not expressed. The observed 
gene instability, bacterial cell death during expression and difficulties during the cloning 
procedures are indicative of protein toxicity. This was somewhat surprising because YopJ 
and AvrA have been shown to acetylate the Ser/Thr loop of eukaryotic kinases and E. 
coli does not have eukaryotic-like protein kinase genes [5, 6]. However, 
phosphoproteomic studies revealed that E. coli has substrates for Ser/Thr 
phosphorylation[7]. Thus, it is likely that interference of YopJ and AvrA with 
phosphorylation processes could have caused the observed toxicity.  
To overcome this challenge YopJ and AvrA were cloned as fusions to GST, a 
common tag used to decrease protein toxicity and increase protein solubility, in a PGEX-
4T-2 plasmid (GE Lifesciences). The resulting YopJ and AvrA fusion proteins were 
expressed as described in section 1-1-2. To determine whether YopJ-GST and AvrA-GST 
fusions were expressed, total cell extract and nickel purified protein were analyzed using 
SDS-PAGE and western blot (Figure 3.1). The expected ~60-kDa bands were present and 





Figure 3.1. Purity of Ni-NTA purified recombinant fusion proteins. (A) Representative 
SDS-PAGE gel for YopJ-GST and mYopJ-GST. Lane 1 is protein standard, lane 2 YopJ-
GST and lane 3 mYopJ-GST. (B) Representative western blot showing anti-5xHis 
antibody recognition of the bands observed in the gel, indicating they are (m)YopJ-GST. 
Two bands are observed, one at the expected molecular weight (60 KDa) and the second 
one at lower molecular weight. The second band is the result of protein degradation from 
the GST terminus, leaving a protein containing the entire (m)YopJ sequence and part of 
the GST sequence.  
 
3-3 Solubility and stability of AvrA-GST and YopJ-GST proteins 
Produced and purified YopJ-GST and AvrA-GST proteins formed large protein 
aggregates when dialyzed or diafiltrated into saline buffers. Since particle production via 
the desolvation method requires the use of soluble protein, multiple studies were 
performed on protein solubility and stabilization methods. 
3-3-1 AvrA-GST 
AvrA-GST proteins were initially purified using denaturing methods and severe 
protein aggregation was observed when proteins were transferred to non-denaturing 
saline buffers or water. In order to prevent aggregation of the protein, several purification 
and dialysis techniques were tested. Purification of AvrA-GST under native conditions, 
 34 
 
in Ni-NTA or glutathione sepharose resins, yielded soluble protein and no visible 
aggregation when buffers were exchanged in diafiltration devices or dialysis. However, 
AvrA-GST was found to have a maximum solubility of ~1 mg/ml. Concentrations above 
1 mg/ml led to protein aggregation and precipitation, as measured by DLS. Increases in 
salt concentrations and addition of detergents and dextrose did not appear to significantly 
affect the solubility of the protein, measured by optical density. 
3-3-2 YopJ-GST 
Native purification of YopJ-GST yielded < 1 mg pure protein per liter of bacterial 
expression, but this protein aggregated irreversibly during storage, dialysis or 
diafiltration. Denaturing purifications yielded ~4 mg of pure protein per liter of bacterial 
expression. Nonetheless, YopJ-GST proteins were not soluble in urea buffers. Analysis of 
elutions in native electrophoresis gels and western blots revealed the presence aggregates, 
visible as long smears of protein (Figure 3.2).  
With the purpose of solubilizing YopJ-GST, the purified protein was dialyzed into 
water and lyophilized. Several buffers, acids, bases and organic solvents, listed in Table 
1, were tested for protein resolubilization.YopJ-GST lyophilized proteins were found to 
form stable 100 nm diameter protein-aggregate nanoparticle suspensions in 2X PBS +5% 
dextrose and DMSO. Small 100 nm protein-aggregate nanoparticles and large micron-
sized aggregates were the result of re-suspension in acetonitrile, 1% Tween-80, 
chloroform and saline solutions at pH values between 3 and 10. YopJ-GST lyophilized 
proteins did not dissolve or re-suspend in toluene, ethyl acetate, acetone, ethanol or 
glycerol.  
Since protein folding and conformation can be affected by the environment, YopJ 
bioactivity in 100 nm protein-aggregate nanoparticles in DMSO and 2X PBS + 5 % 
dextrose was tested by studying the effect of these nanoparticles on cancer cell viability. 
Particles suspended in DMSO were not cytotoxic to SKBR-3 cells, while particles in 2X 
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PBS + 5% dextrose were highly cytotoxic (Chapter 6) to the same cells. Thus, all further 




Figure 3.2. Western Blot of a native protein electrophoresis gel. YopJ and mYopJ are 
observed in the upper section in which smears of these proteins are visible. Smears 
indicate the presence of proteins of different sizes or aggregates of proteins. We used as 
controls mCherry and eGFP which are proteins with high solubilities, these can be 
observed in the lower section in which spots of protein are visible.  
 
Next, direct dialysis and diafiltration into 2X PBS + 5% dextrose buffer was 
studied. Dialysis of denatured YopJ-GST nanoparticles into the buffer led to particle 
aggregation but diafiltration yielded a uniform suspension of the particles. Since these 
observations suggest that particle aggregation occurs during slow buffer exchange the 
rate of exchange via diafiltration was optimized. For this purpose, equal amounts of 
YopJ-GST in 8M urea were diafiltrated at two different rates. A slow rate, in which the 
buffer was changed in eight steps and a rapid one in which the buffer was exchanged in 
three steps. This difference was accomplished by varying the volume of added 2X PBS + 
5% dextrose at each step relative to the initial volume of protein solution; rapid 
diafiltration was performed at a ratio of 5:1 and slow diafiltration at a ratio of 2:1.  
Interestingly, slower diafiltrations yielded higher final average concentrations of total 
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protein (0.360 mg/ml) and less particle aggregation than fast diafiltrations. More 
importantly, faster diafiltration processes lead particles that exhibit 60-75% higher 
cytotoxicity in SKBR-3 cancer cells.  
 
 
3-4 GST removal 
In order to evaluate the effect of GST on YopJ-GST nanoparticle stability and its 
effect on the biochemical function of YopJ, GST was cleaved from the fusion using 
thrombin. pGEX-4T-2 vectors encode the recognition sequence for site-specific cleavage 
by thrombin between the GST domain and the multiple cloning site, thus allowing 
cleavage of YopJ from GST. For this purpose, bacterial lysates for YopJ-GST and 
mYopJ-GST expressions were purified in Ni-NTA resins under denaturing conditions but 
purified proteins were not eluted. Instead the purified proteins were washed several times 
with PBS and then incubated for 16 hours with thrombin, as indicated by the 
manufacturer’s instructions. GST and thrombin were removed by washing the resin 
several times with PBS and then YopJ proteins were eluted either in native or denaturing 
buffers. 
Western blot analysis of these elutions demonstrated that GST was cleaved from 
the majority of the YopJ proteins (Figure 3.3). Nonetheless, YopJ proteins did not remain 
soluble in either native or denaturing buffers and large aggregates were visible in the 
elutions after 12 hours of storage. Analysis of the supernatants indicated that YopJ had 
precipitated into large fiber-like aggregates that were attached to the tube wall. These 










Figure 3.3.  Results of digest reaction for YopJ and mYopJ with thrombin. Western Blot 
image of purified and cleaved YopJ using penta-HIS antibody. Notice in the western blot 
image that most of the protein has been cleaved but small amounts remain as full length 
fusion protein. Native (nat) and denaturing (denat) elutions were performed.  
 
3-5 Summary 
The results presented in this chapter illustrate the feasibility of recombinant 
production of bacterial effector protein, and highlights the need for GST fusion in protein 
production and YopJ-GST nanoparticle stability. Chapters 4 and 5 will describe the 
application of bacterial effector proteins and particle production methods for delivery of 
YopJ and AvrA in two different disease models. 
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Enzyme therapeutics offer multiple advantages over small molecule drugs, but 
require modification, encapsulation or immobilization on biocompatible matrices to 
improve their stability and limited distribution, promote activity retention and decrease 
immunogenicity [1-3]. The desolvation method, which has been extensively 
characterized for particle production with serum albumin and gelatin [4-8], is modified 
and studied for the production of enzyme nanoparticles. β-galactosidase (β-gal), a 
hydrolase homo-tetramer, is used as a model enzyme. Hydrolysis of ortho-nitrophenyl-D-
galactopyranoside (ONPG) is used to quantify β-gal enzymatic activity and pure enzyme 
nanoparticles are shown to retain only 25% of enzymatic activity. Therefore, bovine 
serum albumin (BSA) and enhanced green fluorescent protein (eGFP) are studied as 
enzyme carriers.  
Effective internalization of nanoparticles depends on particle size, shape and 
surface charge.  Nanoparticle size control is studied with the pure carrier proteins by 
varying the cross-linker type, cross-linking time, NaCl concentration, imidazole 
concentration and desolvation agent. Particle size is shown to be sensitive only to the 
type of cross-linker, cross-linking time, and the presence of imidazole. Using these 
results, a series of β-gal+eGFP nanoparticles are prepared under different conditions and 
enzymatic activity, particle size and enzyme delivery are characterized. Evidence 
indicates that the type of cross-linker affects size but not enzymatic activity and cross-
linking time affects both factors. Flow cytometry, microscopy, ONPG hydrolysis and 
western blot are used to evaluate the performance of the different cross-linkers and 
formulations. In multiple cell types, enzyme delivery via nanoparticles is shown to be 
                                                
a Material from this section has been published.91 
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greater than for soluble protein. Finally, successful intracellular delivery of active 
enzyme is achieved in vitro and the potential of protein nanoparticles as therapeutic 
enzyme drug carriers is demonstrated. 
 
4-1 Experimental details 
4-1-1 Particle preparation 
Protein particles were prepared by the desolvation technique as described by 
Weber et al. [4]. The desolvation method was modified to decrease the initial protein 
concentration from 50-200 mg/ml to <10 mg/ml while keeping particle diameter below 
300 nm. This was done because the solubility of effector proteins and other enzymes is 
not as high as that of BSA and gelatin, which are the most common proteins used for 
desolvation. Particles presented in this chapter were prepared using BSA (fraction V, 
purity 99%, Sigma), β-gal (from E. Coli, lyophilized powder > 500 U/g, Sigma) and 
eGFP produced in E. coli and purified under native conditions using Ni-NTA (Qiagen), 
as explained in Chapter 3.  
In general, 2-10 mg of protein or enzyme was dissolved per ml of water, 150 mM 
NaCl solution (pH 8) or imidazole solution (250 mM imidazole, 300 mM NaCl, 50 mM 
NaH2PO4; pH 8). Particles that combine eGFP and β-gal were prepared with a molar ratio 
of 1:24 β-galactosidase to eGFP. 100 µl of protein solution are placed in a small glass 
vial with a magnetic microspin bar (flea) and placed on a hot plate magnetic stirrer at 
25°C and 650 rpm. The protein solution was desolvated by continuous, drop-by-drop 
addition of 400 µl of ethanol or acetone at a rate of 1 ml/min, using a syringe pump. 
Immediately after desolvation, the cross-linker was added at a ratio of cross-linker to 
lysines of 1:2.2. Three different cross-linkers were used: glutaraldehyde (GTA)(8% 
solution, Sigma-Aldrich), 3,3´-Dithiobis(sulfosuccinimidylpropionate) (DTSSP) (Pierce) 
and bis(sulfosuc-cinimidyl)suberate (BS3)(Pierce). All cross-linkers were dissolved or 
diluted in water and 60 µl of solution were added to the desolvated protein suspension.  
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After 10 min to 2 h of stirring, the cross-linking reaction was stopped by 
transferring the particle suspension to a 2 ml centrifuge tube, centrifuging at 1000 g for 1 
min and removing the supernatant. Particles were re-suspended in phosphate buffered 
saline (PBS, 10 mM NaH2PO4, 137 mM NaCl, 2.7 mM KCl, 2 mM KH2PO4; pH 7.4) and 
sonicated on ice for 1s every 15 s at 30% amplitude, for a total of 5 minutes.  
Particle supernatant was stored for analysis and particles were characterized 
within the next few hours. To determine the yield, the amount of protein that was not 
precipitated during the desolvation process was measured using a BCA protein assay 
(Pierce). 
4-1-2 Determination of particle size and zeta potential 
Particle size distribution was measured by dynamic light scattering using a 
Zetasizer Nano ZS90 (Malvern Instruments Ltd). The samples were measured at 25°C 
and a scattering angle of 90°. Average particle size was calculated as the arithmetic mean 
of the distribution of at least 3 batches of particles and the standard deviation was 
calculated as the variance between average diameters of the batches. Number 
distributions were used to describe particle size in order to remove artifacts and 
additional peaks caused by the presence of aggregates, that due to their size obscure the 
main population. Nonetheless, in all cases the main population peak in number 
distribution was observed to match the peak for the main population in intensity 
distribution.  
The zeta potential of the particles was determined by measuring the 
electrophoretic mobility of the nanoparticles using the same instrument. Zeta potentials 
were measured in PBS and 10 mM HEPES buffer, which provided information about the 
intrinsic surface charge and the surface charge once biologically relevant ions have 
adsorbed to the particles. Average particle zeta potential was calculated as the arithmetic 
mean of the distribution of at least 3 batches of particles and the standard deviation was 
calculated as the variance between average zeta potential of the batches 
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4-1-3 Determination of β-gal activity 
The activity of β-gal was measured by quantification of the hydrolysis of ortho-
nitrophenyl-D-galactopyranoside (ONPG) using a colorimetric β-Gal Assay Kit 
(Invitrogen). Activity in particles was measured by diluting the particles to a final 
concentration of 0.5 ng/ml of β-gal and analyzing according to the instructions for the kit. 
β-gal activity in nanoparticles was compared to measured activity of the equivalent 
concentration of β-gal in solution.  
For quantification of the activity of β-gal in cells, HeLa and 3T3 cells were 
seeded at a density of 1x104 per well in a 96-well plate in their growth medium. After 16 
h the cells were incubated with particles (87.5 ng/ml) in growth medium for 6 h. The cells 
were washed five times with PBS, then lysed and assayed following the kit instructions.  
4-1-4 Determination of eGFP nanoparticle fluorescence  
The effect of particle fabrication and the different cross-linkers on eGFP 
fluorescence was quantified by measuring the fluorescence intensity of eGFP before 
(soluble) and after (nanoparticles) desolvation and cross-linking. Equal amounts of 
nanoparticles and soluble eGFP, at the same concentration, were placed in a 96-well 
plate. Fluorescence intensity was measured in a synergy H4 multi-mode microplate 
reader (Bio-Tek), using filter set 1 with an excitation wavelength of 485 nm and emission 
wavelength of 528 nm, with optics set at the bottom, 50% gain and read height of 4 mm. 
4-1-5 Cell Culture  
HeLa, SK-BR-3 and NIH/3T3 cells were purchased from the American Type 
Culture Collection (ATCC). All cells were cultured following ATCC protocols and in the 
recommended growth medium. HeLa cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) and supplemented with 10% (v/v) fetal bovine serum (FBS). SK-BR-3 
cells were grown in McCoy 5A Media and supplemented with 10% FBS. 3T3 cells were 
cultured in DMEM and supplemented with 10% calf serum. All media and serum was 
purchased from Cellgro, Mediatech and supplemented with 1% (v/v) 
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penicillin/streptomycin. Cells were incubated at 37°C in a 5% CO2 humidified 
atmosphere.  
Cells used in this work were passaged at 80-90% confluency and following 
ATCC protocols. Cells used for experiments were passaged at least two times before use 
and did not exceed passage number 20. Cell morphology and normal behavior were 
verified before use. 
4-1-6 Cellular internalization of nanoparticles 
Uptake of particles was assessed by flow cytometry and confocal microscopy. For 
flowcytometry, HeLa, SK-BR-3 and 3T3 cells were seeded at a density of 2.5x105 per 
well in a 24-well plate in complete growth medium. After 16 h the media was changed 
and cells were incubated with particles (71 ng/ml eGFP or 87.5 ng/ml eGFP+β-gal) in 
complete growth medium for 6 h. After this period the cells were washed twice with 
PBS, trypsinized, and collected in 1.7 ml tubes. Cells were washed twice more by 
centrifugation (500 rpm for 5 min) in PBS, re-suspended in PBS, filtered with a 35 µm 
cell strainer and placed on ice. The cells were immediately analyzed in an Accuri C6 
(Becton Dickinson and Company) flow cytometer and relative particle uptake was 
quantified as the ratio of mean fluorescence of the sample population to mean 
fluorescence of the control population (no particles given).  
To ensure the observed fluorescence increase corresponded to internalized 
particles and not surface binding, 4°C controls were performed. For this purpose cells 
were seeded and incubated as previously described. But after cell attachment the media 
was changed and cells were incubated at 4°C for 1h to ensure cell and media temperature 
was low before exposure to the particles. Following this, 71 ng/ml eGFP or 87.5 ng/ml 
eGFP+β-gal particles were added and incubated for 6 h at 4°C. The cells were prepared 
and analyzed as previously described. 
For confocal microscopy, HeLa cells were seeded at a density of 1.5x104 cells per 
well in an 8-well chamber slide system (Nunc LabTek II, Thermo Scientific) with 
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complete growth medium. After 16-24 hours, cells were incubated with 87.5 ng/ml 
eGFP+β-gal nanoparticles or soluble protein in complete growth medium for 6 hours. 
Following incubation, cells were washed three times with PBS and fixed in 3.7% 
paraformaldehyde for 15 min at room temperature. Cells were rinsed three times in PBS 
and incubated with Hoechst (Anaspec Inc.) and 0.165 µM rhodamine phalloidin 
(Biotium) in blocking buffer for 20 min at room temperature. Cells were washed three 
times with PBS and mounted for imaging in a Zeiss LSM 700 confocal microscope. All 
images were captured using the same settings. 
4-1-7 Particle break-up in cell lysate and in vitro 
The effect of the cross-linking agent on particle break-up was studied by 
incubating eGFP nanoparticles in HeLa cell lysate for different periods of time, from 0 to 
30 minutes. Particle degradation was analyzed by Western blot. For this purpose, 3 x 106 
HeLa cells were lysed in 0.5 ml of NP-40 buffer (150 mM NaCl, 1% NP-40 and 50 mM 
Tris-HCl at pH=8). Particles were incubated in equal volume of cell lysate for the 
specified period of time and immediately loaded on a 10% SDS-PAGE gel, using native 
loading buffer (25% glycerol, 62.5 mM Tris-HCl). A SeeBlue Plus2 (Thermo Scientific) 
pre-stained standard was loaded for reference and gels were run at 135 V for 2.5 h. After 
this, the proteins were transferred to nitrocellulose membranes at 400 mA for 35 min. 
Next, the membranes were imaged using the blue laser and Alexa 488 filter in a Typhoon 
(GE Healthcare Life Sciences).  
Similarly, the effect of cross-linker on β-gal release in cells was studied by 
incubating confluent monolayers of HeLa cells in 24-well plates with 650 µg/ml 
eGFP+β-gal nanoparticles (particles used for this assay contained 1:5 molar ratio β-
gal:eGFP) for 6 h. Particle degradation was analyzed by Western blot, using 80µl of NP-
40 buffer per well to lyse the cells and followed the protocol described above. This time, 
after transfer, the membranes were blocked with 5% milk in PBS-T for 1 h and washed 3 
times for five minutes each time with PBS-T. Next, membranes were incubated with anti 
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β-gal and anti β-actin antibodies (Abcam) overnight at 4°C. After 16h, the membranes 
were washed as previously described with PBS-T, incubated for 1h with HRP-
chemiluminescent secondary antibodies at room temperature, washed and imaged 
according to the manufacturer’s instructions. 
4-1-8 Statistical analysis 
All quantitative experiments were triplicated (N=3) and presented as arithmetic 
mean ± standard deviation. One-way analysis of variance (ANOVA) was used to 
determine significance among groups, using StatPlus. P values <0.05 among groups were 
considered statistically significant. 
 
4-2 Pure enzyme nanoparticles 
With the aim of understanding and optimizing the production of enzyme 
nanoparticles, β-gal and lysozyme were used as model enzymes and particles were 
produced from pure enzyme. β-gal was desolvated with ethanol and cross-linked with 
DTSSP for 2h. The produced particles were relatively large (402 ± 138 nm in diameter) 
and retained only 25% of the enzymatic activity, compared to soluble β-gal. These results 
indicate, not unexpectedly, that β-gal is highly sensitive to the particle formation process. 
During the particle production the enzymes are desolvated in ethanol and then cross-
linked, which can induce changes in the folded structure of the molecules. β-gal is only 
active as a tetramer and loss of either quaternary or tertiary structure will lead to activity 
loss.  
Lysozyme particles were produced following the same protocol used for the 
fabrication of β-gal nanoparticles. Resulting particles were 1-1.6 µm in diameter, ~3-4 
times larger than pure β-gal particles. Particle diameter was observed to decrease up to 
25% when NaCl concentration in the initial protein solution was increased and when 
acetone was used a desolvation agent, instead of ethanol. Greater than 95% enzymatic 
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activity was lost during particle fabrication. Due to the large particle size and loss of 
activity, lysozyme was no longer studied as a model enzyme. 
In literature, there are examples of pure enzyme microparticles produced by 
protein crystallization and posterior cross-linking of these [9, 10]. Proper crystallization 
methods prevent structural damage and thus, prevent activity loss. However, the large 
size of protein crystals (>1 µm) leads to large micron-size particles, which hinders 
efficient delivery and intracellular uptake. Considering that a protein environment may 
also help alleviate activity loss, albumin protein particles have been used to encapsulate a 
few active proteins and enzymes [11-13]. However, most of these particles are micron-
sized and hence, are not suitable for intracellular delivery. Thus, the incorporation of a 
carrier protein was henceforth used to reduce activity loss.  
 
4-3 Optimization of carrier protein nanoparticle   
The production of protein particles with BSA is well established, making it a good 
carrier candidate for enzyme-protein particle production [5, 14]. Reproducible BSA 
nanoparticles have been fabricated with high protein concentrations (> 50 mg/ml), which 
are ideal for encapsulation of small molecules. However, many proteins and enzymes 
often have a lower solubility than BSA and therefore, it was desirable to work at low 
carrier protein concentrations that could yield higher therapeutic enzyme to carrier ratios. 
For this purpose, it was necessary to optimize the desolvation method for the production 
of small nanoparticles with low protein concentrations (< 10mg/ml). 
Different concentrations of BSA in PBS, ranging from 2-10 mg/ml, were tested 
for particle fabrication using ethanol as a desolvation agent and DTSSP as a cross-linker. 
Particle size was observed to depend on protein concentration and varied between 100-
500 nm; low concentrations produced larger particles (400-500 nm) and wider size 
distributions, whereas concentrations higher than 6 mg/ml produced reproducible small 
nanoparticles (< 200 nm). Nonetheless, desolvation of BSA always produced a 
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population of aggregates (> 5 µm). Varying the desolvation agent, ratio of protein volume 
to desolvation agent volume, type of cross-linker, cross-linking time and sonication 
method were not enough to prevent the formation of such aggregates. 
Due to the challenge of BSA particle aggregates and with the purpose of 
facilitating cellular uptake measurements and tracking of particle internalization, 
fluorescent proteins were chosen as protein carrier candidates. Green fluorescent protein 
(GFP), enhanced green fluorescent protein (eGFP) and mCherry were tested and eGFP 
was identified as the best candidate. eGFP consistently produced small (< 300 nm 
diameter) and highly fluorescent nanoparticles, at concentrations as low as 6 mg/ml, 
whereas GFP produced nanoparticles with low fluorescence. mCherry did not produce 
stable nanoparticles when cross-linked with GTA or DTTSP.  
The following sections will present the effect of various desolvation fabrication 
parameters on carrier particle properties. 
4-3-1 Effect of desolvation agent  
Particle production via the desolvation method depends on the ability of the 
desolvation agent to induce protein precipitation. Two common desolvation agents, 
ethanol and acetone, were studied. Carrier proteins were desolvated at a ratio of 1:4 
protein solution to desolvation agent volume and cross-linked with DTSSP for 2 hours. 
No significant difference in average particle diameter or size distribution was observed 
between ethanol and acetone, for eGFP or BSA carrier proteins (Figure 4.1). Therefore, 




Figure 4.1. Effect of desolvation agent on the size of protein nanoparticles made with 
eGFP and BSA, at 1:4 protein solution to desolvation agent ratio and cross-linked with 
DTSSP for 2 h. There is no significant difference in measured particle diameters. 
 
4-3-2 Effect of NaCl on nanoparticle fabrication 
The desolvation process was hypothesized to be the result of a balance between 
protein solubility, salt type and concentration, and the amount of desolvant that is added. 
In order to establish the effect of salt content, the concentration of sodium chloride in the 
starting protein solution was varied. In all cases the protein concentration was kept at 6 
mg/ml and the amount of ethanol added was 4 times the volume of the initial protein 
solution. The presence of NaCl, as an additive, at low protein concentrations (<10mg/ml) 
was observed to be a critical factor for the production of particles. In the absence of NaCl 
the protein did not precipitate, which indicates that at such protein concentrations the 
contribution of salting-in and salting-out effects is important for particle formation. Wang 
et al.[13] showed that increasing the concentration of protein leads to formation of 
smaller nanoparticles. This is presumed to be the result of increased nucleation of the 
protein upon exposure to the desolvation agent. The low concentrations of proteins used 
in this work may delay or prevent the nucleation process and thus lead to the absence of 





















initial protein solution concentration would lead to decreased enzyme to carrier ratios, 
which is undesirable. 
With the addition of NaCl we observed particle formation. Increase in salt 
concentration changed the distribution from a single population into multiple populations, 




Figure 4.2. Effect of NaCl concentration on the diameter of protein nanoparticles: (a) 
size distribution curves for representative samples of BSA nanoparticles, (b) average 
diameter of BSA nanoparticles, (c) size distribution curves for representative samples of 
eGFP nanoparticles, and (d) average diameter of eGFP nanoparticles.  
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Formation of particles appears to be the result of combined effects of the salting 
out process, the excluded volume effect produced by ethanol, and hydrogen bonds that 
form between water and ethanol. Salt influences protein precipitation according to the 
salting-out principle, in which the solubility of a protein decreases as the ionic strength of 
the solution increases [15]. When there is a low concentration of salt molecules in the 
protein solution, more water molecules are available for solvating the protein. As the salt 
concentration increases, the water molecules interact with the salt ions and fewer are 
available for solvating the protein. This brings the protein molecules closer to each other, 
leading to precipitation. Ethanol also interacts with water molecules and forms hydrogen 
bonds, leading to decreased protein solvation. Additionally, ethanol has a higher excluded 
volume than water and therefore, can lead to protein precipitation [16]. 
4-3-3 Effect of imidazole on carrier particle size 
In addition to salt, protein precipitation is also affected by the presence of other 
additives in the initial protein solution [16]. Since many recombinant proteins are purified 
with histidine tags (His-tag), the effect of imidazole on particle production was explored. 
The effect of imidazole on both carriers, eGFP with a His-tag and BSA without, was 
analyzed. The results indicated that imidazole affects the size of particles made with both 
carriers (Figure 4.3). The diameter of eGFP nanoparticles decreased as the concentration 
of imidazole increased (Figure 4.3A-B). Furthermore, the size distribution changed 
significantly. Increasing the concentration of imidazole from 0 mM to 90 mM yielded the 
formation of two separate populations of particles, one at approximately 60 nm and 
another at 120 nm. Each of these peaks is narrower than the peak observed when no 
imidazole is present. A further increase in imidazole concentration to 250 mM yields a 
single peak with a narrow distribution, which indicates that imidazole not only controls 





Figure 4.3. Effect of imidazole concentration on particle size: (A) size distribution curves 
for eGFP nanoparticles, (B) average diameter of eGFP nanoparticles, (C) size distribution 
for BSA nanoparticles, and (D) average BSA particle diameter. 
 
Interestingly, in the case of BSA, particle size is not affected by the amount of 
imidazole only by its presence (Figure 4.3C-D). The diameter of BSA particles decreased 
approximately 60% when imidazole was present. Varying the concentration of imidazole 
in between 62.5-250 mM did not significantly affect the size but it did change the size 
distribution from one population to two populations. The difference in response between 
BSA and eGFP suggests that each protein interacts differently with imidazole and 
therefore, the effect of imidazole on size will vary from protein to protein and that the 
effect depends on how imidazole interacts with each protein. 
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Imidazole has been reported to increase the solubility of histidine tagged proteins, 
although the mechanism is still unknown [17]. It is possible that by increasing the 
solubility of eGFP, imidazole is decreasing the size of eGFP particles. Higher protein 
solubility was hypothesized to delay protein nucleation and thus, lead to the formation of 
smaller particles. Although the effect of imidazole on the solubility of BSA has not been 
characterized, imidazole has been observed to bind to BSA, which contains 17 histidine 
residues [18]. This binding could affect the solubility of the protein and/or interaction 
with ethanol, and explain the decrease in particle size. In addition, imidazole affected the 
polydispersity of the particles; the width of the size distribution decreased in the presence 
of imidazole. This could be the result of a more uniform nucleation process possibly due 
to increased solubility. Thus, imidazole can be used to tune particle size according to the 
requirements of the application.  
It is important to note that the particle fabrication process is reproducible, 
resulting in similar size distributions and average diameter of particle made from the 
same batch of protein (Figure 4.4). However, particle size and size distribution were 
observed to depend on protein purity. The presence of protein impurities resulted in 
larger average particle diameters and wider size distribution peaks. Possibly as a result of 
the different solubilities, that may cause one protein to precipitate before others and begin 




Figure 4.4. Variation in particle size distribution across three different particle 
productions made from the same batch of eGFP and same fabrication conditions (125mM 
imidazole buffer and DTSSP). No significant variation in particle size and size 
distribution is observed within the same batch of protein.  
 
 
4-3-4 Effect of cross-linker on carrier particle size 
Once the particles have been formed via desolvation it is necessary to cross-link 
them in order to stabilize them. Otherwise, removal of ethanol can lead to re-
solubilization of the protein. The effect of three different cross-linkers was evaluated. The 
first, glutaraldehyde (GTA), has historically been the most commonly used cross-linking 
agent for production of protein nanoparticles. GTA is a highly reactive and irreversible 
cross-linker that interacts with multiple functional groups, such as amine, thiol, phenol 
and imidazole groups [19]. The second cross-linker is a degradable primary amine cross-
linking agent 3,3´-Dithiobis(sulfosuccinimidylpropionate) (DTSSP). DTSSP contains a 
disulfide bond, which is cleaved in reducing environments. The intracellular environment 
is known to have reducing conditions [20], and therefore could trigger release of soluble 
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enzyme. The final cross-linking agent, bis[sulfosuccinimidyl] suberate (BS3), is identical 
to DTSSP but does not contain the disulfide bond, making it irreversible.  
In order to establish the effect of these cross-linkers on size, particles were 
produced with the carrier proteins, eGFP and BSA, dissolved in PBS. Particles were 
cross-linked for 2 hours keeping the cross-linker to lysine ratio constant. The resultant 
particles showed significantly higher particle size when GTA was used as the cross-linker 
(Figure 4.5A,C). There was no significant difference in particle diameter between DTSSP 
and BS3 (Figure 4.5B,D). These results indicate that highly reactive cross-linkers, like 
GTA, lead to the formation of larger particles than those formed with less reactive cross-
linkers, such as DTSSP, and BS3 [19]. Given the similarity of the chemical structure and 
identical sulfo-NHS ester reactive ends of DTSSP and BS3, similar reactivity levels are 
expected. Furthermore, the sulfo-NHS ester ends react only with primary amines. 
However, GTA is a smaller molecule with carbonyl reactive ends and is known to be 
highly reactive to multiple functional groups [19]. Thus, there are more reactive sites that 





Figure 4.5. Effect of cross-linkers on particle size: (a) size distribution curves for eGFP 
nanoparticles, (b) average hydrodynamic diameter of eGFP nanoparticles, (c) size 
distribution curves for BSA nanoparticles (note GTA cross-linking time was 20 min) and 
(d) average hydrodynamic diameter of BSA nanoparticles. 
 
 
4-3-5 Effect of cross-linker on fluorescence and particle break-up 
Precipitation and cross-linking affects the structure of proteins and enzymes, as 
was observed during pure β-gal particle fabrication. In order to establish the effect of the 
particle production process on carrier proteins we used eGFP. The fluorescence of eGFP 
depends on its structure, a β-barrel fold with a chromophore-containing helix running 
through the core of it[21]. Though eGFP is highly stable, changes in conformation greatly 
affect its fluorescence intensity[22]. Thus, the effect of particle production and cross-
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linking was evaluated. Analysis of the fluorescence of eGFP in particles compared to the 
fluorescence of soluble eGFP, demonstrated that there is a 9-18% loss in fluorescence 
after desolvation and stabilization with the three cross-linkers. However, there was no 
significant difference between the cross-linkers (Figure 4.6). The small loss in 
fluorescence, compared to high enzymatic activity loss of β-gal in pure enzyme particles, 
indicated that eGFP retained its structure better than β-gal. This suggests that eGFP could 
be used to help protect enzyme structure during protein fabrication. 
 
Figure 4.6. Effect of cross-linker on eGFP fluorescence. Relative fluorescence of 
nanoparticles suspended in PBS, after protein desolvation and cross-linking with BS3, 
DTSSP and GTA for 2 h. Data are the measured fluorescence of eGFP nanoparticles 
relative to soluble eGFP (* p<0.05). 
 
Next, the capacity of particles fabricated with the three different cross-linkers to 
break-up and release fluorescent eGFP was assessed. For this purpose, eGFP particles 
were incubated in HeLa cell lysate, which simulates intracellular conditions, for 0 to 30 
minutes. Particle break-up and protein release were analyzed by western blot, using the 
fluorescence of eGFP. DTSSP and BS3 cross-linked particles were observed to 
disassemble and release soluble fluorescent eGFP in HeLa lysates (Figure 4.7A). 
However, GTA cross-linked particles did not release soluble eGFP (Figure 4.7B). These 






















observations indicate that DTSSP and BS3 should be used when intracellular protein or 




Figure 4.7. eGFP particle break-up in HeLa cell lysates. (a) Western blot showing break-
up of particles cross-linked with BS3 (Bt) or DTSSP (Dt) over time in minutes (indicated 
by subscript). (b) Western blot for eGFP particles cross-linked with GTA at 0 and 30 
minutes. All particles were produced with ethanol and cross-linked for 2 h.  
 
4-4 Optimization of carrier and enzyme nanoparticles 
Just as eGFP and BSA desolvate differently when formulated as particles under 
different conditions, addition of an enzyme has the potential to alter particle size and 
distribution, which are highly relevant to cellular particle internalization. Studies with 
eGFP demonstrated that the presence of protein impurities lead to the production of 
larger particles and wide size distributions. These observations indicated that the addition 
of an enzyme would also change particle size and size distribution.  
Differences between the carrier protein and enzyme size, charge and solubility 
affect the desolvation process. Therefore, it was necessary to optimize the desolvation 
process for particle size tuning and enzymatic activity retention. Incorporation of β-gal 
into eGFP and BSA yielded larger particles than pure carrier desolvation. BSA continued 
to produce large aggregates and thus, further studies with β-gal were performed using 
only eGFP as a carrier.  
The following sections present the effect on particle properties and enzymatic 






4-4-1 Effect of enzyme addition on particle size and fabrication yield 
The properties of different added proteins may vary considerably from those of 
eGFP and hence, affect the nucleation and precipitation process. Introducing β-gal in the 
eGFP formulation (eGFP+β-gal) yielded slight variations in the particle size and size 
distribution (Figure 4.8a). Increasing imidazole concentration to 250 mM significantly 
increased particle size (Figure 4.8b). This behavior is contrary to the observed effect of 
imidazole on eGFP particle size.  
 
 
Figure 4.8. Effect of enzyme on particle size: (a) size distribution curves of eGFP 
nanoparticles, eGFP+βgal and eGFP+AvrA nanoparticles produced with 250 mM 
imidazole buffer and (b) average particle diameter of eGFP+βgal nanoparticles with 
varying imidazole concentrations. 
 
The pH for particle fabrication in this work (7.4) was above the pI of eGFP (6.2) 
and β-gal (4.6) and thus, both proteins were negatively charged. However, their level of 
ionization was different and so was their solubility. The closer a protein is to its pI the 
lower its solubility and the more prone it is to aggregation; therefore, desolvation will 
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yield larger aggregates or particles [13]. In this case, eGFP is closer to its pI than β-gal, 
which could explain the slight decrease in particle size when the enzyme was added. 
 Some additional differences between eGFP and β-gal that may also affect the size 
distribution behavior are their size (26.9 kDa and 465.2 kDa, respectively), solubility in 
aqueous buffers (eGFP > β-gal) and presence of His-tag (eGFP contains His-tag, β-gal 
does not). The absence of the histidine tag in β-gal could imply that imidazole has no 
effect on protein solubility. Imidazole is also known to form strong hydrogen bonds with 
water [23]. This last characteristic of imidazole is shared with salts and thus, can lead to a 
salting-out effect. Proteins with lower solubility precipitate sooner in the desolvation 
process, which leads to longer particle growth periods after nucleation and hence, larger 
particles.  
The addition of β-gal also affected the yield of the particle production process, 
which was measured by quantifying the amount of protein that remains soluble after 
desolvation and cross-linking and comparing to the initial amount of protein used. The 
average amount of protein that formed eGFP particles was 94%. But when β-gal is 
introduced in the formulation the yield is 85%. These yields are high compared to many 
polymeric or lipid nanoparticle formulations containing protein [1].  
 
4-4-2 Effect of cross-linker on enzymatic activity 
Cross-linking can alter the structure and activity of enzymes; hence, the effect of 
GTA, DTSSP and BS3 on enzymatic activity was evaluated. The substrate of β-gal 
(ONPG) is small enough to diffuse into cross-linked particles. Therefore, bioactivity and 
therapeutic potential could be measured for both reversible and irreversible cross-linkers. 
eGFP+β-gal particles were prepared with each cross-linker. β-gal was observed to lose 
approximately 25% of activity after desolvation and cross-linking (Figure 4.9A). This 
loss is 3 times lower than the observed activity loss of pure β-gal nanoparticles. The level 
of activity of β-gal in particles produced with these cross-linkers did not vary 
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significantly between cross-linkers for a cross-linking time of 2 h (Figure 4.9B). This 





Figure 4.9. (A) Relative β-gal activity retention for different particle formulations. 
Particles were produced from pure β-gal (β-gal NP) or a mixture of eGFP and β-gal 
(eGFP+β-gal) and cross-linked for 2 h with DTSSP. Data are the measured β-gal activity 
in the nanoparticles relative to soluble β-gal. (B) Effect of cross-linker on β-gal activity              
(* p<0.05, ** p<0.01). 
 
 In order to reduce particle size when using GTA, for intracellular delivery, it was 
necessary to shorten the cross-linking time, this limits the extent of the reaction and 






























prevents the possible binding of smaller particles into large aggregates. By decreasing the 
cross-linking time of eGFP+β-gal particles with GTA from 2 hours to 20 minutes we 
observed a significant decrease in particle size. The resulting particles were 
approximately 270 nm in diameter, compared to 700 nm after 2 hours of reaction. Thus, 
reduction of cross-linking time yielded GTA cross-linked nanoparticles of comparable 
size to those produced with DTSSP and BS3. Not surprisingly, enzymatic activity and 
activity retention increased significantly when the cross-linking time was reduced (Figure 
9b). This indicates that the process of cross-linking inactivates the enzyme, or that higher 
cross-linking levels inhibit substrate access to the enzyme for the irreversible cross-
linkers GTA and BS3.  
 
4-4-3 Protective effect of particle on enzyme activity 
There are many challenges associated with the stability of enzymes given their 
large size and complex tertiary or quaternary structure that can be highly sensitive to the 
environment [1]. With the purpose of establishing the capacity of protein nanoparticles 
for protecting their enzyme cargo, eGFP+β-gal particles were incubated in simulated 
intestinal fluid (SIF) or human serum for 0.5-2 hours. Preliminary assays with DTSSP 
cross-linked eGFP nanoparticles indicated that incubation in human serum yields 15-20% 
protein fluorescence loss. Whereas, soluble eGFP incubated in human serum lost only 
10%. Further studies using eGFP+β-gal particles showed that there was no significant 
difference in enzymatic activity loss for nanoparticles and soluble enzyme incubated in 
SIF; both soluble and nanoparticle formulations lost 25-30% enzymatic activity.  
Similar studies performed with human serum, indicated there was no enzymatic 
activity loss for soluble enzymes incubated in it, instead a 10% increase in activity is 
onserved, relative to incubation in PBS. eGFP+β-gal particles exhibit 40% higher activity 
levels in human serum  than those observed for particles in PBS. These results were 
unexpected and could be the result of higher enzymatic activity in the new environment 
 62 
 
or an artifact of the assay. Further studies with eGFP+β-gal nanoparticles confirmed the 
increase in enzymatic activity. Assessment with another enzyme, lysozyme, confirmed 
increased enzymatic activity in human serum for soluble and particle formulations, 
compared to PBS.  
SIF and human serum were chosen for in vitro bioactivity assessment of enzyme-
carrier nanoparticles. However these two fluids are very different from each other and 
hence, assess different conditions. SIF is a harsh complex mix of bile salts and lecithin at 
pH=6.5, thus is meant to simulate the environment in the small intestine and correlates to 
oral delivery; whereas human serum can be used to assess conditions in the blood stream. 
Protein nanoparticles did not exhibit enzymatic activity protection in SIF, suggesting that 
further protection may be necessary for gastrointestinal stability. Unfortunately, the effect 
of protein nanoparticles on enzyme stability protection for blood delivery is not clear.  
 
 
4-5 Intracellular delivery of enzymes  
To assess the potential of protein particles for intracellular delivery of enzymatic 
drugs, cellular uptake studies with different types of cells were performed. Three well 
established cell lines, NIH/3T3 (murine fibroblasts), HeLa (human cervix 
adenocarcinoma cells) and SK-BR-3 (human breast adenocarcinoma cells), were used as 
representative cell types. eGFP+β-gal and eGFP only particles were prepared in 0 mM 
imidazole solution and cross-linked with DTSSP for 2 h, as previously described, to 
obtain similar particle size distributions. eGFP+β-gal particles had an average diameter of 




Figure 4.10. Size distribution curves of particles used for cell experiments. eGFP or 
eGFP+β-gal particles were produced with ethanol and cross-linked with DTSSP and BS3 
for 2 h, or with GTA for 20 min to obtain similar nanoparticle average sizes and size 
distributions. 
 
In addition to size, particle surface charge is also important for effective particle 
delivery and internalization. It is well established that neutral particles decrease immune 
recognition and increase circulation times, but charged particles exhibit higher cellular 
internalization [13]. For protein particles, the surface charge is dictated by the identity of 
the protein and specifically, which residues are exposed. eGFP and eGFP+β-gal 
nanoparticles exhibit very similar zeta-potentials as a result of the high content of eGFP 
in all formulations.  eGFP+β-gal particles had an average zeta-potential of -12.9 mV in 
PBS or -26.4 mV in HEPES and eGFP particles  of -11.5 mV in PBS or -27.5mV in 
HEPES. The results shown here prove that the produced protein particles are inherently 
charged, as indicated by the strongly negative zeta-potentials measured in HEPES buffer. 
However, in the presence of ions, such as those observed in physiological conditions 
(PBS), the measured zeta-potential value decreases drastically. This indicates that ions 
adsorb to the surface of the particles and shield its charge, which causes the particles to 
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seem only slightly charged [24]. Particle charge is important for three main reasons: first, 
cell membranes are negatively charged and positively charged particles bind to the cell 
surface which can lead to particle internalization; second, neutral particles have longer 
blood circulation times; and third, neutral particles are prone to aggregation.  
In order to establish if the produced protein-enzyme nanoparticles are capable of 
effectively delivering their cargo to cells, particle uptake was quantified using flow 
cytometry. The increase in green fluorescence of cells incubated with nanoparticles or 
soluble protein was measured and compared to cells incubated with PBS only. First, 
soluble eGFP and eGFP nanoparticles were used to establish particle internalization in 
the different cell lines. Despite the low particle charge, there was significant eGFP 
particle uptake in all cell lines. HeLa cells exhibited the highest particle uptake; the mean 
fluorescence of cells incubated with nanoparticles was 4.7 times higher than the 
fluorescence of cells incubated with soluble protein (Figure 4.11a). Mean fluorescence 
increased 1.62 and 1.22-fold for SKBR-3 and 3T3 cells, respectively. While particle 
uptake varied among cell types, in all cases higher intracellular protein levels were 
achieved with particles than soluble protein. Further confirmation of particle 
internalization was obtained by confocal imaging of HeLa cells incubated with eGFP+β-
gal nanoparticles or soluble eGFP and β-gal. Figure 4.11b shows that there is higher 





Figure 4.11. Uptake of protein nanoparticles compared to soluble protein: (a) Relative 
fluorescence of different cell lines after 6 hours of incubation with eGFP nanoparticles 
and (b) SK-BR-3 cell uptake of eGFP nanoparticles over time. Data reported here shows 
the measured fluorescence of cells treated with soluble or nanoparticle protein relative to 
the fluorescence of cells treated with PBS. Error bars represent standard deviation, N=3 




A time-lapse study revealed the strong dependence of particle uptake on 
incubation time (Figure 11c). Cells incubated with DTSSP cross-linked eGFP particles 
for 3 h show a 1.67 fold increase in fluorescence above those incubated for only 1 h. 
After an additional 3 h of incubation (6 h time point) a fluorescence increase of 2.3 fold, 
with respect to those incubated for 1 h, was observed. Cells incubated with soluble eGFP 
for 3h show negligible increase in fluorescence, but after 6h show a 1.7 fold increase in 
fluorescence, with respect to those incubated for 1h. Experiments at 4°C showed no 
increase in fluorescence over time (Figure 4.12). The low particle uptake reported at 4°C, 
compared to 37°C, indicates that particles are internalized by active uptake mechanisms, 
such as endocytic processes [25, 26]. 
 
Figure 4.12. Energy dependent particle uptake. SK-BR-3 cells were incubated with eGFP 
nanoparticles for 6 h at 4°C and 37°C. Particles used for this experiment were produced 
with ethanol, 250 mM imidazole buffer and cross-linked with DTSSP for 2 h. Average 
particle diameter was 117 nm and zeta potential was –11.5 mV in PBS. Data are the 
measured fluorescence of cells incubated with soluble or nanoparticle eGFP relative to 
the fluorescence of cells incubated with PBS. Error bars represent standard deviation, 




To establish the presence of active β-gal inside cells, we measured hydrolysis of 
ONPG in HeLa cells following particle uptake and cell lysis. β-gal activity in cells 
incubated with eGFP+βgal nanoparticles was substantially higher than in cells incubated 
with a solution of β-gal and eGFP (Figure 4.13). The 5-fold increase in activity of 
particles over soluble is comparable to the 4.7-fold increase in fluorescence 
corresponding to higher particle uptake. These results confirm that enzymatic activity is 
retained not only during the particle fabrication process but also following cellular uptake 
and a significant amount of active enzyme can be delivered intracellularly. 
To test the effect of the different cross-linkers on particle internalization and 
activity of delivered β-gal, we incubated 3T3 cells for 6 hours with eGFP+β-gal 
nanoparticles cross-linked with DTSSP, BS3 and glutaraldehyde. Since the size of 
glutaraldehyde cross-linked nanoparticles depends strongly on reaction time, we used 
particles cross-linked for 20 min to match the particle diameter to BS3 and DTSSP 
particles. Particles with similar distributions and zeta potentials were used (Figure 4.10). 
The relative fluorescence of the cells was not significantly different, suggesting particle 
uptake is not affected by cross-linker (Figure 4.14A). This was expected due to the 
similarity in particle size and zeta potential.  
 
 
Figure 4.13. β-gal activity levels in HeLa cells after 6h of incubation. Cells were 
incubated with PBS, soluble of eGFP and β-gal, or eGFP+β-gal nanoparticles. The latter 
 68 
 
two samples contain the same amount of total protein and a 1:24 molar ratio of β-gal to 
eGFP.  Error bars represent standard deviation, N=3 (* indicates p<0.05) 
 
Measured β-gal activity after intracellular delivery was also similar for DTSSP, 
BS3 and GTA particles (Figure 4.14B). Previous experiments in which the activity of the 
enzyme was measured after particle production (Figure 4.9B) indicated that there is no 
significant difference in activity between BS3 and DTSSP. This supports the observed 
similarity in activity levels of the enzyme inside the cells. However, the activity of the 
internalized GTA cross-linked particles was expected to be higher than that of 
internalized particles cross-linked with BS3 and DTSSP. The activity of β-gal in 20min 
GTA cross-linked particles, measured after particle production, was significantly higher 
than the activity of the enzyme in particles cross-linked with BS3 and DTSSP (Figure 
4.5). This difference could be the result of GTA-linked particles allowing less substrate 




Figure 4.14. Effect of cross-linkers on: (a) eGFP+β-gal particle uptake in 3T3 cells, and 
(b) β-gal activity levels in 3T3 cells incubated with eGFP+β-gal nanoparticles relative to 
cells incubated without particles. Error bars represent standard deviation, N=3. 
 
 
Studies performed with the three types of particles in HeLa cell lysates indicated 
that DTSSP and BS3 particles are broken apart at similar rates, possibly by the reducing 
agents and proteases found in cells; whereas, particles cross-linked for 2h with GTA are 
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not degraded (Figure 7). Additional studies with eGFP+ β-gal indicate that that BS3 and 
DTSSP particles break apart while inside of the cells, releasing the enzyme and achieving 
the same activity levels of their higher activity counterpart, 20 min GTA cross-linked 
particles, which do not break apart (Figure 4.15). Intact GTA particles may have 
increased mass transfer limitations for substrate access compared to the DTSSP and BS3 
cross-linked particles. DTSSP and BS3 cross-linked nanoparticles break up inside the 
cells, which cancels the increased activity seen for the GTA particles when all are 
evaluated intact in solution. Thus the use of reducible or degradable cross-linkers may 
prove advantageous for enzyme or protein intracellular delivery. The relative importance 
of each particle property must now be evaluated in specific disease models both in vitro 
and in vivo.  
 
Figure 4.15. eGFP+β-gal particle break-up in cells. Western blot showing break-up of 
particles cross-linked with GTA (G), DTSSP (D) or BS3 (B). Confluent monolayers of 
HeLa cells were incubated with particles for 6h. eGFP+β-gal (1:5 enzyme:eGFP) 
particles were produced with ethanol and cross-linked with DTSSP and BS3 for 2 h, or 




4-6 Particle stability during storage 
We observed that particles stored in PBS at 4°C formed large aggregates after 6 
months; however, these aggregates will dissociate into the original nanoparticles after 
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brief sonication (Figure 4.16). However, the enzymatic activity of the enzyme decreased 
40-80% after dissociation of the aggregates. Pharmaceutical proteins and enzymes are 
often stored in solid form to achieve an acceptable shelf life. eGFP+β-gal nanoparticles 
lyophilized in PBS, retain 84% ± 10% of β-gal enzymatic activity after re-suspension, 
while their size decreases by 5 to 35% depending on the type of cross-linker and cross-
linker time (Figure 18). The observed decrease in size is most likely the result of particle 
drying. As the water trapped inside the particles is removed, they collapse into smaller 





Figure 4.16. Effect of storage at 4°C on eGFP+β-gal (representative) particle size 
distribution. GTA cross-linked nanoparticles and DTSSP cross-linked particles are shown 
immediately after fabrication and after 6 months of storage and sonication. 
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Figure 4.17. Effect of lyophilization on eGFP+β-gal (representative) particle size. GTA 
cross-linked nanoparticles and DTSSP cross-linked particles are shown after fabrication 




The results presented in this chapter illustrate the feasibility of producing protein 
nanoparticles for delivery of therapeutic enzymes. It was demonstrated that particle size 
can be tuned by adjusting fabrication parameters and the effect of each parameter is 
dependent on the carrier protein and enzyme. Salt and imidazole concentration and cross-
linking time were identified as crucial parameters for size control. In addition, high 
enzymatic activity retention was observed after desolvation and cross-linking of enzymes 
with carrier proteins. Multiple cell lines exhibited greater internalization of enzyme-
protein nanoparticles than soluble protein. Most significantly, it was established that this 
protein particle delivery system effectively delivers active enzymes inside cells. These 
results are very promising for therapeutic enzyme delivery and provide a new application 
for protein nanoparticles drug carriers. The next two chapters will describe the 
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5CHAPTER 5: USE OF BACTERIAL EFFECTOR 




 Bacterial pathogens have evolved mechanisms to suppress inflammatory 
and immunoregulatory pathways through active modulation of intracellular signalling 
pathways [1, 2]. Salmonella, is one such pathogen. It uses AvrA, an acetyltransferase 
protein effector, to covalently modify and inactivate members of the MAPK and NF-κB 
pathways [3]. AvrA specifically blocks activation of NF-κB and MAPK JNK signaling 
[4, 5] and thus, can act as a potent inflammatory suppressor.  
For this reason, AvrA has potential as a therapeutic agent for inflammatory bowel 
disease (IBD), a group of chronic relapsing disorders of the intestinal tract. IBD 
manifests with acute and chronic inflammation orchestrated by inflammatory 
cytokines[6] that could be decreased by the activity of AvrA. However, delivery through 
the harsh environment of the gastrointestinal tract to the resident epithelial and immune 
cells remains a challenge. As shown in Chapter 4, nanoparticles deliver protein and 
enzymes to a variety of cells more efficiently than soluble formulations. Multiple types of 
nanoparticles have been investigated for delivery of IBD therapeutics [7-11]. 
Nanoparticles enable drug accumulation in inflamed tissue with higher efficiency than 
when given in solution [11], reduce side effects and lower dose requirements[12]. In 
addition, these delivery vehicles have the ability to pass through physiological barriers, 
evade phagocytosis and more importantly, induce longer lasting results than soluble 
formulations [10].  
In this chapter, the desolvation process that was previously presented is adapted to 
create environment-responsive eGFP+AvrA nanoparticles using DTSSP as the cross-
linking agent. Particle size is controlled by varying the concentration of imidazole. 
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Resulting particles are 100-300 nm in diameter for different concentrations of imidazole 
and size distribution width is observed to decrease with increasing imidazole 
concentration. eGFP+AvrA nanoparticles are characterized in various buffers that 
simulate reducing conditions in the cytoplasm and harsh conditions in the gastrointestinal 
tract. Evidence suggests that DTSSP cross-linked nanoparticles aggregate in reducing 
buffers but disassemble into single molecules inside of cells. Intestinal fluid simulations 
demonstrate that particle formulations do not offer additional protection to proteins in 
harsh conditions, in comparison to soluble formulations. Finally, particle internalization 
and delivery of active AvrA to model epithelial and immune cells is demonstrated. 
  
5-1 Experimental details 
5-1-1 Particle preparation 
Protein particles were prepared as described in Chapter 4. In brief, 600 µg of 
eGFP and ~25 µg of AvrA or mutant AvrA (mAvrA) in 100 µl imidazole solution (250 
mM imidazole, 300 mM NaCl, 50 mM NaH2PO4; pH 8) were placed in a glass vial. The 
protein solution was desolvated by continuous, drop-by-drop addition of 400 µl ethanol at 
a rate of 1 ml/min. After desolvation, particles were cross-linked with DTSSP (Pierce) at 
a ratio of cross-linker to lysines of 1:2.2. After 2 h stirring at 650 rpm, the cross-linking 
reaction was stopped by centrifugation at 1000 g for 1 min and removal of supernatant. 
Particles were re-suspended in 2 ml of phosphate buffered saline (PBS, 10 mM NaH2PO4, 
137 mM NaCl, 2.7 mM KCl, 2 mM KH2PO4; pH 7.4) and sonicated on ice for 1s every 
15 s at 30% amplitude, for a total of 5 minutes. 
 
5-1-2  Calculation of AvrA molecules in particles 
In order to calculate the approximate number of AvrA molecules in a given 
particle the maximal density theorem or Kepler conjecture was used. Kepler stated that 
the maximal density of sphere packing in three dimensions occurs for face-centered cubic 
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or hexagonal close packing, in which 𝜋 18 of the volume is occupied by spheres [13, 
14].  This theorem assumes that all spheres are the same size and that they are uniformly 
packed. For this reason, all proteins were assumed to be spheres of the same diameter. 
Since, eGFP and GST are ~4 nm in diameter when measured with DLS and AvrA-GST 
fusion proteins are ~6-8 nm, the fusion proteins were assumed to be two independent 
spheres (each d= 4 nm) bound together by a flexible bridge. Thus, the number of AvrA 
molecules was calculated as follows: 
 The number of protein spheres per particle 






!         
And the number of AvrA molecules per particle  
𝑁!"#! = 𝑁! ∙ 𝑋!"#! 
Where rn is the radius of the particles, rp is the radius of the protein spheres (2 nm) 
and XAvrA is the molar fraction of AvrA in the particle. 
5-1-3 Determination of particle size and zeta potential 
Particle size distribution and zeta potential were measured and reported as 
explained in Chapter 4.  
5-1-4 Particle preparation for scanning electron microscopy and atomic force 
microscopy 
Scanning electron microscopy (SEM) and atomic force microscopy (AFM) were 
used to visualize the size and shape of produced eGFP+AvrA and eGFP+mAvrA 
particles. Particles were prepared for imaging by further crosslinking with glutaraldehyde 
after fabrication. 5 µl droplets of nanoparticles suspended in water were placed on an 
SEM specimen stub or on a glass slide. The droplet was then frozen in liquid nitrogen 
vapor and immediately lyophilized for 24 hours. Samples were coated with 




5-1-5 Cell Culture  
J774 macrophage cells were purchased from the American Type Culture 
Collection (ATCC) and SK-CO15 epithelial cells were a generous gift from Dr. Andrew 
Neish. J774 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM), 
supplemented with 10% (v/v) fetal bovine serum (FBS). SK-CO15 epithelial cells were 
cultured in DMEM with 10% FBS and 1% non-essential amino acids. All media and 
serum was purchased from Cellgro, Mediatech and supplemented with 1% (v/v) 
penicillin/streptomycin. Cells were incubated at 37°C in a 5% CO2 humidified 
atmosphere.  
Cells used for experiments were passaged at least two times before use and did 
not exceed passage number 20. Cell morphology and normal behavior were verified 
before use.  
5-1-6 Cellular internalization of nanoparticles 
Uptake of particles was assessed by flow cytometry. Cells were seeded at a 
density of 1x105 per well in a 48-well plate in complete growth medium. After 16 h cell 
culture media was changed and cells were incubated with eGFP+AvrA particles (150 
µg/ml) in complete growth medium for 6 h. Cells were washed twice with PBS, 
trypsinized, and collected in 1.7 ml tubes. Cells were washed twice more by 
centrifugation (500 rpm for 5 min) in PBS, re-suspended in PBS, filtered with a 35 µm 
cell strainer and placed on ice. The cells were immediately analyzed in an Accuri C6 
(Becton Dickinson and Company) flow cytometer and relative particle uptake was 
quantified as the ratio of mean fluorescence of the sample population to mean 
fluorescence of the control population (no particles given).  
 
 
5-1-7 Intracellular detection of AvrA particles 
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J774 macrophages or SK-CO15 epithelial cells were plated at a density of 2x105 
cells per well in a 24-well dish. After 14-16 hours of incubation, cell media was replaced 
with fresh media containing 300 µg/ml AvrA nanoparticles or soluble AvrA and 
incubated for 6 hours. Control cells were incubated with AvrA nanoparticles or soluble 
AvrA at 4oC. Next, cells were washed twice with ice cold PBS and scrapped or 
trypsinized and fixed with 3.7% paraformaldehyde for 15 minutes at room temperature. 
Fixed cells were washed 3 times by centrifugation with ice cold PBS and then 
permeabilized with 0.25% Triton X-100 in PBS for 15 minutes at room temperature. 
Cells were rinsed three times in PBS and incubated with anti-AvrA serum in 6% BSA 
and 10% FBS in PBS for 1h. After this, cells were washed 3 times with PBS and then 
incubated with 20nM Qdot 655 VIVID secondary antibody conjugate (Invitrogen) in 6% 
BSA in PBS, for 1h. Finally, cell were washes 3 more times with PBS. Labeled cells and 
controls were analyzed in an LSR II flowcytometer (Becton Dickinson and Company) 
flow cytometer. Positive events were identified as cells with simultaneous increase in 
green fluorescence and quantum dot fluorescence.  
5-1-8 Particle break-up in cell lysate and in vitro 
To detect the break-up of eGFP+AvrA nanoparticles 200 µg/ml of particles were 
incubated 1-10 mM GSH in PBS, to simulate reducing conditions observed in the 
intracellular cell environment. After 0-60 minutes of incubation particles were loaded 
onto 12% SDS-PAGE gels using a non-reducing loading buffer (62.5 mM Tris-HCl, 10% 
glycerol, 1% SDS and 0.005% Bromophenol blue). Gels were run at 135 V for 120 
minutes and proteins were transferred to nitrocellulose membranes at 400mV for 40 
minutes. Proteins were detected using anti-penta HIS antibodies conjugated to Alexa 488 
(Qiagen). Membranes were imaged in a Typhoon Imager (GE Healthcare) at 550 PMT. 
5-1-9 Statistical analysis 
All quantitative experiments were triplicated and presented as arithmetic mean ± 
standard deviation. One-way analysis of variance (ANOVA) was used to determine 
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significance among groups, using StatPlus. P values <0.05 among groups were 
considered statistically significant. 
 
5-2 AvrA nanoparticle design considerations 
IBD presents a challenging target for drug delivery. Contrary to most oral 
therapeutic regimes, maximal intestinal wall drug absorption is required while minimal 
systemic levels are desired [15]. Several delivery strategies are currently being employed 
to accomplish this goal. Local enemas, drug molecule modification for X benefit/goal, 
controlled and delayed-release particle formulations are some examples of these 
strategies [16, 17] .  
Nanoparticles have been found to accumulate in inflamed tissue in the gut and 
thus, can increase drug levels in the affected intestinal wall while reducing systemic 
absorption [11]. For this reason, encapsulation of AvrA in nanoparticles was 
hypothesized to be advantageous for effective delivery to intestinal epithelial and 
immune cells affected by IBD. In order for these particles to serve as a successful 
delivery system, three conditions must be met. First, particles must be able to cross the 
mucosal layer that lines the intestine and reach the target cells. Second, AvrA must be 
released from the nanoparticles in the cell cytoplasm for it to bind and acetylate its 
molecular targets in the MAPK/JNK and NF-κB pathways. Third, drug doses must be 
carefully balanced to reduce inflammation while preventing systemic alterations such as 
immunosuppression.  
5-2-1 Effector delivery to cells  
Though nanoparticles provide a major advantage for IBD drug delivery in their 
ability to accumulate in inflamed tissues, penetration of the surface mucus layer and entry 
into cells are important barriers that must be overcome, as per the first condition. Particle 
size and surface chemistry have been identified as key factors that greatly affect both 
mucus penetration and cellular internalization [18].  
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The initial barrier the particles will encounter is the surface mucus layer that lines 
the intestine (Figure 5.1). Mucus is a complex viscoelastic gel, which serves as a physical 
barrier that protects tissue that would otherwise be exposed to the external environment. 
At the microscopic level, mucus is a hydrated network of cross-linked and entangled 
mucin fibers [19]. In order for particles to traverse the mucus layer low particle adhesive 
interaction with mucin fibers and particle diameter must be smaller or of similar size as 
the average interfiber spacing [18-20]. Mucin is negatively charged and highly 
hydrophobic. To prevent adhesion to mucin fibers, the AvrA nanoparticle surface should 
be hydrophilic and anionic or neutral. In addition, particle diameter should be smaller 
than ~500nm to be able to fit through the average interfiber spaces and diffuse through 
the mucus [20].  
The next barrier the particles will encounter is entry into cells. In IBD, immune 
cells and epithelial cells are at the core of alterations in mucosal immunity and 
gastrointestinal physiology [21, 22]. Epithelial cells are the major constituents of the 
intestine, and these undergo rapid and remarkable changes in response to elevated levels 
of inflammatory cytokines produced by immune cells. For this reason, AvrA particles 
must be able to deliver their cargo to both types of cells.  
Epithelial cells internalize particles through a variety of mechanisms that include 
clathrin-mediated, caveolae-mediated and receptor-mediated endocytosis, or 
macropinocytosis [23]. Immune cells, such as macrophages, continuously sample their 
environment and thus, uptake significant amounts of particles [24, 25]. Though 
macrophages are usually associated with phagocytosis, macropinocytosis and endocytosis 
are also common particle internalization mechanisms, especially nanoparticles. All of 
these particle internalization routes are energy dependent and are affected by particle 
size, shape and surface chemistry. Small particles (50-200 nm in diameter) are 
internalized at higher rates than larger particles [26]. Increased particle internalization has 
been observed for charged particles versus neutral particles [27]. Internalization of 
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nanoparticles with higher-aspect-ratio occurs more rapidly and efficiently than more 
symmetric particles [28]. 
 
 
Figure 5.1. Schematic representation of the effect of particle size and surface properties 
on effective AvrA delivery to cells. Large particles (>500 nm) are unable to penetrate the 
mucus layer and thus, are unable to deliver the effector to the cells. Medium sized 
particles (200-500 nm) are able to penetrate the mucus layer but are not readily 
internalized by cells. Small particles that adhere to mucin are able to penetrate the 
mucosa but do not effectively reach the cells. Small particles (<200nm) traverse the 
mucosal layer and are readily internalized by cells. Adhesive nanoparticles (hydrophobic 
and/or cationic) bind to mucin fibers and are unable to deliver the effector to the cells. 
Schematic representation not drawn to scale. 
In order to effectively deliver AvrA to cells, particles must simultaneously meet 
the necessary conditions for traversing mucus and particle internalization. In general, 
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small particles (50-200 nm in diameter) would be able to diffuse through the mucus pores 
formed by mucin mesh spacing and be easily internalized by cells (Figure 5.1). In 
addition, particles must not adhere to mucin fibers so should be hydrophilic and near 
neutral. Since AvrA contains several hydrophobic patches within its sequence, it is 
possible that it may adhere to the fibers if unfolded by the desolvation process. This 
possibility and the enzymatic activity loss observed in chapter 4, indicate that AvrA 
particles should include a carrier protein. BSA and eGFP are good candidates for carrier 
proteins, but as previously shown eGFP yields reproducible particles that are easy to 
visualize inside cells. Additionally, eGFP is highly hydrophilic and negatively charged at 
physiological pH and hence, would not adhere to mucin.  
5-2-2 AvrA release inside cells 
Next, as per the second condition, AvrA particles must be able to release their 
cargo inside cells so that the effector protein reaches its target molecules in the 
cytoplasm. As shown in the previous chapter, DTSSP and BS3 cross-linking of 
enzyme+carrier particles yields particle break-up inside cells and active enzyme release. 
Consequently, AvrA particles were cross-linked with DTSSP to enable AvrA release 
from nanoparticles inside cells.  
5-2-3 AvrA dosage 
The dose of AvrA must be balanced to reduce inflammation while preventing 
systemic immunosuppression and other side effects. Real time imaging of a Salmonella 
model infection has shown that a different TTSS-secreted effector, SipA, mediates 
biochemical functions within minutes of infection at a concentration of 1000 
molecules/cell [29]. Thus, pathogens efficiently modulate cellular activity with low 
effector doses. For this reason, mimicking these low doses was hypothesized to provide a 
balance between function and prevention of side effects. By applying the maximal 
density theorem [13, 14] and assuming that each protein is a sphere, the number of 
molecules of AvrA in a particle can be estimated. Each 150 nm-diameter particle made 
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entirely of AvrA contains ~19,500 AvrA-GST molecules. eGFP+AvrA particle, 
containing 3.5wt% AvrA, has ~550 AvrA-GST molecules. In summary, particles were 
designed to efficiently deliver AvrA to affected cells by selecting eGFP as a carrier, 




Figure 5.2. eGFP+AvrA nanoparticle design. Small particles (50-200nm) made of 
DTSSP cross-linked AvrA and eGFP are expected to penetrate the mucus barrier, enter 
target cells and break-up in reducing conditions observed inside cells to release AvrA. 
 
To account for side effects induced simply by the presence of bacterial proteins 
and establish that therapeutic activity results solely from enzymatic action of AvrA, a 
mutant version of AvrA (mAvrA) was used. The mutant form contains a single cysteine 
substitution (C186A) that renders the acetyltransferase inactive and eliminates JNK 
inhibition and attenuates NF-κB suppressive activity [4]. Since mAvrA differs from 
AvrA by a single amino acid mutation in the catalytic site, particle production, 
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optimization and characteristic were expected to be similar. The next sections show 
particle size optimization, characterization and delivery of AvrA/mAvrA to cells.  
 
5-3 Optimization of AvrA+eGFP nanoparticles   
In the previous chapter, production of β-gal+eGFP nanoparticles was studied, 
characterized and optimized. However, the properties of eGFP, β-gal and AvrA-GST 
vary significantly and so will the exact fabrication conditions for optimal particles. The 
main differences between eGFP, β-gal and AvrA-GST/mAvrA are size (26.9 kDa, 465.2 
kDa and 61 kDa, respectively), solubility (eGFP > β-gal>> AvrA-GST) and presence of 
His-tag (eGFP and AvrA-GST contain His-tag, β-gal does not). These differences affect 
the desolvation process and yield different particle sizes and process efficiencies. This 
section focuses on optimization of eGFP+AvrA/mAvrA particle size to fit the 
requirements for traversing mucus and cellular internalization.           
     
 
5-3-1 Pure AvrA nanoparticles 
Production of particles directly from AvrA/mAvrA yielded large particles. 
Average particle diameter was >400 nm and  larger aggregates were observed. Due to the 
large particle size of pure enzyme particles, possible enzyme activity loss during 
fabrication, AvrA dosage requirements and imaging capabilities when eGFP is used as a 
carrier protein, pure AvrA/mAvrA nanoparticles were not pursued any further. 
 
5-3-2 Effect of imidazole on particle size 
Introducing β-gal in the eGFP formulation (eGFP+β-gal) was previously shown to 
yield two distinct particle populations. However, incorporation of AvrA to eGFP 
formulations (eGFP+AvrA) yielded a single population of particles with average 
diameters of 303 ± 45nm (Figure 5.3); similar results were observed with mAvrA. Since 
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the maximum desirable particle diameter was 200 nm, the process was optimized for 
smaller particle production.  
 
 
Figure 5.3. Effect of imidazole on eGFP+AvrA particle size and distribution. Different 
concentrations of imidazole were used in the initial protein solution to control particle 
size. 
 
Earlier studies showed imidazole decreases eGFP particle size as a result of 
increased protein solubility. Similarly, imidazole was observed to control 
eGFP+AvrA/mAvrA particle size; increasing imidazole concentration significantly 
decreased average particle diameter (Figure 5.3). As mentioned in the previous chapter, 
high protein solubility delays protein nucleation and thus, leads to the formation of 
smaller particles. Both AvrA/mAvrA and eGFP contain a C-terminal 6-His tag. Thus, 
their solubility is increased in the presence of imidazole, which in turn explains the 
observed decrease in particle size. In addition to controlling particle size, imidazole 
affected the polydispersity of the particles. The width of the size distribution peak 
Diameter [nm]


















decreased as the amount of imidazole increased (Figure 5.4). This could be the result of a 
more uniform nucleation process due to increased solubility.  
 
  
Figure 5.4.  Effect of imidazole on eGFP+AvrA particle size polydispersity. (A) 
comparison of size distribution peak width for particles fabricated in 0 mM and 250 mM   
(B) average full-width at maximum height (FWMH) for particles fabricated in different 
imidazole concentrations. Error bars represent standard deviation, N=3. 
 
Particles produced in the presence of imidazole exhibit average diameters within 
the desirable size range (50-200 nm). eGFP+AvrA particles produced in 125 and 250 mM 
imidazole were 131±47 nm and 95±18 nm in average diameter, respectively. Since 
smaller delivery vehicles could lead to higher accessibility to target cells, in vitro and in 
vivo studies were performed only with eGFP+AvrA/mAvrA particles produced in 250 
mM imidazole. Production yield of these particles was measured by quantifying the 
amount of protein that remains soluble after desolvation and cross-linking, and 
comparing it to the initial amount of protein used. The average amount of protein that 
formed eGFP+AvrA/mAvrA particles was 91% of the initial amount. 
After particle size was optimized, the surface charge of particles was established. 










































No significant difference in surface charge was observed between eGFP+AvrA and 
eGFP+mAvrA particles. All particles exhibited negative zeta-potential in 10 mM 
HEPES, a low ionic strength buffer, indicating inherent negative surface charge. In the 
presence of biologically relevant concentrations of ions (PBS), only slightly negative 
zeta-potentials were observed. This indicates that in physiological milieu ions adsorb to 
the particle surface and partially shield the surface charge. Nonetheless, near neutral or 
negatively charged particles can prevent attractive electrostatic interactions with 
negatively charged mucin fibers and decrease the potential for adhesion to mucus. These 
observations demonstrate that optimized eGFP+AvrA/mAvrA particles meet the size and 
surface charge criteria specified in the nanoparticle design.  
5-3-3 SEM and AFM characterization of nanoparticles 
The morphology of eGFP+AvrA/mAvrA particles was studied by SEM and AFM. 
Initial SEM imaging attempts demonstrated that DTSSP cross-linked nanoparticles are 
soft, which leads to shape loss during dehydration and preparation for imaging. Particles 
were also observed to fuse together, possibly during preparation or exposure to the 
electron beam, even at low acceleration voltage. Since particle features were not visible, 
new sample preparation techniques were implemented.  
In order to increase particle stiffness and shape retention, particles were cross-
linked a second time with GTA after fabrication and DTSSP crosslinking. Particles were 
then frozen, lyophilized and imaged, but shape loss and particle fusion persisted. Hence, 
the sample preparation process was modified and particles were frozen in liquid nitrogen 
vapor prior to lyophilization. This technique partially decreased particle fusion and shape 
loss, enough to allow visualization of some individual nanoparticles (Figure 5.5).  
Individual nanoparticles were in the expected size range and exhibited sphere-like 
morphology. Interestingly, some small particulates were also visible on the surface of the 
protein nanoparticles and on the stub. SDS-PAGE analysis of eGFP+AvrA/mAvrA 
particles under non-reducing conditions revealed the presence of a band that corresponds 
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to eGFP, indicating there are soluble or “free” protein molecules in the particle 
suspension. It remains unclear if these proteins are on the surface of the particles, inside 
the particles or in solution. The small particulates observed in these images could be 
small clusters of the “free” eGFP protein, which are probably held together by the GTA 
used to stabilize the particles before imaging since they were not observed in samples 
without GTA crosslinking. 
 
 
Figure 5.5. SEM image of eGFP+AvrA nanoparticles. Particles were further cross-linked 
with GTA after fabrication, frozen in liquid nitrogen and then lyophilized.  
 
 
eGFP+AvrA/mAvrA particles were also imaged using atomic force microscopy. 
Images revealed the presence of small particles (<200 nm) and a few large aggregates 
(Figure 5.6). These large aggregates could be the result of additional cross-linking with 




Figure 5.6. AFM image of eGFP+AvrA nanoparticles. 3D simulation of surface 
topography, note the existence of the small particles and large aggregates. Particles were 




5-4 Characterization of nanoparticles in biologically relevant fluids 
5-4-1 Effect of intestinal simulation fluids  
Enzymes are highly sensitive to harsh environments and therefore, effective 
delivery to intestinal cells presents a challenge. Gastrointestinal fluids contain bile salts, 
lecithin and proteases, that could greatly affect enzymatic activity. In order to predict in 
vivo performance of eGFP+AvrA/mAvrA nanoparticles the effect of simulated intestinal 
fluids on eGFP fluorescence was measured.  
Particles were incubated in fasted-state simulated intestinal fluid (FaSSIF) with or 
without 10 mg/ml pancreatin [30], for up to 5 hours. The fluorescence of soluble eGFP, 
eGFP nanoparticles and eGFP+AvrA nanoparticles was measured over time. No 
significant differences in fluorescence loss were observed between soluble and 
nanoparticle formulations incubated in FaSSIF with or without pancreatin. These results 
suggest that the nanoparticle formulation does not offer shielding or additional protection 




5-4-2 Effect of intracellular reducing conditions 
eGFP+AvrA/mAvrA nanoparticles were designed to release effector proteins only 
inside cells. DTSSP, the cross-linking agent, contains a disulfide bond that breaks in 
reducing conditions, as is observed inside cells. To establish the capacity of DTSSP 
cross-linked nanoparticles to break-up and release AvrA or mAvrA inside cells, 
intracellular conditions were simulated. For this purpose, particles were incubated in 
simulated intracellular reducing conditions using 1-10 mM glutathione (GSH) in PBS for 
0-60 minutes. Particle breakup was studied using SDS-PAGE and western blot.  
Particles incubated in GSH solutions were observed to release individual proteins 
before and after reducing treatments. However, longer incubation times yielded signal 
loss and hence, protein/enzyme release results were inconclusive. Figure 5.7 shows a 
preliminary study using eGFP+AvrA particles incubated in 5 mM GSH, separated in 
native PAGE and analyzed by western blot. Results were compared to particles cross-
linked with GTA after standard fabrication (DTSSP, 250 mM imidazole), and to soluble 
eGFP+AvrA. GTA cross-linked particles served as non-reducible particle controls and 
soluble proteins indicated the location of soluble protein bands. As expected, no soluble 
protein bands were observed for GTA cross-linked particles. DTSSP cross-linked 
particles released single proteins with and without incubation in GSH. Intact particles did 













Figure 5.7. eGFP+AvrA particle degradation in 5mM GSH. Western blot probed with 
anti penta-His antibody showing release of soluble protein separated using a native 
protein electrophoresis gel. GTA cross-linked particles and soluble eGFP were used as 
controls 
 
Further studies on eGFP+AvrA/mAvrA particle break-up were performed in non-
reducing SDS-PAGE gels, in order to visualize intact particles. Several GSH 
concentrations were tested and no significant difference in particle break-up was 
observed for a range of 1-10 mM GSH. Similarly, no differences were observed in 
particle disassembly between eGFP+AvrA or eGFP+mAvrA. Figure 5.8 shows a time 
analysis of protein release in 10 mM GSH. SDS-PAGE and western blot results show the 
presence of “free” or soluble protein before and after exposure to reducing conditions. 
These findings suggest that particles are only partially cross-linked when DTSSP is used 
and SDS or the electric field helps to extract soluble protein.  
By using SDS-PAGE gels instead of native gels intact particles or large pieces of 
the particles were able to partially penetrate the gel and thus, were visible in both the gel 
and western blot. Interestingly, the intensity of the nanoparticle bands was observed to 
decrease with time in the western blot but gel band intensity did not follow the same 
trend. Additional assays revealed that soluble or “free” protein band intensity also 
decreases with incubation time, in both gel and western blot studies.  




Figure 5.8. Time analysis of AvrA-eGFP nanoparticle break-up in 10mM GSH solution. 
(left) SDS-PAGE gel stained with coomasie blue (right) western blot probed with anti 
penta-His antibodies.  
 
To understand these observations, particle size was monitored over time. Particles 
were incubated in 5 mM GSH and particle size distributions were measured every 15 
minutes. DLS measurements indicated that particles aggregate in reducing buffers 
(Figure 5.9). Similar behavior has been reported in literature. Cheng et al. found that 
polymeric micelles cross-linked with DTSSP aggregate in reducing buffers, but 
interestingly not in cells [31]. Studies presented in chapter 4 show that DTSSP cross-










Figure 5.9. Effect of reducing conditions on size distribution of AvrA-eGFP 
nanoparticles. Particles were incubated with 5 mM GSH for 10-30 minutes. Size 
distribution of particles before incubation is shown for comparison (0 mM).  
 
Since large aggregates or particles can mask signal from free proteins in DLS 
measurements, protein aggregates were removed by centrifugation (10,000g for 5 
minutes) and samples were re-analyzed. Individual and smaller protein aggregates were 
observed (Figure 5.10). With the purpose of measuring the amount of free protein over 
time, 100 kDa ultrafiltration devices were used to separate particles and aggregates from 
free protein. However, the separation was not successful because intact particles went 
through the filters and consequently, changes in free protein concentration could not be 























Figure 5.10. DLS measurements of eGFP+AvrA nanoparticles in 5 mM GSH (left) 
comparison of size distribution before and after centrifugation, and (right) size 
distribution detail of centrifuged eGFP+AvrA nanoparticles in 5mM GSH.  
 
 
5-5 Delivery of AvrA effector to cells 
Efficient delivery of AvrA to intestinal cells is crucial for effective treatment of 
IBD. Therefore, eGFP+AvrA/mAvrA nanoparticle uptake was measured in model 
epithelial and immune cells. Particle uptake was evaluated by quantifying the increase in 
cell fluorescence due to the presence of eGFP and using anti-AvrA antibodies to establish 
the presence of AvrA specifically within cells.  
 
5-5-1 Particle internalization  
As shown in chapter 4, internalization of particles varies from one cell type to 
another. For this reason, the particle uptake behavior of model intestinal epithelial cells 
and immune cells was performed. SK-CO15, a human intestinal epithelial cell line and 
J774.A1, a murine macrophage cell line, were used to measure uptake of soluble and 
nanoparticle formulations of AvrA. Particle internalization quantification by flow 
cytometry, measured by the increase in green fluorescence of cells, revealed that J774.A1 
cells internalize much larger quantities of particles than SK-CO15 cells. The fluorescence 
of macrophages incubated with soluble and nanoparticle formulations of AvrA increased 































increased 2.2 and 2.4-fold when incubated with soluble AvrA with eGFP and 
eGFP+AvrA particles, respectively (Figure 5.12). These results were not surprising, since 
macrophages constantly sample their environment and are known to uptake higher 
amounts of particles than many other types of cells [25].  
Cells were also incubated with AvrA at 4°C and uptake of particles and soluble 
protein was evaluated. Macrophages showed a 40-fold fluorescence increase when 
incubated with eGFP+AvrA particles and 2-fold increase when incubated with soluble 
formulations. Meanwhile, SK-CO15 did not show significant fluorescence increase when 
incubated with particle or soluble formulations of AvrA and eGFP. These results 
suggested that epithelial cells use only energy dependent mechanisms to internalize 
AvrA+eGFP nanoparticles and macrophages use a combination of energy dependent and 




Figure 5.11. Particle internalization of J774.A1 cells. Representative flowcytometry 
fluorescence intensity histogram for cells incubated for 6 hours with PBS, soluble AvrA 






Figure 5.12. Particle internalization of SK-CO15 cells. Representative flowcytometry 
fluorescence intensity histogram for cells incubated for 6 hours with PBS, soluble AvrA 
with eGFP and eGFP+AvrA nanoparticles. 
 
 
5-5-2 Intracellular detection of AvrA particles 
Particle internalization assays presented above did not directly establish the 
presence of AvrA inside the cells. The evidence of internalized eGFP only suggested that 
AvrA was also co-delivered and internalized. To specifically quantify the uptake of 
AvrA, flow cytometry and anti-AvrA antibodies were used. Since the dose of AvrA 
delivered to the cell is very low (each 100nm particle contains approximately 117 
molecules of AvrA), signal from the antibody was amplified using secondary antibodies 




Figure 5.13. AvrA internalization studies on SK-CO15 cells. Topographical map shows 
distribution of cell populations for cell incubated for 6 hours with cell media, 
eGFP+AvrA nanoparticles or eGFP nanoparticles (from left to right). Cells were studied 








Figure 5.14. AvrA internalization studies on J774 cells. Heat map shows distribution of 
cell populations for cell incubated for 6 hours with cell media, eGFP+AvrA nanoparticles 
or eGFP nanoparticles (from left to right). Cells were studied for anti-AvrA antibody 
fluorescence (y-axis) and eGFP fluorescence (x-axis). 
 
 
Uptake of eGFP+AvrA nanoparticles was established by counting the population 
of cells that showed a simultaneous increase in eGFP and anti-AvrA (quantum dot) 
fluorescence. SK-CO15 cells incubated with eGFP+AvrA antibodies exhibit a shift in 
population fluorescence of both fluorescent signals, greater than when incubated with 
eGFP only particles (Figure 5.13). This simultaneous increase is indicative of the 
presence of both eGFP and AvrA within the cells. Similarly, J774.A1 macrophages 
incubated with eGFP+AvrA nanoparticles form a new population that is positive for 
eGFP fluorescence and AvrA antibody binding (Figure 5.14). These results suggest that, 






Figure 5.15. Summary of flow cytometry internalization data measuring AvrA in SK-
CO15 and J774.A1 cells incubated with protein for 6 hours. Positive events were 
established by counting the population of cells that showed a simultaneous increase in 
eGFP and anti-AvrA.  
 
 
5-6 Cytotoxicity of AvrA nanoparticles  
Treatment of IBD requires reduction of inflammation in affected tissues without 
damage or cytotoxicity to the intestinal tissue. Salmonella injected AvrA has been 
previously shown to subvert the MAPK JNK and NF-κB pathways without inducing cell 
death [5]. Therefore, nanoparticle formulations were not expected to be cytotoxic to cells. 
Particle and soluble formulations of recombinant eGFP and AvrA/mAvrA were incubated 
with cells and no significant difference in cytotoxicity is observed between them and a 





Figure 5.16. LDH cytotoxicity assay for J774.A1 cells incubated with soluble and 
nanoparticle formulations of eGFP+AvrA/mAvrA for 6 or 24 hours. Control cells were 




5-7 Evaluation of eGFP+AvrA particles in vitro and in vivo 
Once particles were optimized, the Neish lab at Emory University evaluated the 
performance of eGFP+AvrA nanoparticles in in vitro and in vivo models of the disease. 
AvrA nanoparticles were shown to disassemble and release soluble AvrA in model 
polarized intestinal epithelial monolayers (T84 cells) and macrophages. Delivered AvrA 
was successful in partly suppressing both TNF-α induced JNK activation and IκB 
degradation in T84 cells. Additionally, AvrA nanoparticles markedly reduced secretion of 
the pro-inflammatory cytokine IL-8. eGFP+AvrA nanoparticles strongly inhibited 
primary murine polymorphonuclear leukocyte translocation across T84 monolayers, a 
critical inflammatory behavior.  
To detect particle uptake into immune and endothelial cells in vivo, eGFP+AvrA 
nanoparticles were administered to mice via transrectal instillation into healthy and 
inflamed colons. Immediately after instillation, eGFP fluorescence was observed in the 
extracellular mucosal layer of normal and inflamed colon. After 3 hours, in healthy colon, 
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eGFP fluorescence was detected in epithelial cells and occasionally in immune cells. In 
inflamed colon, fluorescence markedly increased immune cells. This data proved that 
optimized eGFP+AvrA nanoparticles were capable of traversing the mucosal layer and 
were effectively internalized by epithelial and immune cells. 
Furthermore, the anti-inflammatory potential of AvrA nanoparticles was 
demonstrated in multiple murine models. In a traditional murine peritonitis model of 
acute inflammation, pretreatment with AvrA particles resulted in significant reduction of 
neutrophil influx into the peritoneal cavity, an indicator of reduced inflammation. TNBS 
and DSS murine colitis models also showed eGFP+AvrA particles suppressed histologic 
inflammation and clinical symptoms for both pretreated tissues and in simulated therapy 
of existing disease.  
 
5-8 Summary 
The results presented in this chapter demonstrate the versatility of the 
protein+enzyme particle fabrication method and show the potential of bacterial effectors 
for therapeutic purposes. Specifically, this chapter focused on application of the effector 
AvrA for treatment of IBD. AvrA particles were designed to cross the mucosal layer that 
lines the intestine and deliver the enzyme to epithelial and immune cells that drive and 
sustain the disease. AvrA was successfully incorporated into eGFP nanoparticle 
formulations and particle size was controlled by varying imidazole concentration during 
fabrication. eGFP+AvrA nanoparticles were shown to aggregate in reducing buffers but 
disassembled into single proteins in reducing cellular environments. Furthermore, it was 
established that these protein particles effectively delivered AvrA to cells without 
cytotoxic effects. Significantly, in vivo studies performed by the Neish lab at Emory 
demonstrated eGFP+AvrA nanoparticles cross the mucosal layer, deliver the enzyme to 
epithelial and immune cells, and reduce inflammation. These results show the potential of 
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AvrA and other effectors as therapeutic agents and provide proof of the promise of 
protein particles for intracellular enzyme delivery. 
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6CHAPTER 6: SELF-ASSEMBLED YOPJ NANOPARTICLES FOR 
THE TREATMENT OF BREAST CANCER 
 
 
 Bacterial pathogen evolution has produced proteins that can trigger 
apoptosis of host cells during infection by inhibiting protein synthesis, forming pores on 
cell membranes, or by activating the death machinery of cells[1]. Some of these proteins, 
known as bacterial effectors, activate the death machinery by co-targeting multiple 
intracellular signaling pathways [2-5]. These effectors have high potential as therapeutic 
agents for cancer because they can trigger apoptosis through a variety of different 
mechanisms[6].  
YopJ and its homologue, YopP, are potent pro-apoptotic effectors from Yersinia 
pestis and Yersinia pseudotuberculosis. These effectors inhibit the MAPK and NF-κB 
pathways by acetylating key kinases [7, 8]. Among these inhibited pathways is the 
extracellular signal-regulated kinase (ERK), which has been correlated to invasion and 
metastasis in multiple breast cancer models [9]. In addition, YopJ/P is cell selective, as it 
induces apoptosis in macrophages but not in endothelial cells or neutrophils [10, 11]. 
These traits make YopJ/P an exceptional candidate for treatment of breast cancer. 
Nonetheless, the intrinsic bacterial pathogenicity, lack of targeting, and possible genetic 
instability are difficult challenges that currently preclude the use of Yersinia or other 
bacterial pathogens in the clinic.  
In this chapter, feasible YopJ cancer therapeutics are created by replacing the 
pathogen secretion mechanism with a delivery vehicle made of YopJ protein itself. For 
this purpose, YopJ is genetically fused to glutathione S-transferase (GST) to induce self-
assembly, via protein-protein interactions, into stable 100 nm diameter particles. These 
nanoparticles are characterized under different conditions and are shown to successfully 
deliver YopJ to cancer cells. The effect of YopJ-GST particles on various breast cancer 
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cell lines is studied and compared to a common chemotherapeutic agent, doxorubicin 
(dox). Evidence indicates that YopJ-GST is more effective than dox in inducing cell 
death in all breast cancer cell lines. Unlike dox, sub-lethal doses of YopJ-GST particles 
are shown to decrease cell migration and down-regulate the ERK1/2 pathway. Finally, 
the selective cytotoxicity of the nanoparticles is demonstrated as YopJ-GST nanoparticles 
are not cytotoxic to NIH/3T3 or HeLa cells, unlike dox.  
 
6-1 Experimental details 
6-1-1 Determination of particle size and zeta potential 
Particle size distribution was measured by dynamic light scattering using a 
Zetasizer Nano ZS90 (Malvern Instruments Ltd). The samples were measured at 25°C 
and a scattering angle of 90°. Average particle size was calculated as the arithmetic mean 
of the distribution of at least 3 batches of particles and the standard deviation was 
calculated as the variance between average diameters of the batches. Number 
distributions were used to describe particle size in order to remove artifacts and 
additional peaks caused by the presence of aggregates, that due to their size obscure the 
main population. Nonetheless, in all cases the main population peak in number 
distribution was observed to match the peak for the main population in intensity 
distribution.  
The zeta potential of the particles was determined by measuring the 
electrophoretic mobility of the nanoparticles using the same instrument. Zeta potentials 
were measured in PBS and 10 mM HEPES buffer, which provided information about the 
intrinsic surface charge and the surface charge once biologically relevant ions have 
adsorbed to the particles. Average particle zeta potential was calculated as the arithmetic 
mean of the distribution of at least 3 batches of particles and the standard deviation was 




6-1-2 Nanoparticle disassembly 
Conditions for particle disassembly were evaluated using SDS-PAGE and western 
blot after suspending particles in reducing Laemmli buffer (10% glycerol, 60 mM Tris-
HCl, 2% SDS, 1.25% 2-mercaptoethanol), non-reducing Laemmli buffer (10% glycerol, 
60 mM Tris-HCl, 2% SDS) or native buffer (25% glycerol, 62.5 mM Tris-HCl). Treated 
particles were run in 10% SDS-PAGE gels and stained with coomassie blue, or 
transferred to a nitrocellulose membrane and immunostained with anti-5xHis tag Alexa 
488-conjugated antibody (Qiagen).  
6-1-3 Cell culture  
SKBR-3, MCF-7, MDA-MB-231, MDA-MB-468, HeLa and NIH/3T3 cells were 
purchased from American Type Culture Collection. SK-BR-3 cells were grown in 
McCoy 5A Media supplemented with 10% fetal bovine serum (FBS). MCF-7 cells were 
grown in Eagle’s minimum essential medium supplemented with 0.01 mg/ml human 
recombinant insulin and 10% FBS. MDA-MB-231 and MDA-MB-468 were cultured in 
Leibovitz’s L-15 medium supplemented with 10% FBS. HeLa cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% FBS. NIH/3T3 
cells were cultured in DMEM supplemented with 10% calf serum. All media was 
supplemented with 1% penicillin/streptomycin and cells were incubated at 37°C in a 5% 
CO2 humidified atmosphere, except for MDA-MB-231 and MDA-MB-468 which were 
incubated without CO2. Dox resistant SKBR-3 cells were derived from the parental cell 
line by continuously exposing cells to increasing dox concentrations that began at 0.05 
µM and ended at 0.4 µM. Cells were allowed to recover from treatment for 3 days in dox 
free media before increasing the dox dose.  
Cells used in this work were passaged at 80-90% confluency and following 
ATCC protocols. Cells used for experiments were passaged at least two times before use 
and did not exceed passage number 20. Cell morphology and normal behavior were 
verified before use.  
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6-1-4 Confocal microscopy 
Cells were seeded at a density of 1.5x104 cells per well in an 8-well chamber slide 
system (Nunc LabTek II, Thermo Scientific) with growth medium. After 16-24 hours, 
cells were incubated with mYopJ-GST particles (0.8 µM) or equivalent volume of 2X 
PBS + 5% dextrose in growth medium for 72 hours. After incubation cells were washed 
three times with PBS and fixed in 3.7% paraformaldehyde for 15 min at room 
temperature. They were rinsed with PBS three times, for 5 min each and incubated in 
blocking buffer (PBS with 1% BSA and 0.3% Triton X-100) for 1 hour. After blocking, 
cells were incubated in blocking buffer containing diluted anti-GST Dylight-488 antibody 
(1:100) for 1 hour. Cells were rinsed three times in PBS and incubated with 2 µM TO-
PRO-3 (Invitrogen) and 0.165 µM rhodamine phalloidin (Biotium) in blocking buffer for 
20 min at room temperature. Cells were washed three times with PBS and mounted for 
imaging in a Zeiss LSM 700 confocal microscope. 
6-1-5 Cellular internalization of nanoparticles 
Uptake of particles was assessed by flow cytometry. Cells were seeded at a 
density of 3x105 per well in a 24-well plate in growth medium. After 16 hours the cells 
were incubated with mYopJ-GST particles (0.4 µM) or equivalent volume of 2X PBS + 
5% dextrose in growth medium for 72 hours, unless otherwise stated. After incubation 
cells were washed three times with PBS to remove surface bound particles, trypsinized, 
and collected. Cells were prepared following Cell Signaling Technology flow cytometry 
protocol. In brief, cells were washed twice by centrifugation (500 rpm for 5 min), re-
suspended in 3.7% para-formaldehyde, and fixed for 10 minutes at 37°C. Immediately 
after fixing, cells were permeabilized by addition of ice-cold methanol to a final 
concentration of 90% and incubated on ice for 30 min. Next, cells were washed twice 
with PBS and incubated with blocking buffer (0.5% bovine serum albumin (BSA) in 
PBS) for 10 minutes. Cells were washed with blocking buffer by centrifugation, 
resuspended in blocking buffer containing 1:100 anti-GST conjugated to Dylight-488 
 108 
 
(Rockland Inc.) and incubated for 1 hour. Finally, cells were washed three times with 
blocking buffer by centrifugation, resuspended in cold PBS, and filtered with a 35 µm 
cell strainer. Labeled cells and controls were analyzed with an Accuri C6 (Becton 
Dickinson and Company) flow cytometer. Relative uptake was quantified as the ratio of 
mean fluorescence intensity of the sample population to mean fluorescence of the control 
population (no particles given).  
6-1-6 Cytotoxicity evaluation of YopJ nanoparticles 
Cytotoxicity of YopJ was evaluated using flow cytometry. For flow cytometry 
studies, cells were seeded at 9x104 cells per well in a 48-well plate in growth medium. 
After 12 hours of incubation the medium was changed and cells were incubated with 0.4 
µM YopJ-GST or mYopJ-GST nanoparticles, 0.4 µM or 2 µM dox, or 2X PBS + 5% 
dextrose in growth medium for 72 hours. Cells were washed with PBS, trypsinized and 
collected. Cells were prepared for live/dead staining or cell counting. Live/dead staining 
of cells was performed with annexin V Alexa Fluor 488 and Sytox green dye (Invitrogen) 
or using annexin V Alexa Fluor 488 and propidium iodide (Invitrogen), as indicated by 
the manufacturer’s protocol. At least 104 cells and controls were analyzed with an Accuri 
C6 flow cytometer. Since YopJ-GST nanoparticles induced cell fragmentation, whole 
cells were counted to measure the viable population. Cells were prepared for counting by 
resuspension in cold PBS and cells within the normal cell population gate were counted 
to excluded cell fragments. Percent live cells were calculated as number of gated cells in 
sample relative to average number of gated cells in control.  
MTT cell metabolic activity assays were used to confirm flow cytometry results. 
For this purpose, 1x104 cells were seeded in each well of a 96-well plate and incubated in 
growth medium. After 16 hours the medium was changed and cells were incubated with 
0.4 µM YopJ-GST or mYopJ-GST nanoparticles, 0.4 µM or 2 µM dox, or 2X PBS + 5% 
dextrose in growth medium for 72 hours. Then the media was changed with fresh media 
and samples were prepared by the manufacturer’s MTT assay protocol (Biotium). 
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6-1-7 Evaluation of ERK 1/2 Activity 
The activity levels of the ERK 1/2 pathway were assessed by flow cytometry. 
1x106 SKBR-3 cells per well were seeded in a 6-well plate and incubated in growth 
medium for 16 hours. Next, cells were incubated in serum-free growth medium with 0.16 
µM YopJ-GST, mYopJ-GST, or 2X PBS + 5% glucose for 24 hours. Cells were 
stimulated with 20 ng/ml EGF for 15 minutes, fixed, permeabilized and blocked as 
described in section 5-1-7. Cells were incubated in 1:2000 dilution of anti-phospho ERK 
1/2 (Thr202/Tyr204) (Cell Signaling Technology) in blocking buffer for 1 hour. This was 
followed by three washes in blocking buffer and incubation with 1:5000 dilution of anti-
mouse antibody conjugated to Alexa Fluor® 635 (Invitrogen). Cells and controls were 
analyzed with an Accuri C6 flow cytometer. 
6-1-8 Evaluation of NF-κB Activity 
Activation of the NF-κB pathway was assessed using western blots, ELISA and 
flowcytometry. SKBR-3 cells were seeded at a density of 1.5x106 cells/well in a 6-well 
plate for western blotting, 3x105 cells/well in 24-well plate and 1x104 cells/well in a 96-
well ELISA plate, these were incubated overnight. Cell media was then substituted with 
Hank’s balanced salt solution (Gibco) and nanoparticles (0.16 µM) or 2X PBS + 5% 
dextrose were added. After 24 hours of incubation, the NF-κB pathway was stimulated 
with 20 ng/ml rhTNFα (R&D systems).  
Cells were harvested for western blotting after 15 minutes, washed in PBS and 
lysed in RIPA buffer (150 mM sodium chloride, 1.0% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris, pH8.0). Lysates were separated by 10% SDS-
PAGE at 130 V for 120 minutes. Proteins were transferred to nitrocellulose membranes 
and immunostained with anti-IκBα antibodies. 
For flowcytometry assays cells were harvested after 15 minutes, washed twice in 
PBS fixed, permeabilized and blocked as described in section 5-1-7. Cells were incubated 
in 1:2000 dilution of anti-phospho IκBα (Cell Signaling Technology) in blocking buffer 
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for 1 hour. This was followed by three washes in blocking buffer and incubation with 
1:5000 dilution of anti-mouse antibody conjugated to Alexa Fluor® 635 (Invitrogen). 
Cells and controls were analyzed with an Accuri C6 flow cytometer. 
Human phospho-IκBα (S32/S36) cell-based ELISA (R&D systems) procedures 
were prepared, ran and analyzed as recommended by the manufacturer for adherent cells.  
6-1-9 Evaluation of cell migration and invasion 
Migration of SKBR-3 cells was studied in a Cultrex® migration assay (Trevigen). 
For this purpose, cells were starved by incubation in serum-free medium for 24 hours 
prior to the assay. 5 x 104 cells per well were suspended in 200 µL serum-free medium 
with 0.16 µM YopJ-GST, mYopJ-GST, dox, or 2X PBS + 5% dextrose and seeded in the 
upper chamber. The lower chamber was filled with growth medium containing 10% FBS 
as the chemoattractant. After 48 hours, cells on the upper side of the membrane were 
aspirated and cells in the bottom chamber were dissociated and stained with Calcein AM. 
Fluorescence was determined in a Biotek Synergy H4 plate reader and compared to a 
standard curve as described by the assay’s protocol.  
An in vitro wound-healing assay was used to assess the effect of YopJ-GST 
nanoparticles on cell motility. Briefly, 5 x 105 SKBR-3 cells per well were seeded in 6-
well plates in complete growth medium. When the culture had reached 90% confluency, 
the cell layer was scratched with a sterile 200 µl plastic tip, washed twice with PBS, and 
cultured in complete growth medium with 0.16 µM YopJ-GST, mYopJ-GST, dox, or 2X 
PBS + 5% dextrose for 24 hours. Phase contrast images of the plates were acquired with 
an Axio Observer Z1 (Carl Zeiss) microscope and analyzed as described by Valster et al. 
[12] Wound healing was measured at 0 and 48 hours. 
6-1-10 Statistical analysis 
All quantitative experiments were triplicated and presented as arithmetic mean ± 
standard deviation. One-way analysis of variance (ANOVA) was used to determine 
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significance among groups, using StatPlus. P values <0.05 among groups were 
considered statistically significant. 
 
6-2 YopJ nanoparticle design considerations 
Breast cancer remains as the second leading cause of death for women worldwide. 
However, the main cause of death is not usually the primary tumor, but metastases that 
develop in the liver, lungs, and bones [13]. To effectively treat this disease and reduce 
metastasis risk, many women undergo chemotherapy. Chemotherapy, while effective at 
increasing the rate of patient survival, has a variety of acute and long-term adverse 
effects. As most chemotherapeutic agents are small molecules, their size allows them to 
reach almost any tissue in the body, leading to off-target activity and significant side 
effects [14]. For these reasons, there is a need for new therapeutics that can decrease the 
risk of metastases while having fewer adverse side effects.  
Proteins, unlike chemotherapeutics and small molecule targeted therapies, are 
large macromolecules with complex structures that can confer the specificity and 
selectivity [15] necessary for better therapeutics. However, given their size and 
complexity there are many challenges associated with their biodistribution, effective 
intracellular delivery and activity retention [16]. For optimal therapeutic efficacy, 
sufficient amounts of protein must reach malignant tissues and enter the cells to induce 
cancer cell death while simultaneously not inducing adverse effects on normal tissues.  
As discussed in Chapter 4, efficient intracellular delivery of therapeutic proteins 
requires the use of nanoparticles that not only increase the amount of protein delivered 
but that may also help reduce immunogenicity. Protein nanoparticles are ideal for this 
task and, as shown in the previous chapters, have high potential for therapeutic protein 
and enzyme delivery. Transport of these particles to cancer cells is a three-step process in 
which particles must first reach the tumor area and extravasate from blood vessel walls. 
Then they must diffuse through the interstitial space and be internalized by cancer cells. 
 112 
 
In order for these steps to occur, the size, surface charge, shape and rigidity of the 
proteins or delivery vehicles must be controlled.  
6-2-1 Dose considerations 
For effective cancer therapy it is desirable to deliver a sufficient number of 
therapeutic molecules to completely inhibit the MAPK and NF-κB pathways and rapidly 
induce apoptosis of cancer cells. Thus, it is advantageous to produce YopJ delivery 
particles entirely from YopJ-GST, without adding a carrier protein. Applying the 
maximal density theorem, as explained in section 5-1-2, it is estimated that in a 100 nm 
spherical particle there are approximately 5,785 YopJ-GST molecules. This is more than 
5 times the amount of SipA molecules, a Salmonella effector, that has been found to 
affect biochemical functions within minutes [17] and was hypothesized to be sufficient 
for rapid induction of apoptosis.  
6-2-2 Surface charge 
Nanoparticle surface charge plays a crucial role in extravasation to tumors, 
interstitial transport and cellular internalization, which are fundamental steps for effective 
delivery of YopJ to tumor cells. Neutral particles have been shown to have longer 
systemic circulation times than charged particles [18]; but among charged particles, 
anionic particles show lower serum protein binding and longer circulation times than 
cationic particles [19]. Longer systemic circulation times can enhance delivery to target 
tissues by allowing more passes through the body.  
Once nanoparticles have reached the tumor vicinity they must cross the vascular 
wall to enter the tissue. Cationic nanoparticles exhibit higher vascular permeability than 
their neutral or anionic counterparts [20]. However, neutral nanoparticles diffuse faster 
and achieve more homogeneous distributions inside the tumor interstitial space, as a 
result of lower interactions with positively charged collagen and negatively charged 
hyaluronan in the extracellular matrix [21]. Finally, nanoparticles must enter target cells 
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in order to deliver the drug. Higher particle internalization has been observed for charged 
particles versus neutral particles [22].  
Together, these findings indicate that in order to effectively deliver YopJ to the 
cells, it is preferable to produce particles with neutral or near neutral surface charge. 
Nevertheless, the charge of YopJ-GST will determine surface charge and thus, surface 
modification with polymers or peptides could be necessary to improve delivery.  
6-2-3 Nanoparticle size 
One of the main reasons nanomedicine for cancer therapy is advantageous over 
conventional soluble therapies, is its potential to enable preferential delivery of drugs to 
tumors. It is well established that the endothelial lining of tumor vasculature is more 
permeable than in normal tissue. The increased permeability is the result of blood vessels 
with defective architecture and larger pores (Figure 6.1), which leads to higher hydraulic 
conductivity [23]. As a result, particles ranging from 50-500 nm in size can leave the 
vascular bed and accumulate in tumor tissue [21, 24]. This is known as the enhanced 
permeability and retention (EPR) effect that has now become the “gold standard” for 
cancer drug delivery design. In addition, the EPR effect has not only been observed in 
advanced solid tumors, it has also been observed during the early stages of 
carcinogenesis, such as dysplasia and hyperplasia lesions [25]. Therefore, this effect can 
also facilitate treatment of cancer at early stages.  
However, the defective blood vessel architecture can also make homogeneous 
particle delivery difficult. Unlike normal blood vessels, tumor vessels are heterogeneous 
in their spatial distribution, leaving avascular spaces [21]. Thus, once nanoparticles have 
reached the tumor the main challenge for effective treatment becomes uniform delivery 
throughout the tumor or lesion. In order for nanoparticles to reach the avascular spaces 
they must diffuse through the dense extracellular matrix in the interstitial spaces. The 
tumor interstitial matrix consists of a highly interconnected network of collagen fibers. 
Collagen content varies between tumors and is a major determinant of nanoparticle 
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diffusion; diffusion is hindered to a greater extent in tumors rich in collagen [26]. 
Spherical rigid particles larger than 60 nm in diameter are not able to effectively 
penetrate the tumor interstitial space, but elongated, semi-flexible and soft particles 




Figure 6.1. EPR effect in tumor vasculature. Passive targeting of nanoparticles between 
50-550 nm to tumors occurs through the increased permeability of the tumor vasculature 
(schematic not drawn to scale). 
 
Particle size also plays a crucial role in cellular internalization. Cancer cells have 
been found to uptake relatively large amounts of particles via energy dependent 
mechanisms, which are highly affected by particle size [29]. Published data has shown 




6-2-4 General design 
In order to replace the T3SS mechanisms and effectively deliver YopJ to breast 
cancer cells to induce cell death, it is necessary to produce particles that meet the 
necessary conditions for extravasation into tumor tissue, diffusion through the interstitial 
space, internalization into mammalian cells. Since it desirable to deliver sufficient 
therapeutic molecules to completely inhibit the MAPK and NF-κB pathways and rapidly 
induce apoptosis in cancer cells, YopJ delivery vehicles particles should be made directly 
from YopJ-GST. These particles, like those described in Chapter 4 and 5, must be able to 
release their cargo inside cells (Figure 6.2). As shown in the previous chapters, particles 
held together by disulfide bonds are environment-responsive and disassemble inside 
cells, releasing soluble proteins. Thus, YopJ-GST nanoparticles held together by disulfide 
bonds could also release their cargo inside of cells.  
In general, small soft particles (50-100 nm in diameter) would be able to leave 
systemic circulation and accumulate in tumor tissues, while still being able to diffuse 
through the intracellular matrix and be internalized by cancer cells. It was hypothesized 
that protein nanoparticles can be made soft by cross-linking the proteins at a low ratio of 
cross-linker to lysine residues (≤ 1:2.2, ratio used in Chapters 4 and 5) or by using self-
assembly methods. This would allow particles to be semi-flexible and diffuse easier 
through the extracellular matrix. In addition, YopJ delivery vehicles should be neutral or 
nearly neutral to increase blood circulation times, and decrease adhesion and interaction 





Figure 6.2. Schematic representation of bacterial T3SS effector delivery and proposed 
protein nanoparticle delivery. Bacterial pathogens inject effector proteins directly into the 
cytoplasm of host cells through needle-like structures (left). In the cytoplasm effectors 
bind their co-activator or chaperone that refolds them and potentiates their action [31]. 
Effectors are capable of subverting multiple intracellular pathways to control multiple 
cellular functions. The proposed strategy is to deliver the YopJ in self-assembled effector 
nanoparticles (right) to cancer cells to induce cell death and decrease activity in 
metastasis-associated pathways. 
 
6-3 Production and characterization of YopJ-GST nanoparticles 
Bacterial protein effectors have several advantages as therapeutic agents for 
cancer, including their ability to target pathways associated with cancer hallmarks, cell 
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migration and metastasis [32, 33]. However, bacterial effector proteins cannot be 
therapeutically delivered by the pathogenic bacteria that produce them. In order to deliver 
active proteins to cancer cells, it is necessary to engineer a delivery system. 
Recombinant technology was used to produce YopJ in E. coli, as explained in 
Chapter 3. In brief, production of YopJ in E. coli required fusion to GST, a common 
protein tag used to decrease protein toxicity and increase solubility. An inactive C172A 
mutant of YopJ fused with GST (mYopJ-GST) was also cloned and produced. This 
mutation removes acetyltransferase activity, and serves as a control for nonspecific 
effects of bacterial proteins [31].  
Fusion of YopJ and mYopJ to GST induced protein self-assembly into stable 
nanoparticles with zeta potential of –17.4 ± 3.4 mV in 20 mM Hepes buffer. This 
indicates that YopJ-GST nanoparticles are negatively charged in low ionic strength 
buffers. However, as was also observed in the previous chapters, the zeta potential 
increases between 40-45% in physiologically relevant salt concentrations to -10.2 ± 2.9 
mV. This increase, caused by ion adsorption, leads to low apparent negative surface 
charge and can prevent particle interaction with extracellular matrix components. 
Dynamic light scattering (DLS) indicated that both fusion proteins self-assembled 
into nanoparticles during expression and purification processes. As shown in Figure 6.3, 
the average YopJ-GST particle diameter was 150 nm in 8 M urea purification buffer. 
However, the average hydrodynamic diameter decreased to 100 nm when the particles 
were suspended in 2X phosphate buffered saline (PBS) with 5% dextrose (nanoparticle 
storage buffer) or in organic solvents. Particles with 100 nm diameter are ideal for cancer 
treatment due to the enhanced permeability and retention effect in tumors[18]. In 
addition, this small size and will allow diffusion through the interstitial space and 
internalization of particles by tumor cells [34]. The observed difference in particle size 
between saline buffers and denaturing agents suggests that denaturing conditions unfold 
or partially unfold the proteins in the particles causing them to expand or swell. 
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Interestingly, denaturing conditions are not sufficient to cause particle disassembly, 
which indicates that YopJ-GST nanoparticles are highly stable. 
 
 
Figure 6.3. Characterization of self-assembled YopJ-GST nanoparticle size. (A) 
Representative DLS nanoparticle size distribution in 2X PBS + 5% dextrose. (B) 
Representative DLS nanoparticle size distribution in 8M urea, shows particle swelling in 
denaturing conditions.  
 
To establish which forces stabilize YopJ-GST nanoparticles, particles were 
exposed to denaturing agents (SDS buffer, heat), reducing agent (1% β-mercaptoethanol) 
and native conditions (Tris-HCl buffer). Treated particles were evaluated by SDS-PAGE 
and western blot to identify which conditions led to particle disassembly and release of 
soluble YopJ-GST protein. Figure 6.4 shows that a combination of reducing and 
denaturing conditions are necessary for complete particle disassembly. Denaturing 
conditions alone release some soluble protein, evidenced by a less intense band at 60 
kDa. Under native conditions a very dim band was observed, indicating little protein was 




Figure 6.4. Analysis of SDS-PAGE gel shows YopJ-GST nanoparticle disassembly in 
the presence of denaturing agents (detergent: SDS and heat: 100°C), reducing agent (β-
mercaptoethanol) or under native conditions. Band intensity is correlated to amount of 
protein released. 
 
These results indicate that hydrophobic interactions and disulfide bonds stabilize 
the particles. Both YopJ and GST contain cysteine (Cys) residues and hydrophobic 
regions that can initiate and sustain particle self-assembly. GST contains 4 Cys residues 
that have been shown to be accessible and facilitate oxidative aggregation when GST or 
GST fusions are overexpressed [35]. Furthermore, there are multiple small segments 
within GST that can form strong intermolecular hydrophobic interactions, such as the 
“lock and key” formed by the phenyl ring of phenylalanine at position 52 and a pocket 
between α-helices 4 and 5 of a neighboring GST molecule [36]. YopJ contains 2 cysteine 
residues in its sequence and a large number of hydrophobic residues that are potentially 
exposed when the protein is unfolded or partially folded following E. coli expression. 
YopJ requires binding to a mammalian co-activator for proper protein folding[31], and 
prior to this, the exposed hydrophobic domains may interact with each other. Also, many 
effector proteins, including YopJ, are kept unfolded by a chaperone in the native bacteria 
[37]. This chaperone is not present in the E. coli expression system, which can lead to 
interactions that cause aggregation. The combination of these intermolecular interactions 
is likely responsible for the initial assembly of YopJ-GST nanoparticles and their stability 




6-4 Delivery and effect on SKBR-3 cells 
6-4-1 Intracellular delivery of particles to SKBR-3 cells 
The bacterial pathogen Yersinia, uses the needle-like type III secretion system 
(T3SS) to directly inject effector proteins into the cytoplasm of host cells [3]. To 
determine whether nanoparticles could replace the T3SS mechanism and deliver effector 
proteins to breast cancer cells, SKBR-3 cells were used. SKBR-3 is a breast cancer cell 
line that over-expresses human epidermal receptor-2 (HER2) and is estrogen receptor 
(ER) and progesterone receptor (PR) negative [38]. In addition, these cells show 
upregulation of MAPK and NF-κB pathways [39].  
To evaluate particle internalization, cells were incubated with 0.4 µM mYopJ-
GST nanoparticles and washed to remove externally bound particles. The mutant fusion 
protein was used to avoid interference of cell death with the assay. The fusion protein 
was detected by fluorescent immunolabeling with anti-GST. As shown by flow 
cytometry, treated cells exhibited a time dependent increase in fluorescence intensity 
(Figure 6.5A). At 24 hours, mYopJ-GST is detected in cells at very low levels. After 72 
hours of incubation, cells showed a 1.2-fold increase in median fluorescence intensity. 
Confocal microscopy images support this data (Figure 6.5B-E). A significant amount of 
protein was located inside cells, indicating the self-assembled YopJ-GST particles 






Figure 6.5. Interaction of YopJ-GST nanoparticles with SKBR-3 cells. (A) Flow 
cytometry analysis of untreated cells (black) compared to cells treated with 0.4 µM 
mYopJ-GST nanoparticles for 24 or 72 hours (green, red), labeled with anti-GST Dylight 
488. (B-E) Confocal immunofluorescence analysis of (B, C) untreated cells or (D, E) cells 
treated with 2x dose (0.8 µM) of mYopJ-GST nanoparticles for 72 hours, using anti-GST 
Dylight 488 (green). Actin filaments are labeled with rhodamine phalloidin (red) and 
DNA (nucleus) with TO-PRO-3 (blue). Scale bar is 20 µm.  
 
 
6-4-2 Cytotoxic effect of YopJ-GST nanoparticles 
To establish the effect of YopJ on SKBR-3 cell viability, multiple concentrations 
of particles were tested. A concentration of 0.4 µM YopJ-GST nanoparticles was 
sufficient to induce significant cell death, but lower concentrations (0.05, 0.12, and 0.25 
µM YopJ-GST) did not affect cell viability. Doxorubicin (dox), a highly cytotoxic 
chemotherapeutic agent often administered to breast cancer patients [40], was used as a 
reference. The cytotoxic effect of YopJ-GST nanoparticles was assessed by microscopy, 
flowcytometry, live/dead dyes, and MTT assay.  
Treatment with YopJ-GST induced 84% cell death in 24 hours (Figure 6.6), even 
though the presence of the particles was barely detectable within this time period. This is 
indicative of the high potency of YopJ [17]. After 72 hours, only 3% of cells remained 
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viable, while 11% of cells treated with the same molar concentration of dox survived. To 
achieve the same level of cell death as YopJ-GST, the dox concentration had to be 
increased 5-fold, to 2 µM. Microscopy studies of cells incubated with YopJ-GST 
nanoparticles revealed that after 72 hours only a few cells had survived and remained 




Figure 6.6. Viability of SKBR-3 cells treated with YopJ-GST nanoparticles. Cell 
metabolic activity, measured by flowcytometry, after 72 hours of treatment with 0.4 µM 
YopJ-GST or mYopJ-GST nanoparticles or 2 µM dox, compared to control cells 



































Figure 6.7. Fluorescence microscopy images of cells incubated with YopJ-GST 
nanoparticles and controls for 72 hours. Cell nuclei were stained with Hoechst and cells 































Figure 6.8. Cytoxicity of YopJ-GST nanoparticles on SKBR-3 cells. Cell metabolic 
activity, measured by MTT assay, after 72 hours of treatment with 0.4 µM YopJ-GST or 
mYopJ-GST nanoparticles or 2 µM dox, compared to control cells incubated with 2X 
PBS + 5% dextrose. Error bars represent standard deviation, N=3 (*p<0.01). 
 
YopJ-GST nanoparticles caused fragmentation of cells and staining with annexin 
V, SYTOX® green and propidium iodide (PI) did not indicate apoptosis or necrosis as 
the cause of death (Figure 6.9). Flow cytometry analysis using annexin V-Alexa 488 and 
PI was used to characterize cells after 24 hours of treatment. Dox was used as a positive 
control for apoptosis and necrosis. Dot plots of PI fluorescence versus annexin V 
fluorescence were used to establish the live/dead status of treated cells (Figure 6.9A). The 
lower right quadrant (LR) indicates annexin-positive, early apoptotic cells. The cells in 
the upper right quadrant (UR) are annexin-positive and PI-positive, indicating late 
apoptotic or necrotic cells. Cells in the upper left quadrant (UL), PI-positive, indicate 
necrotic cells. Interestingly, cells treated with YopJ-GST nanoparticles appear in the 
lower left quadrant that indicates live cells, but fewer cells were counted in comparison to 
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mYopJ and the control. After 72 hours of treatment there were not enough whole cells in 
the YopJ-GST sample to establish mechanism of cell death. Since these observations 
indicate that cells fragment during or after YopJ-induced death, shorter periods of time, 
lower doses and other dyes (Sytox green) were used. Nonetheless, similar results were 
obtained and no indication of apoptosis or necrosis was observed.  
 
Figure 6.9. In vitro assessment of apoptosis in SKBR- 3 breast cancer cells treated with 
YopJ-GST. (A) Flow cytometry analysis using annexin V-Alexa 488 and PI was used to 
observe the induction of apoptosis or necrosis. Doxorubicin was used as a positive 
control for annexin-V and PI staining. (B) Flow cytometry analysis using annexin V-
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Alexa 488 and Sytox green. An increase in population fluorescence intensity indicates the 
presence of apoptotic or necrotic cells.  
 
 
6-4-3 Effect of YopJ-GST nanoparticles on MAPK ERK1/2 activity 
In an effort to establish if the observed cytotoxicity was the result of the 
biochemical activity of YopJ on cellular signaling, the effect of YopJ-GST nanoparticles 
on the ERK 1/2 pathway activity was measured. YopJ is known to irreversibly acetylate 
the serine and threonine residues of Mitogen/Extracellular signal-regulated Kinase 1/2 
(MEK 1/2), directly preventing phosphorylation of MEK 1/2 and subsequently inhibiting 
ERK 1/2 phosphorylation and activation of the pathway [41]. Levels of phosphorylated 
ERK 1/2 were measured following incubation with a sub-lethal dose of YopJ-GST 
nanoparticles (0.16 µM) for 24 hours and stimulation of the pathway with epidermal 
growth factor (EGF). Phosphorylated ERK 1/2 in cells was fluorescently immunolabeled 
and quantified by flow cytometry. Figure 6.10 shows lower fluorescence intensity, 
representing lower levels of phosphorylated ERK 1/2, for stimulated cells pretreated with 
YopJ-GST nanoparticles compared to cells pre-treated with mYopJ-GST or untreated. 
This suggests that YopJ-GST nanoparticles block the ERK 1/2 pathway in breast cancer 



































Figure 6.10. Phosphorylation of ERK 1/2 pathway measured as relative fluorescence 
intensity of cells treated with sub-lethal doses (0.16 µM) of nanoparticles in serum-free 
media and stimulated with 20 ng/ml EGF for 15 min, compared to stimulated control. 
Error bars represent standard deviation, N=3 (*p<0.05). 
 
 
6-4-4 Effect of YopJ-GST on NF-κB activity 
In addition to its effect on MAPK signaling, YopJ is also known to exert 
inhibitory activity on NF-κB signaling [8]. Thus, the effect of YopJ on the NF-κB 
pathway was also examined. In inactivated cells, NF-κB is complexed with its inhibitor 
IκB and retained in the cytoplasm. When the pathway is activated IκB is phosphorylated, 
ubiquitinated and degraded, freeing NF-κB to enter the nucleus and affect transcription 
[41]. To evaluate pathway activation IκB degradation was assessed.   
Western blot analysis of cell lysates showed that stimulation with TNF-α caused 
IκBα degradation, even for cells pretreated with sublethal doses of YopJ-GST 
nanoparticles (Figure 6.11). Nonetheless, bands for cells pretreated with YopJ-GST and 
mYopJ-GST nanoparticles appear to have slightly higher intensities. In order to quantify 
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NF-κB pathway activation the phosphorylation of IκBα was quantified using a phospho- 
IκBα ELISA.  
 
Figure 6.11. Effect of YopJ-GST nanoparticles on IκBα degradation. Western blot on 
cell lysates probed with anti-IκBα antibody. NFκB pathway was stimulated with 20 ng/ml 
TNFα in Hank’s buffer and basal pathway levels were accomplished by incubating the 
cells in Hank’s buffer for 24h.  
 
Given the inhibition of ERK 1/2 signaling observed in cell pretreated with YopJ-
GST nanoparticles, it was hypothesized that delivered YopJ would also inhibit NF-κB 
signaling in breast cancer cells. Nevertheless, the results of the phospho-IκBα ELISA 
indicate that YopJ-GST nanoparticles do not prevent phosphorylation of IκBα or that 
other factors involved in the process upregulate signaling (Figure 6.12). These results 
were also confirmed in additional studies conducted using flowcytometry with phospho-





Figure 6.12. Effect of YopJ-GST nanoparticles on phosphorylation of IκBα. Results 
shown here represent measured phospho-IκBα normalized with GADPH. Cells were 
serum starved and incubated with YopJ or mYopJ for 24 hours, then stimulated with 20 
ng/ml of TNFα for 15 minutes. 
 
 
6-4-5 Effect of YopJ-GST nanoparticles on cell migration 
Since the ERK 1/2 pathway has been correlated to cancer cell migration, invasion 
and metastasis [42], the effect of YopJ-GST nanoparticles on SKBR-3 cell migration and 
invasion was evaluated. Cell motility was measured using a transwell assay, with FBS as 
the attractant and a sub-lethal dose (0.16 µM) of YopJ-GST nanoparticles. The number of 
cells that migrated to the lower chamber was quantified after 48 hours of treatment. 
Decreased cell migration was observed in the presence of YopJ-GST nanoparticles but 
not in the presence of equimolar concentrations of mYopJ-GST nanoparticles or dox 
(Figure 6.13). Similarly, a scratch assay showed that the invasive capacity of SKBR-3 
cells is lower after treatment with YopJ-GST nanoparticles than with dox (Figure 6.14).  
Inhibition of the ERK 1/2 pathway by YopJ decreased the migration and invasion 
capabilities of SKBR-3 cells, while dox did not. This suggests that surviving cells, or 
those receiving a sub-lethal dose of YopJ-GST nanoparticles, are less likely to migrate 



























correlates with mortality [43]. Though most studies focus on cell death, the “state” of 
surviving cells is just as critical for long-term remission. During treatment, not all cancer 
cells within a tumor or in the surrounding area will receive the same dose, due to 
transport limitations in avascular spaces and concentration gradients that develop. It is 
essential that cells receiving sub-lethal doses do not develop the characteristics necessary 
to metastasize. It has been demonstrated that many chemotherapeutic agents, including 
dox, activate ERK 1/2 and related pathways, thus, increasing cell motility and the 



































Figure 6.13. Cell migration of treated SKBR-3 cells. Migration of cells treated for 24 
hours with sub-lethal doses of nanoparticles in Boyden chambers, stimulated with 10% 
FBS as a chemoattractant. Migration of samples is normalized to migration of stimulated 























Figure 6.14. Relative cell invasion of SKBR-3 cells treated with YopJ-GST and dox. 
Invasion was measured in a wound healing assay. Wounds were created at t=0 and cells 
were treated with 0.4 µM nanoparticles or 0.4 µM dox for 24 hours. Error bars represent 
standard deviation, N=3 (*p<0.05). 
 
 
6-4-6 Cytotoxic effect of YopJ-GST nanoparticles on doxorubicin resistant cells 
Resistance to chemotherapy has also been correlated to ERK 1/2 activation [40] 
and thus, the response of dox resistant cells to YopJ-GST nanoparticle treatment was 
evaluated. Through repeated exposure cycles, SKBR-3 cells were made dox resistant at 
0.4 µM. The resistant cells were treated with 0.4 µM YopJ-GST particles or dox for 72 
hours, immediately after dox exposure and recovery. SKBR-3 resistant cells treated with 
YopJ-GST nanoparticles showed low viability, 3.5%, similar to normal SKBR-3 cells 
(Figure 6.15). Conversely, dox treatment showed approximately 30% cell viability, about 
3 times that for normal SKBR-3 cells. This data suggests that YopJ-GST nanoparticles 
could be used not only as a primary adjuvant therapeutic, but also for patients who have 
previously received dox, to overcome resistance and inhibit metastasis-related pathways 






Figure 6.15. Cytotoxic effect of YopJ-GST nanoparticles on SKBR-3 doxorubicin 
resistant cells. Relative cell viability after 72 hours of treatment with 0.4 µM nanoparticle 
or dox, measured as number of live cells in sample relative to control. Error bars 
represent standard deviation for N=3 (* p<0.05, ** p<0.01). 
 
 
Further studies performed with SKBR-3 dox resistant cells demonstrated that after 
three or more passages without exposure to dox, the cells recovered and dox resistance 
levels doubled (Figure 6.16). Furthermore, cells no longer responded to YopJ-GST or 
mYopJ-GST nanoparticle treatment. Additional studies in which cells were incubated 
with a combination of dox and YopJ-GST did not show higher cytotoxicity levels or 
synergistic activity. Similarly, step treatment studies in which cells were first treated with 
YopJ-GST nanoparticles for 72 hours and then with dox for 72 more hours, showed there 






















Figure 6.16. Cytotoxic effect of YopJ-GST nanoparticles on SKBR-3 doxorubicin 
resistant cells after several passages. Relative cell viability after 72 hours of treatment 
with 0.4 µM nanoparticle or dox, measured as number of live cells in sample relative to 
control. Error bars represent standard deviation for N=3 (* p<0.05, ** p<0.01). 
 
 
6-5 Effect of YopJ-GST nanoparticles on a breast cancer cell line panel 
The cytotoxicity of YopJ-GST nanoparticles on other breast cancer cell lines was 
also investigated. A panel of breast cancer cell lines (MCF-7, MDA-MB-231, and MDA-
MB-468) belonging to different molecular subclasses of breast cancer was used. MCF-7 
cells are Luminal A subtype, ER and PR positive, and HER2 negative. MDA-MB-468 is 
a basal cell line that is negative for ER, PR and HER2. MDA-MB-231 is claudin-low 
subtype and is ER, PR and HER2 negative. Despite the molecular variations among these 
cell lines, response to YopJ-GST nanoparticles was observed in all of them. SKBR-3 
cells were the most responsive breast cancer cell line, followed by MCF-7 with 90% cell 
death (Figure 6.17A). The viability of MCF-7 cell after 72 hours of treatment was 
comparable to that induced by a 5 times higher molar dose of dox. MDA-MB-468 and 
MDA-MB-231 cells were less responsive, with 83% and 65% cell death, respectively 
(Figure 6.17C,E). In these cells YopJ-induced cytotoxicity was comparable to dox at the 




















Figure 6.17. Effect of YopJ-GST nanoparticles on a breast cancer cell line panel. (A, C, 
E) Relative cell viability after 72 hours of treatment with 0.4 µM nanoparticle or dox, 
unless otherwise indicated, for (A) MCF-7 (dox 2 µM), (C) MDA-MB-468, and (E) 
MDA-MB-231, measured as number of live cells in sample relative to control. (B, D, F) 
Flow cytometry analysis of particle internalization comparing untreated (black) or 0.4 
µM mYopJ-GST nanoparticle-treated cells for 72 hours (red) using anti-GST Dylight 
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488, for (B) MCF-7, (D) MDA-MB-468, and (F) MDA-MB-231. Error bars represent 





Figure 6.18. Cytotoxicity of a panel of breast cancer cell lines treated with YopJ-GST. 
(A) MCF-7, (B) MDA-MB-468, and (C) MDA-MB-231 cells were assessed by MTT 
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assay and reported as percentage MTT-positive cells in sample relative to control. Cells 
were treated for 72 hours with 0.4 µM YopJ-GST or mYopJ-GST nanoparticles, or 2 µM 
dox. Control cells were treated with 2X PBS + 5% dextrose. Error bars represent standard 
deviation, N=3 (*p<0.05). 
 
Particle internalization by the different cell lines was measured to identify any 
correlation with the viability trends (Figure 6.17B,D,F). After 72 hours of incubation with 
mYopJ-GST nanoparticles, MCF-7, MDA-MB-468 and MDA-MB-231 cells showed a 
1.3, 2 and 1.8-fold increase in median fluorescence intensity, respectively (Figure 6.19). 
MDA-MB-468 cells showed the highest level of uptake, indicating there was no 
correlation between particle internalization and viability. Interestingly, SKBR-3 and 
MCF-7 cells internalized less particles than the other cell types but higher levels of cell 
death were observed. This suggests that these cell lines could be more sensitive to the 
acetylation effect of YopJ, potentially due either to aberrations in the MAPK and NF-κB 
pathway targets of YopJ, or to higher nanoparticle disassembly efficiency. SKBR-3 cells 
have shown higher NF-κB expression and activity than MCF-7 cells, but less than MDA-
MB-231 and MDA-MB-468 [45]. However, SKBR-3 cells have shown greater MAPK 
activity and dependence than all the other cell lines, due to the relationship of HER2 with 
MAPK signaling [39]. Similarly, in MCF-7 cells the MAPK pathway has been found to 
be central to cell survival and proliferation due to the connection with ER [46, 47]. The 
importance of these pathways to particular breast cancer subtypes may be the cause of the 






Figure 6.19. Relative median fluorescence intensity increase for breast cancer cell lines 
treated with 0.4 µM mYopJ-GST nanoparticles. Error bars represent standard deviation 
for N=3 (*p<0.05, **p<0.01). 
 
6-6 Cytotoxic effect of YopJ-GST nanoparticles on other cell lines 
The reported cell-type selectivity of YopJ cytotoxicity suggests that YopJ-GST 
nanoparticles could also exhibit cell-type selectivity. HeLa cells, a cervical cancer cell 
line, and NIH/3T3 cells, healthy non-cancerous murine fibroblasts, were used to establish 
if YopJ-GST nanoparticles display such cell selectivity. HeLa cells treated with 0.4 µM 
YopJ-GST nanoparticles for 72 hours exhibited no significant cytotoxicity (Figure 
6.20A). However, treatment with 0.4 µM dox resulted in high cytotoxicity, with 5% 
viability. Similarly, 0.4 µM YopJ-GST nanoparticles did not show significant cytotoxic 
effects on NIH/3T3 fibroblasts (Figure 6.20C). The same dose of dox reduced viability 
by more than 75%. Results were confirmed using MTT assay (Figure 6.21). Interestingly, 
particle internalization studies showed that HeLa cells internalize mYopJ-GST 
nanoparticles but that NIH/3T3 cells do not (Figure 6.20B,D). The median fluorescence 
intensity increased by 1.75-fold in HeLa cells while there was no significant increase in 
NIH/3T3 cells. 
These results suggest that YopJ-GST nanoparticles have an additional benefit: 
cell-type selectivity. Lack of cytotoxicity in NIH/3T3 cells could be attributed to low 
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nanoparticle uptake. Our previous work showed a 33% reduction in uptake for NIH/3T3 
cells compared to SKBR-3 for green fluorescent protein nanoparticles [48]. However, we 
observed that statistically insignificant quantities of internalized YopJ-GST nanoparticles 
induced 86% cell death in SKBR-3 cells so internalization may not be the only factor. 
HeLa cells, which internalized more YopJ-GST nanoparticles than SKBR-3 cells, did not 
respond. It has been reported that inhibition of MAPK pathways in HeLa cells is not 
sufficient for induction of apoptosis, but that inhibition of ERK 1/2 does sensitize the 
cells to chemotherapy and radiotherapy [49]. 
 
Figure 6.20. Cytotoxicity of other cell lines treated with YopJ-GST. (A) HeLa and (B) 
NIH/3T3 cells were assessed by MTT assay and reported as MTT-positive cells in 
sample relative to control. Cells were treated for 72 hours with 0.4 µM YopJ-GST or 
mYopJ-GST nanoparticles, or 2 µM dox. Control cells were treated with 2X PBS + 5% 







6-7 Modification of YopJ-GST for improved intracellular delivery 
Cell penetrating peptides (CPP) are a group of short 10-30-mer peptides that 
possess the ability to cross cell membranes either alone or carrying a cargo [50]. 
Chemical ligation, fusion and physical assembly of CPPs with peptides, proteins, 
oligonucleotides, and nanoparticles has been shown to increase rate and efficiency of 
intracellular delivery and endosomal escape [51]. YopJ-GST nanoparticle internalization 
was shown to be time dependent and small amounts of particles are internalized in the 
first 24 hours. In order to improve internalization of these particles, YopJ-GST fusion 
were modified to include a C-terminal CPP. 
A histidine modified version of the well-characterized TAT peptide, an arginine 
rich CPP from HIV, was selected for its ability to promote intracellular delivery and 
endosomal escape of its cargoes [52]. The 6xHis-TAT-6xHis CPP was fused to YopJ-
GST proteins to produce a larger fusion protein YopJ-HIS-TAT with encoded abilities to 
facilitate the cellular internalization process. Fusion of this peptide to YopJ-GST 
prevented the self-assembly of the protein into the previously observed nanoparticles. 
DLS measurements indicate that YopJ-HIS-TAT is soluble in saline buffers (Figure 





















Figure 6.21. Size distribution of purified YopJ-HIS-Tat fusion proteins in saline buffer.  
 
The monomeric state of YopJ-HIS-TAT allowed fine tuning of YopJ dosing to 
cells in soluble delivery and carrier+YopJ-HIS-TAT nanoparticles, similar to 
eGFP+AvrA nanoparticles presented in Chapter 5. Fabrication of YopJ nanoparticles 
using monomeric red fluorescent protein (mRFP) as a carrier protein was performed 
following the desolvation method used to produce eGFP+AvrA nanoparticles. Different 
amounts of YopJ-HIS-TAT were included in the particles and nanoparticle size was 
found to increase as YopJ content increases(Figure 6.23). Average particle diameter 
varied between 80-120 nm and increased as YopJ content increased from 0.7-2.2% of the 
total protein content.  
 
 
Figure 6.22. Effect of YopJ-HIS-TAT on mRFP+YopJ-HIS-TAT particle size 
distribution in saline buffer. Nanoparticles made of pure mRFP, mRFP and 2.2% YopJ-
HIS-TAT (mRFP+YopJHT1), and mRFP with 0.7% YopJ-HIS-TAT (mRFP+YopJHT2). 
 
Figure 6.24 shows the effect of 0.4 µM soluble YopJ-HIS-TAT on SKBR-3 and 
MDA-MB-231 cells after 72 hours of incubation. Not surprisingly, the cytotoxicity of 

















mRFP +YopJ HT 2 
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is likely the result of higher internalization in particle form than soluble form, as 
established in Chapter 4. Therefore, the effect of mRFP+YopJ-HIS-TAT nanoparticles on 
SKBR-3 cell viability was measured. Particles with different YopJ-HIS-TAT contents 
were used to vary effector dosage. Due to the limited solubility of the modified effector 
fusion protein the maximum dose that was accomplished was 0.1 µM YopJ-HIS-TAT. 
Therefore, the cytotoxic of effect of mRFP+YopJ-HIS-TAT nanoparticles was 70% 





Figure 6.23. Effect of soluble YopJ-HIS-TAT on breast cancer cells. Cells were 
incubated for 72 hours with 0.4 µM YopJ-HIS-TAT or 2X PBS+5% dextrose (A) SKBR-






































Figure 6.24. Effect of mRFP+YopJ-HIS-TAT nanoparticles on SKBR3 cell viability 
after 72h of incubation. Error bars represent standard deviation, N=3. 
 
6-8 Summary 
The results presented in this chapter illustrate the potential of protein 
nanoparticles and bacterial proteins as therapeutic agents for cancer. A second method for 
production of protein nanoparticles was presented, fusion of YopJ to GST for assembly 
into stable nanoparticles during protein production, removing the need for additional 
delivery vehicle synthesis steps and materials. The self-assembled nanoparticles induce 
cell death in multiple breast cancer cell lines with different molecular profiles. Despite 
variations among cell lines, YopJ performed as well as dox or better in inducing cell 
death. In addition, YopJ-GST nanoparticles decrease the migration and invasive nature of 
surviving cancer cells, due to down-regulation of the ERK 1/2 pathway, which has been 
correlated to metastatic pathology. Though downregulation of NF-κB was not 
established, the observed biochemical activity of YopJ on MAPK and the strong 
relationship of MAPK signaling with several of the hallmarks of cancer (including 
proliferation, chemotherapy resistance and metastasis)[42, 53], grant YopJ-GST 


























Clinical trials have demonstrated that MAPK targeted therapeutics have more 
tolerable side effects than traditional chemotherapeutics. Common side effects of ERK 
1/2 pathways inhibition are rash, edema and transient blurred vision[54]. Therefore, the 
observed cell-type cytotoxic selectivity and the mechanism of action of YopJ-GST 
nanoparticles, compared to dox, suggests that this type of therapy could potentially have 
less side effects than traditional chemotherapeutics. We expect YopJ-GST nanoparticles 
and other bacterial effector constructs to be potent cytotoxic agents that have molecular 
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7CHAPTER 7: CONCLUSIONS AND OUTLOOK  
 
 
As protein therapeutics have increased dramatically in number and frequency of 
use, it has become essential to improve current techniques and explore the development 
of new techniques for effective delivery. The work contained in this thesis focuses on the 
creation of protein-based vehicles for intracellular delivery of therapeutic proteins and 
enzymes. Various aspects of engineering and production of protein nanoparticles via 
covalent bonds or strong protein-protein interactions are explored.  
This work presents and establishes two distinct particle production methods: 
desolvation and self-assembly. Nanoparticles produced using the desolvation method 
require stabilization with environment-responsive cross-linkers for release of soluble 
active protein inside the cells. The desolvation method is optimized using β-galactosidase 
as a model enzyme and then applied to a bacterial effector protein, AvrA, a potential 
therapeutic enzyme for inflammatory bowel disease. Particles produced by self-assembly 
with GST are held together by strong hydrophobic interactions and disulfide bonds. The 
self-assembly method was applied to YopJ, another bacterial effector protein and 
potential therapeutic candidate for breast cancer.  
Both methods are optimized to control nanoparticle properties and accomplish 
intracellular delivery and release of active therapeutic proteins or enzymes.  The 
effectiveness of therapeutic protein nanoparticles is evaluated in two different disease 
models. The key findings in this work are: 
 
1. Fabrication of protein enzyme delivery vehicles via the desolvation method 
requires the use of a carrier protein. Particles produced directly from enzymes 
exhibit high loss of enzymatic activity due to desolvation and cross-linking. 
Incorporation of a carrier protein decreases loss of enzymatic activity. Highly 
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soluble and stable proteins such as eGFP, mRFP and BSA are effective carrier 
proteins. However, fluorescent proteins present the added advantage of easy 
particle detection and tracking.  
 
2. The size of protein nanoparticles produced by the desolvation method can be 
tuned by adjusting a variety of parameters. Concentration of imidazole 
decreases particle size of 6xHis tag proteins. Highly reactive cross-linkers like 
GTA produce larger particles than less reactive cross-linkers like DTSSP. 
Cross-linking time also affects particle size, shorter cross-linking times 
decrease particle diameter. The presence of salts in initial protein solutions is 
necessary for particle formation via the desolvation method at low protein 
concentrations. 
 
3. Protein particles stabilized with a reducing environment-responsive cross-
linker, DTSSP, release their therapeutic protein/enzyme cargo inside of cells.  
 
4. Fusion of GST to YopJ was necessary for recombinant protein expression and 
leads to self-assembly of stable nanoparticles during the production process. 
This self-assembly removes the need for additional delivery vehicle synthesis 
steps. Self-assembled YopJ-GST nanoparticles are held together by disulfide 
bonds and strong protein-protein interactions.  
 
5. Bacterial protein effector nanoparticles control key intracellular pathways and 
retain the biochemical activity and effect of the original effector protein. 
 
6. Bacterial protein effector nanoparticles are promising and highly innovative 
alternatives to current therapies. eGFP+AvrA nanoparticles successfully 
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delivered AvrA to intestinal cells, disassembled inside cells, downregulated 
NF-κB and MAPK signaling and reduced inflammation in IBD models. YopJ-
GST nanoparticles effectively delivered YopJ to cancer cells and performed as 
well as a common therapeutic agent, dox, or better for the treatment of breast 
cancer. YopJ-GST nanoparticles decreased metastatic markers and were only 
cytotoxic to breast cancer cells.  
 
These findings illustrate the feasibility of producing and using protein 
nanoparticles for intracellular delivery of therapeutic enzymes. This work helps bridge 
the divide between the well-established potential of protein/enzyme therapeutics and their 
effective delivery to intracellular spaces. The two particle production methods presented 
in this work are simple, fast and cost-effective. Most importantly, these methods are 
versatile and can be adapted for particle production with many therapeutic proteins and 
enzymes.  
Evidence presented in this thesis points to the importance of using delivery 
vehicles to increase and enhance intracellular protein or enzyme delivery. Designed and 
produced therapeutic protein nanoparticles shown in this work are capable of effectively 
penetrating mucosal layers, tissue and cell membranes in vitro and in vivo. In addition, 
these particles deliver more active protein to multiple types of cells than soluble protein 
formulations. These results are very promising for therapeutic protein and enzyme 
delivery and provide a new application for protein nanoparticles as drug carriers.  
This thesis also explores the potential of bacterial effector proteins for therapeutic 
purposes. The bacterial effectors evaluated in this work are easily incorporated into 
protein nanoparticles and are capable of modulating intracellular pathways to control the 
fate of target cells. YopJ and AvrA are shown to induce cell death and decrease 
inflammatory signals, respectively, and thus are potential therapeutic agents for breast 
cancer and IBD.  
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These findings give future researchers a platform to more deeply explore 
applications of bacterial effector proteins. This cutting-edge translational approach has 
the potential to add a new class of biologic drugs to treatment strategies against a wide 
variety of diseases Additionally, the existing knowledge of the molecular basis of 
different diseases can be paired with known effector mechanisms and target pathways, to 
find and formulate new potential therapies.  
This research provides a solid foundation for future work centered both on 
creating bioactive protein-based delivery vehicles and developing new therapeutic 
alternatives based on bacterial proteins. Potential thrusts for such work are as follows: 
 
1. Particle internalization mechanism. 
Results presented in this thesis suggests that protein nanoparticles are internalized 
via energy dependent mechanisms. Data on the precise uptake mechanism would 
provide information on the conditions and environment the particle will be 
exposed to. This information coupled with knowledge on specific receptors that 
are overexpressed on the surface of targets cells can be useful to fine tune the 
particle design to achieve higher internalization rates. By decorating the surface of 
the particles with specific ligands the rate and path of internalization can be 
controlled.  
 
2. Subcellular particle localization.  
Data gathered on the localization of protein/enzyme nanoparticles inside the cells 
would be helpful in establishing the need for additional engineering of the 
particle. If particles are trapped in endosomes and are routed to lysosomes for 
degradation, for example, cell penetrating peptides can increase cellular 




3. Particle disassembly characterization.  
The disassembly of DTSSP cross-linked particles has been proven but the process 
and kinetics have not been elucidated. The location within the cell in which 
particle disassembly occurs, how long the process takes and the extent of particle 
disassembly remains unknown. The seemingly small amount of YopJ-GST 
nanoparticles internalized within the first 24 hours shows potent induction of 
breast cancer cell death. Information on disassembly kinetics would provide 
information on the amount and state (soluble/particle) of effector proteins within 
the cell required for biochemical activity. 
 
4. Engineering of protein particles for in vivo stability. 
The results of stability studies on protein nanoparticles exposed to body fluids and 
simulated body fluids indicates that these vehicles do not protect their cargo from 
damage in harsh environments. Engineering the protein particle surface with 
polymers, peptides or further cross-linking could improve enzyme stability.  In 
addition, YopJ-GST nanoparticles have not been tested in blood serum and little 
is known about the stability of YopJ in biological fluids.  
 
5. In vivo studies of breast cancer treatment.  
While the treatment of breast cancer in vitro has been proven to be highly 
successful with YopJ-GST nanoparticles, it remains unclear if these particles will 
be able to specifically induce cell death of malignant cells, decrease cell migration 
and reduce side effects in vivo. Animal models would provide information on 
immune response to YopJ-GST nanoparticles and efficacy of YopJ for breast 





6. Application to other diseases 
Novel potent molecularly targeted therapies can be formulated by pairing 
bacterial protein effectors to diseases where their biochemical function can restore 
cellular functions. For example, neurodegenerative diseases such as Parkinson’s 
and Alzheimer’s disease, lung cancer, colorectal cancer and melanoma 
progression have been linked to de-regulated MAPK activity.  In particular, in 
Alzheimer’s and Parkinson’s disease the p38 MAPK cascade has been linked to 
neuronal cell death. OspF, from Shigella, irreversibly inactivates this particular 
pathway and thus, could be studied as a potential therapeutic agent for 
neurodegenerative disorders. Other potential pairings include NleE from EPEC 
and OspZ from Shigella that block NF-κB activation and decrease aberrant IL-8 
production and hence, could be potentially used to treat chronic inflammation 
such as that observed in rheumatoid arthritis and psoriasis.  
In addition, protein particles can be modified to incorporate these or other 
potential therapeutic proteins and engineered to fit requirements and needs for the 
treatment of other diseases.  Additionally, combination therapies could be 
formulated in these protein nanoparticles. For example, particles could be 
formulated to include two or more enzymes with different functions or a mix of 
enzymes and small molecule drugs in each formulation. These strategies would 
allow the particles to potentially be multifunctional and could help increase 









8APPENDIX A: BACTERIAL EFFECTOR SEQUENCES 
 
 
 The DNA sequences of bacterial effector proteins, YopJ and AvrA, used in this 
work are presented here:  
 
YopJ 
ATGATCGGACCAATACCACAAATAAATATCTCCGGTGGCTTATCAGAAAAAGAGACC
AGTTCTTTAATCAGTAATGAAGAGCTTAAAAATATCATAACACAGTTGGAAACTGAT
ATATCGGATGGATCCTGGTTCCATAAAAATTATTCACGTATGGATGTAGAAGTCATG
CCCGCATTGGTAATCCAGGCGAACAATAAATATCCGGAAATGAATCTTAATCTTGTT
ACATCTCCATTGGACCTTTCAATAGAAATAAAAAACGTCATAGAAAATGGAGTTAGA
TCTTCCCGCTTCATAATTAACATGGGGGAAGGTGGAATACATTTCAGTGTAATTGATT
ACAAACATATAAATGGGAAAACATCTCTGATATTGTTTGAACCAGCAAACTTTAACA
GTATGGGGCCAGCGATGCTGGCAATAAGGACAAAAACGGCTATTGAACGTTATCAA
TTACCTGATTGCCATTTCTCCATGGTGGAAATGGATATTCAGCGAAGCTCATCTGAAT
GTGGTATTTTTAGTTTTGCACTGGCAAAAAAACTTTACATCGAGAGAGATAGCCTGTT
GAAAATACATGAAGATAATATAAAAGGTATATTAAGTGATGGTGAAAATCCTTTACC
CCACGATAAGTTGGACCCGTATCTCCCGGTAACTTTTTACAAACATACTCAAGGTAA
AAAACGTCTTAATGAATATTTAAATACTAACCCGCAGGGAGTTGGTACTGTTGTTAA
CAAAAAAAATGAAACCATCGTTAATAGATTTGATAACAATAAATCCATTGTAGATGG
AAAGGAATTATCAGTTTCGGTACATAAAAAGAGAATAGCTGAATATAAAACACTTCT
CAAAGTA 
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AvrA 
ATGATATTTTCGGTGCAGGAGCTATCATGTGGAGGGAAAAGTATGCTAAGTCCTACG
ACTCGTAATATGGGGGCGAGTTTATCGCCTCAGCCTGACGTCAGCGGGGAGCTAAAC
ACCGAAGCATTGACCTGTATTGTTGAGCGTCTGGAAAGTGAAATTATAGATGGCAGC
TGGATTCATATCAGTTACGAGGAAACCGATCTCGAAATGATGCCTTTTCTTGTTGCAC
AGGCCAATAAGAAGTATCCAGAGTTAAATCTTAAATTTGTTATGTCAGTCCATGAGC
TTGTTTCCTCTATAAAGGAGACCAGAATGGAAGGCGTTGAATCTGCCCGATTTCTCGT
AAATATGGGAAGTTCAGGTATCCATATTTCAGTCGTCGATTTTAGAGTTATGGACGG
AAAGACATCGGTGATTTTGTTCGAACCAGCAGCGTGTAGCGCTTTTGGACCTGCACT
GGCGTTGAGGACCAAAGCAGCTCTTGAACGTGAACAACTGCCTGATTGTTATTTTGC
TATGGTCGAGCTGGACATTCAACGAAGCTCTTCTGAATGCGGTATTTTTAGCCTGGCG
CTCGCCAAAAAACTTCAGCTTGAATTTATGAACTTAGTAAAAATTCATGAAGATAAT
ATTTGTGAACGTCTGTGTGGTGAAGAACCTTTTCTCCCGTCCGATAAAGCAGACCGCT
ATCTGCCGGTGAGTTTTTACAAACATACTCAAGGCGCACAACGATTAAATGAATATG
TGGAGGCCAATCCGGCGGCGGGAAGCAGTATAGTAAACAAAAAGAATGAAACGCTT
TATGAGCGATTCGATAACAATGCCGTTATGCTAAACGATAAAAAACTCTCTATATCC
GCTCATAAAAAAAGGATAGCTGAATATAAGTCTTTACTTAAACCGTAA 
 
 
